<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Haloperidol versus low‐potency first‐generation antipsychotic drugs for schizophrenia - Tardy, M - 2014 | Cochrane Library</title> <meta content="Haloperidol versus low‐potency first‐generation antipsychotic drugs for schizophrenia - Tardy, M - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009268.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Haloperidol versus low‐potency first‐generation antipsychotic drugs for schizophrenia - Tardy, M - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009268.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009268.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Haloperidol versus low‐potency first‐generation antipsychotic drugs for schizophrenia" name="citation_title"/> <meta content="Magdolna Tardy" name="citation_author"/> <meta content="Technische Universität München Klinikum rechts der Isar" name="citation_author_institution"/> <meta content="magdolnatardy@yahoo.de" name="citation_author_email"/> <meta content="Maximilian Huhn" name="citation_author"/> <meta content="Universitätsklinikum der Technischen Universität München" name="citation_author_institution"/> <meta content="Werner Kissling" name="citation_author"/> <meta content="Technische Universität München Klinikum rechts der Isar" name="citation_author_institution"/> <meta content="Rolf R Engel" name="citation_author"/> <meta content="Ludwig‐Maximilians‐University Munich" name="citation_author_institution"/> <meta content="Stefan Leucht" name="citation_author"/> <meta content="Technische Universität München" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD009268.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/07/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009268.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009268.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009268.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antipsychotic Agents [adverse effects, *therapeutic use]; Dyskinesia, Drug‐Induced; Haloperidol [adverse effects, *therapeutic use]; Patient Dropouts [statistics &amp; numerical data]; Randomized Controlled Trials as Topic; Schizophrenia [*drug therapy]; Weight Gain" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009268.pub2&amp;doi=10.1002/14651858.CD009268.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009268.pub2&amp;doi=10.1002/14651858.CD009268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009268.pub2&amp;doi=10.1002/14651858.CD009268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009268.pub2&amp;doi=10.1002/14651858.CD009268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009268.pub2&amp;doi=10.1002/14651858.CD009268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009268.pub2&amp;doi=10.1002/14651858.CD009268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009268.pub2&amp;doi=10.1002/14651858.CD009268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009268.pub2&amp;doi=10.1002/14651858.CD009268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009268.pub2&amp;doi=10.1002/14651858.CD009268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009268.pub2&amp;doi=10.1002/14651858.CD009268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009268.pub2&amp;doi=10.1002/14651858.CD009268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009268.pub2&amp;doi=10.1002/14651858.CD009268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009268.pub2&amp;doi=10.1002/14651858.CD009268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009268.pub2&amp;doi=10.1002/14651858.CD009268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009268.pub2&amp;doi=10.1002/14651858.CD009268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009268.pub2&amp;doi=10.1002/14651858.CD009268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009268.pub2&amp;doi=10.1002/14651858.CD009268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009268.pub2&amp;doi=10.1002/14651858.CD009268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009268.pub2&amp;doi=10.1002/14651858.CD009268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009268.pub2&amp;doi=10.1002/14651858.CD009268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009268.pub2&amp;doi=10.1002/14651858.CD009268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009268.pub2&amp;doi=10.1002/14651858.CD009268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009268.pub2&amp;doi=10.1002/14651858.CD009268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="jiwTpTuf";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009268\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009268\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009268\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009268\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009268.pub2",title:"Haloperidol versus low\\u2010potency first\\u2010generation antipsychotic drugs for schizophrenia",firstPublishedDate:"Jul 9, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009268.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009268.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009268.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009268.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009268.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009268.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009268.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009268.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009268.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009268.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2058 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009268.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/full#CD009268-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/full#CD009268-sec-0175"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/full#CD009268-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/full#CD009268-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/full#CD009268-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/full#CD009268-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/full#CD009268-sec-0103"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/full#CD009268-sec-0158"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/table_n/CD009268StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/table_n/CD009268StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Haloperidol versus low‐potency first‐generation antipsychotic drugs for schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/information#CD009268-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Magdolna Tardy</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/information#CD009268-cr-0003">Maximilian Huhn</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/information#CD009268-cr-0004">Werner Kissling</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/information#CD009268-cr-0005">Rolf R Engel</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009268.pub2/information#CD009268-cr-0006">Stefan Leucht</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/information/en#CD009268-sec-0188">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 July 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009268.pub2">https://doi.org/10.1002/14651858.CD009268.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009268-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009268-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009268-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009268-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009268-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009268-abs-0001" lang="en"> <section id="CD009268-sec-0001"> <h3 class="title" id="CD009268-sec-0001">Background</h3> <p>Antipsychotic drugs are the core treatment for schizophrenia. Treatment guidelines state that there is no difference in efficacy between antipsychotic compounds, however, low‐potency antipsychotic drugs are often clinically perceived as less efficacious than high‐potency compounds, and they also seem to differ in their side‐effects. </p> </section> <section id="CD009268-sec-0002"> <h3 class="title" id="CD009268-sec-0002">Objectives</h3> <p>To review the effects in clinical response of haloperidol and low‐potency antipsychotics for people with schizophrenia. </p> </section> <section id="CD009268-sec-0003"> <h3 class="title" id="CD009268-sec-0003">Search methods</h3> <p>We searched the Cochrane Schizophrenia Group Trials Register (July 2010).</p> </section> <section id="CD009268-sec-0004"> <h3 class="title" id="CD009268-sec-0004">Selection criteria</h3> <p>We included all randomised trials comparing haloperidol with first‐generation low‐potency antipsychotic drugs for people with schizophrenia or schizophrenia‐like psychosis. </p> </section> <section id="CD009268-sec-0005"> <h3 class="title" id="CD009268-sec-0005">Data collection and analysis</h3> <p>We extracted data independently. For dichotomous data, we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention‐to‐treat basis based on a random‐effects model. For continuous data, we calculated mean differences (MD), again based on a random‐effects model. </p> </section> <section id="CD009268-sec-0006"> <h3 class="title" id="CD009268-sec-0006">Main results</h3> <p>The review currently includes 17 randomised trials and 877 participants. The size of the included studies was between 16 and 109 participants. All studies were short‐term with a study length between two and 12 weeks. Overall, sequence generation, allocation procedures and blinding were poorly reported. We found no clear evidence that haloperidol was superior to low‐potency antipsychotic drugs in terms of clinical response (haloperidol 40%, low‐potency drug 36%, 14 RCTs, n = 574, RR 1.11, CI 0.86 to 1.44 low<i>quality evidence</i> ). There was also no clear evidence of benefit for either group in acceptability of treatment with equivocal difference in the number of participants leaving the studies early due to any reason (haloperidol 13%, low‐potency antipsychotics 17%, 11 RCTs, n = 408, RR 0.82, CI 0.38 to 1.77, <i>low quality evidence</i> ). Similar equivocal results were found between groups for experiencing at least one adverse effect (haloperidol 70%, low‐potency antipsychotics 35%, 5 RCTs n = 158, RR 1.97, CI 0.69 to 5.66, <i>very low quality evidence</i> ). More participants from the low‐potency drug group experienced sedation (haloperidol 14%, low‐potency antipsychotics 41%, 2 RCTs, n = 44, RR 0.30, CI 0.11 to 0.82, <i>moderate quality evidence</i> ), orthostasis problems (haloperidol 25%, low‐potency antipsychotics 71%, 1 RCT, n = 41, RR 0.35, CI 0.16 to 0.78) and weight gain (haloperidol 5%, low‐potency antipsychotics 29%, 3 RCTs, n = 88, RR 0.22, CI 0.06 to 0.81). In contrast, the outcome 'at least one movement disorder' was more frequent in the haloperidol group (haloperidol 72%, low‐potency antipsychotics 41%, 5 RCTs, n = 170, RR 1.64, CI 1.22 to 2.21, <i>low quality evidence</i>). No data were available for death or quality of life. The results of the primary outcome were robust in several subgroup and sensitivity analyses. </p> </section> <section id="CD009268-sec-0007"> <h3 class="title" id="CD009268-sec-0007">Authors' conclusions</h3> <p>The results do not clearly show a superiority in efficacy of haloperidol compared with low‐potency antipsychotics. Differences in adverse events were found for movement disorders, which were more frequent in the haloperidol group, and orthostatic problems, sedation and weight gain, which were more frequent in the low‐potency antipsychotic group. The quality of studies was low, and the quality of evidence for the main outcomes of interest varied from moderate to very low, so more newer studies would be needed in order to draw a definite conclusion about whether or not haloperidol is superior or inferior to low‐potency antipsychotics. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009268-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009268-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009268-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009268-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009268-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009268-abs-0005">Hrvatski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009268-abs-0004" lang="en"> <h3>Haloperidol versus first‐generation low‐potency antipsychotic drugs for schizophrenia</h3> <p>Drugs called antipsychotics are the main treatment for schizophrenia. Schizophrenia is a serious mental illness where sufferers experience both positive symptoms of delusions and hallucinations and negative symptoms such as apathy, lack of drive, disorganisation of behaviour and thought. This review examined whether a high‐potency antipsychotic, haloperidol is more effective than low‐potency antipsychotics. The classification into high‐potency and low‐potency medication means that for low‐potency antipsychotic drugs, higher doses are necessary to obtain the same effect and response in patients. Haloperidol is the most frequently used antipsychotic drug in many countries and, along with other high‐potency antipsychotics is often considered more effective than low‐potency antipsychotics. Typical examples of low‐potency antipsychotic drugs are chlorpromazine, chlorprothixene, thioridazine or levomepromazine. High‐ and low‐potency antipsychotics also seem to differ in their side‐effects. Low‐potency drugs cause sedation and poor muscle strength, whereas high‐potency drugs produce side‐effects such as movement disorders (the inability to sit still, uncontrollable shaking and difficulty in walking). The review is based on results of a search run in 2010 and includes 17 studies with a total of 877 participants comparing haloperidol with low‐potency antipsychotic drugs.The results do not clearly show a superiority of haloperidol compared with low‐potency antipsychotics. However, more participants from the low‐potency drug group experienced weight gain and sedation. The experience of at least one movement disorder was significantly higher with haloperidol. The number as well as the quality of studies is low, for the main outcomes of interest the authors rated quality of evidence for as moderate quality for two of them, two as low quality and one as very low quality. So the evidence is not strong and more newer studies would be needed in order to draw a conclusion about whether or not haloperidol is superior to low‐potency antipsychotics. For people with schizophrenia it is important to know that there is moderate quality evidence that haloperidol and low‐potency antipsychotics are approximately equal in their effectiveness, but there is lower quality evidence that they clearly differ in side‐effects (such as weight gain and movement disorders). </p> <p>This plain language summary has been written by a consumer Benjamin Gray: Service User and Service User Expert, Rethink Mental Illness, Email: <a href="http://mailto:ben.gray@rethink.org" target="_blank"><span class="__cf_email__" data-cfemail="4f2d2a2161283d2e360f3d2a3b2726212461203d28">[email protected]</span></a> </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009268-sec-0175" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009268-sec-0175"></div> <h3 class="title" id="CD009268-sec-0176">Implications for practice</h3> <section id="CD009268-sec-0176"> <section id="CD009268-sec-0177"> <h5 class="title">1. For clinicians</h5> <p>Clinicians should know that we did not find any clear differences in efficacy between haloperidol and low‐potency first‐generation antipsychotics. However, haloperidol produced more movement disorders, while low‐potency antipsychotics produced more weight gain, dizziness and orthostatic symptoms. However, due to the limited number of studies and participants, and due to an overall low quality of the included studies, the results have to be interpreted with caution. </p> </section> <section id="CD009268-sec-0178"> <h5 class="title">2. For people with schizophrenia</h5> <p>For people with schizophrenia, it is important to know that there is moderate quality evidence that haloperidol and low‐potency antipsychotics are approximately equal in their effects on treatment response, and that there is evidence of lower quality and that they clearly differ in side‐effects (such as weight gain and movement disorders).<br/> <br/> They might tell their doctors that they want to be involved in the choice of the antipsychotic that is best for them. </p> </section> <section id="CD009268-sec-0179"> <h5 class="title">3. For managers/policy makers</h5> <p>There were no data on re‐hospitalisation, economic outcomes, healthy days or quality of life, which can be considered very important outcomes for decision makers. Thus, it is not possible to make any recommendations apart from the fact that all of the examined drugs in this review have lost their patents and are therefore rather inexpensive. </p> </section> </section> <h3 class="title" id="CD009268-sec-0180">Implications for research</h3> <section id="CD009268-sec-0180"> <section id="CD009268-sec-0181"> <h5 class="title">1. General</h5> <p>The outcome reporting about the effects of haloperidol versus low‐potency antipsychotics was insufficient. Few data were available, and long‐term effects were not at all reported. Strict adherence to the CONSORT statement (<a href="./references#CD009268-bbs2-0108" title="MoherD , HopewellS , SchulzKF , MontoriV , GøtzschePC , DevereauxPJ , et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ2010;340:c869. ">Moher 2010</a>) would make such studies much more informative. </p> </section> <section id="CD009268-sec-0182"> <h5 class="title">2. Specific</h5> <section id="CD009268-sec-0183"> <h6 class="title">2.1 Reviews</h6> <p>Studies we have had to exclude because they were not directly relevant, however, do still show how this compound has been evaluated in other ways. Some of these remain clinically relevant and may merit further systematic reviews (<a href="#CD009268-tbl-0003">Table 2</a>). </p> <div class="table" id="CD009268-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Comparisons suggested by excluded studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Excluded study tag</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Current relevant Cochrane review</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amitriptyline for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0055" title="TejaJS , GreyWH , ClumJM , WarrenC . Tranquilizers or anti‐depressanrs for chronic schizophrenics: a long term study. Australian and New Zealand Journal of Psychiatry1975;9:241‐7. ">Teja 1975</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0125" title="WhiteheadC , MossS , CardnoA , LewisG , FurtadoVA . Antidepressants for people with both schizophrenia and depression. Cochrane Database of Systematic Reviews2002, Issue 2. [DOI: 10.1002/14651858.CD002305] ">Whitehead 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antipsychotic (various) withdrawal versus continuation for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0023" title="CrowTJ , MacMillanJF , JohnsonAL , JohnstoneEC . A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry1986; Vol. 148, issue 2:120‐7. [MEDLINE: 2870753] JohnstoneEC , CrowJ , JohnsonAL , MacMillanJF . The northwick park study of first episodes of schizophrenia. British Journal of Psychiatry1986;148:115‐20. ">Crow 1986</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Benztropine plus antipsychotic combinations for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0053" title="SinghMM . Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Diseases of the Nervous System1976; Vol. 37:191‐6. SinghMM , KaySR . A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Theoretical implications for potency differences among neuroleptics. Psychopharmacology1975; Vol. 43, issue 2:103‐13. SinghMM , KaySR . A longitudinal therapeutic comparison between two prototypic neuroleptics (haloperidol and chlorpromazine) in matched groups of schizophrenics. Nontherapeutic interactions with trihexyphenidyl. Theoretical implications for potency differences. Psychopharmacology1975; Vol. 43, issue 2:115‐21. SinghMM , KaySR . Therapeutic reversal with benztropine in schizophrenics: practical and theoretical significance. Journal of Nervous and Mental Disease1975; Vol. 160, issue 4:258‐66. ">Singh 1975</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol dose for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0054" title="SmithRC , BaumgartnerR , BurdA , RavichandranGK , MauldinM . Haloperidol and thioridazine drug levels and clinical response in schizophrenia: comparison of gas‐liquid chromatography and adioreceptor drug level assays. Psychopharmacology Bulletin. United States, 1985; Vol. 21, issue 1:52‐8. ">Smith 1985</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0077" title="DonnellyL , RathboneJ , Adams CliveE . Haloperidol dose for the acute phase of schizophrenia. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD001951.pub2] ">Donnelly 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus mid/high‐potency antipsychotic drugs for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0032" title="GiordanaJY , FrenayS . Comparative study of pipotiazine (in its non‐esterified form) and of haloperidol in acute or subacute psychotic states [Etude comparative de la pipothiazine (dans sa forme non esterifiee) et de l'haloperidol au cours d'etats psychotiques aigus et subaigus]. Psychologie Medicale1984;16(10):1803‐15. ">Giordana 1984</a> (pipotiazine), <a href="./references#CD009268-bbs2-0047" title="NahunekK , SvestkaJ , CeskovaE , RysanekR . Blind comparison of oxyprothepin and haloperidol in six‐week treatment periods in schizophrenia. Activitas Nervosa Superior1982; Vol. 24, issue 4:219‐20. ">Nahunek 1982</a> (oxyprothepine) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0029" title="GarryJW , LeonardTJ . Haloperidol: a controlled trial in chronic schizophrenia. Journal of Mental Science1962; Vol. 108:105‐7. ">Garry 1962</a>, <a href="./references#CD009268-bbs2-0041" title="MarjerrisonG , BowmanR , KeoghRP . A comparison of chlorprothixene and haloperidol in acute schizophrenia. Canadian Psychiatric Association Journal1971; Vol. 16, issue 6:533‐6. ">Marjerrison 1971</a>, <a href="./references#CD009268-bbs2-0047" title="NahunekK , SvestkaJ , CeskovaE , RysanekR . Blind comparison of oxyprothepin and haloperidol in six‐week treatment periods in schizophrenia. Activitas Nervosa Superior1982; Vol. 24, issue 4:219‐20. ">Nahunek 1982</a>, <a href="./references#CD009268-bbs2-0055" title="TejaJS , GreyWH , ClumJM , WarrenC . Tranquilizers or anti‐depressanrs for chronic schizophrenics: a long term study. Australian and New Zealand Journal of Psychiatry1975;9:241‐7. ">Teja 1975</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0059" title="Adams CliveE , BergmanH , Irving ClaireB , LawrieS . Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews. John Wiley &amp; Sons, Ltd, 2013, issue 11. [DOI: 10.1002/14651858.CD003082.pub3; CD003082] ">Adams 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine versus first‐generation antipsychotic drugs for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0025" title="deLimaMS , deJesusMJ , BreierA , CostaAM , deSenaEP , HotopfM . Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first‐generation antipsychotics. Journal of Clinical Psychiatry. United States, 2005; Vol. 66, issue 7:831‐8. ">de Lima 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0078" title="DugganL , FentonM , RathboneJ , DardennesR , El‐DosokyA , IndranS . Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD001359.pub2] ">Duggan 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sulpiride for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0021" title="CassanoGB , CastrogiovanniP , ContiL . The computer diagnosis in a multicenter study of psychoactive agents. Psychopharmacology Bulletin1976; Vol. 12, issue 2:22‐4. CassanoGB , CastrogiovanniP , ContiL , BonolloL . Sulpiride versus haloperidol in schizophrenia: a double‐blind comparative trial. Current Therapeutic Research1975; Vol. 17, issue 2:189‐201. CastrogiovanniP , CassanoGB , ContiL , MagginiC , BonolloL , SarteschiP . An automated diagnostic process (PDA) in clinical psychopharmacology. An exemplification of its use in a sulpiride versus haloperidol comparative trial. International Pharmacopsychiatry1976; Vol. 11, issue 2:74‐83. ">Cassano 1975</a>, <a href="./references#CD009268-bbs2-0034" title='GuazzelliM , BarracchiaE , BertolinoA , BertolinolA , CasacchiaM , CiapparelliA , et al. Clinical effects of l‐sulpiride vs haloperidol in acutely relapsed chronic schizophrenics: therapeutic efficacy on "disorganization"?. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 Sep 30 ‐ Oct 4; Venice, Italy1995. '>Guazzelli 1995</a>, <a href="./references#CD009268-bbs2-0044" title="MoriA , KazamatsuriH , KanenoS , KamijimaK , KariyaT , MurasakiM , et al. A double‐blind comparison of a new benzamide compound YM 09151 with haloperidol in the treatment of schizophrenia. Rinsho Hyoka (Clinical Evaluation)1989; Vol. 17, issue 3‐4:349‐77. ">Mori 1989</a>, <a href="./references#CD009268-bbs2-0046" title="GerlachJ , BehnkeK , HeltbergJ , Munk‐AndersonE , NielsenH . Sulpiride and haloperidol in schizophrenia: a double‐blind cross‐over study of therapeutic effect, side effects and plasma concentrations. British Journal of Psychiatry1985; Vol. 147:283‐8. Munk‐AndersenE , BehnkeK , HeltbergJ , NielsenH . Sulpiride versus haloperidol in the treatment of schizophrenia. A short preliminary report [Sulpirid versus haloperidol i behandling af skizofreni. En kort, praeliminaer rapport]. Nordisk Psykiatrisk Tidsskrift1984; Vol. 38, issue 4:223‐8. Munk‐AndersenEM , BehnkeK , HeltbergJ , NielsenH , GerlachJ . Sulpiride versus haloperidol, a clinical trial in schizophrenia. A preliminary report. Acta Psychiatrica Scandinavica Supplementum1984; Vol. 311:31‐41. ">Munk‐Andersen 1984</a>, <a href="./references#CD009268-bbs2-0048" title="OkudaO , AkaueY , OkishioY . The efficacy of sulpiride in the treatment of schizophrenia by the double‐blind method. Yakuri To Chiryo1979; Vol. 7, issue 2:439‐58. ">Okuda 1979</a>, <a href="./references#CD009268-bbs2-0050" title="Rama RaoV , BaileyJ , BishopM , CoppenA . A clinical and pharmacodynamic evaluation of sulpiride. Psychopharmacology1981; Vol. 73, issue 1:77‐80. ">Rama 1981</a>, <a href="./references#CD009268-bbs2-0051" title="RopertR , PayanC , AllardS . Sultopride versus haloperidol for the treatment of acute psychosis. Results of a multicenter double‐blind controlled trial [Sultopride versus haloperidol dans le traitement des etats psychotiques aigus]. Annales de Psychiatrie1989; Vol. 4, issue 1:92‐8. ">Ropert 1989</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0110" title="Omori IchiroM , WangJ , SoaresB , FentonM . Sulpiride versus other antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD008126] ">Omori 2009</a>, <a href="./references#CD009268-bbs2-0117" title="Soares BernardoGO , FentonM , ChueP . Sulpiride for schizophrenia. Cochrane Database of Systematic Reviews1999, Issue 1. [DOI: 10.1002/14651858.CD001162] ">Soares 1999</a> </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD009268-sec-0184"> <h6 class="title">2.2 Trials</h6> <p>The number of studies providing data adverse events was low, as well as the overall quality of the included studies. Thus it would be of interest to have newer and longer studies examining the difference between haloperidol and low‐potency antipsychotic drugs, as first‐generation antipsychotic drugs are still frequently prescribed, not only in developing countries but also in some industrial nations such as Germany. <a href="#CD009268-tbl-0004">Table 3</a> presents an outline for a study design. </p> <div class="table" id="CD009268-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Design of a future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised ‐ clearly described generation of sequence and concealment of allocation.<br/> Blinding: double ‐ described and tested.<br/> Duration: 6 months. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>People with schizophrenia or schizophrenia‐like disorder.<br/> N = 500.<br/> Age: any.<br/> Sex: both.<br/> History: any. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. High‐potency antipsychotic drug (haloperidol).</p> <p>2. Low‐potency antipsychotic drugs.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Response (primary outcome)</p> <p>Global state (number of participants improved)</p> <p>Leaving the study early (including specific causes)</p> <p>Death (natural and unnatural causes)</p> <p>Quality of life</p> <p>Satisfaction with care</p> <p>Days in hospital</p> <p>Number of healthy days</p> <p>Side‐effects</p> <p>Employment and other measures of functioning</p> </td> </tr> </tbody> </table> </div> </section> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009268-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009268-sec-0022"></div> <div class="table" id="CD009268-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Clinical response to treatment</b> <br/> Follow‐up: 2‐12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.11</b> <br/> (0.86 to 1.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>574<br/> (14 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>361 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>401 per 1000</b> <br/> (310 to 520) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>334 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>371 per 1000</b> <br/> (287 to 481) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early ‐ Due to any reason</b> <br/> Follow‐up: 1‐3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.82</b> <br/> (0.38 to 1.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>408<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>164 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>135 per 1000</b> <br/> (62 to 291) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>136 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>112 per 1000</b> <br/> (52 to 241) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects ‐ at least one adverse effect</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.97</b> <br/> (0.69 to 5.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>158<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>346 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>681 per 1000</b> <br/> (239 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>235 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>463 per 1000</b> <br/> (162 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects ‐ movement disorders ‐ At least one movement disorder</b> <br/> Follow‐up: 1‐3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.64</b> <br/> (1.22 to 2.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>170<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>414 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>679 per 1000</b> <br/> (505 to 914) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>375 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>615 per 1000</b> <br/> (458 to 829) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects ‐ other ‐ Sedation</b> <br/> Follow‐up: 6‐12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.3</b> <br/> (0.11 to 0.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>44<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> <br/> (55 to 410) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>420 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b> <br/> (46 to 344) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. <br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: rated 'serious' ‐ many studies did not report the methods for sequence generation and/or allocation concealment, missing or unclear results for incomplete outcome data and selective reporting.<br/> <sup>2</sup> Imprecision: rated 'serious' ‐ the total number of events is less than 300 and the estimate of effect includes appreciable benefit/harm.<br/> <sup>3</sup> Inconsistency: rated 'serious' ‐ the P value for heterogeneity was statistically significant and the I‐square higher than 80%, the direction of the effect was not the same for all the studies.<br/> <sup>4</sup> Imprecision: rated 'serious' ‐ only a few studies contributed to this event and the confidence interval was large. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009268-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009268-sec-0023"></div> <section id="CD009268-sec-0024"> <h3 class="title" id="CD009268-sec-0024">Description of the condition</h3> <p>Schizophrenia is often a chronic and disabling psychiatric disorder. It afflicts approximately one per cent of the population world‐wide with little gender differences (<a href="./references#CD009268-bbs2-0065" title="BergerM . Psychische Erkrankungen. Klinik und Therapie. 2nd Edition. München: Urban &amp; Fischer, 2003. ">Berger 2003</a>). The typical manifestations of schizophrenia are 'positive' symptoms such as fixed, false beliefs (delusions) and perceptions without cause (hallucinations), 'negative' symptoms such as apathy and lack of drive, disorganisation of behaviour and thought, and catatonic symptoms such as mannerisms and bizarre posturing (<a href="./references#CD009268-bbs2-0068" title="CarpenterWT , BuchananRW . Schizophrenia. New England Journal of Medicine1994;330:681‐90. ">Carpenter 1994</a>). The degree of suffering and disability is considerable with 80% to 90% not working (<a href="./references#CD009268-bbs2-0107" title="MarwahaS , JohnsonS . Schizophrenia and employment ? a review. Social Psychiatry and Psychiatric Epidemiology2004;39:337‐49. ">Marvaha 2004</a>) and up to 10% dying by suicide (<a href="./references#CD009268-bbs2-0124" title="TsuangMT . Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry1978;35:153‐5. ">Tsuang 1978</a>). </p> </section> <section id="CD009268-sec-0025"> <h3 class="title" id="CD009268-sec-0025">Description of the intervention</h3> <p>Antipsychotic drugs are the core treatment for schizophrenia. All antipsychotic drugs block, to a greater or lesser extent, D2‐receptors in the brain. They can be classified according to their biochemical structure (e.g. butyrophenones, phenothiazines, thioxanthenes etc.), their risk of producing movement disorders ('atypical' versus 'typical' antipsychotics) and the doses necessary for an antipsychotic effect (high‐potency versus low‐potency antipsychotics). The classification into high‐potency and low‐potency medication means that for low‐potency antipsychotic drugs higher doses are necessary to obtain the same dopamine receptor occupancy and efficacy (<a href="./references#CD009268-bbs2-0115" title="SeemanP , LeeT . Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science1975;188:1217‐9. ">Seeman 1975</a>). In this context, haloperidol belongs to the high‐potency antipsychotic drug group. It is the most frequently used conventional antipsychotic drug in many countries including Germany (<a href="./references#CD009268-bbs2-0096" title="KayeJA , BradburyBD , JickH . Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population‐based observational study. British Journal of Clinical Pharmacology2003;56:569‐75. ">Kaye 2003</a>; <a href="./references#CD009268-bbs2-0105" title="LohseMJ , LorenzenA , Müller‐OerlinghausenB . Psychotropic drugs [Psychopharmaka]. Arzneimittel Verordnungs Report2005:820‐64. ">Lohse 2005</a>; <a href="./references#CD009268-bbs2-0112" title="PatonC , LelliottP , HarringtonM . Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. Journal of Psychopharmacology2003;17:223‐9. ">Paton 2003</a>). Haloperidol is mostly indicated in schizophrenia, acute psychosis and delirium. </p> <p>Low‐potency antipsychotic drugs will be the comparator drugs in this review. Typical examples of low‐potency antipsychotic drugs are chlorpromazine, chlorprothixene, thioridazine or levomepromazine. It is an old psychiatric dogma that can be found in textbooks and guidelines that ‐ with the exception of clozapine ‐ there is no difference in efficacy between any antipsychotic compounds (<a href="./references#CD009268-bbs2-0087" title="GaebelW , FalkaiP , WeinmannS . Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff, 2006. ">Gaebel 2006</a>; <a href="./references#CD009268-bbs2-0098" title="LehmanAF , LiebermanJA , DixonLB . Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry2004;161:1‐56. ">Lehman 2004</a>). Nevertheless, low‐potency antipsychotic drugs are often clinically perceived as less efficacious than high‐potency compounds, and high‐ and low‐potency antipsychotics also seem to differ in their adverse effects. Low‐potency drugs have a high incidence of sedation or hypotonia, whereas high‐potency drugs produce most extrapyramidal adverse effects. </p> </section> <section id="CD009268-sec-0026"> <h3 class="title" id="CD009268-sec-0026">How the intervention might work</h3> <p>The theory is that schizophrenia is a chronic disorder caused by hyper‐dopaminergic states in the limbic system (<a href="./references#CD009268-bbs2-0065" title="BergerM . Psychische Erkrankungen. Klinik und Therapie. 2nd Edition. München: Urban &amp; Fischer, 2003. ">Berger 2003</a>). All antipsychotic drugs block dopamine receptors. Haloperidol was discovered by Paul Janssen and developed in 1957. With regard to dopamine receptor blockade, haloperidol is approximately 50 times more potent than chlorpromazine. It is a butyrophenone antipsychotic that is effective against delusions and hallucinations. It is a strong dopamine (mainly D2) receptor antagonist with antipsychotic properties and antiemetic properties. Haloperidol effectively blocks receptors in the limbic system of the brain. It has a rapid onset of action lasting three to six hours and a bioavailability of 60%. The elimination half‐life period is about 12 to 36 hours. However, the dopaminergic action is blocked in the nigrostriatal pathways and this blockage can lead to extrapyramidal side‐effects. </p> <p>Low‐potency medications have a lower affinity for dopamine receptors so that a higher dose is required to effectively treat symptoms of schizophrenia. In addition, they block other than dopamine receptors, such as cholinergic or histaminergic receptors. This also explains the occurrence of adverse effects, which are potentially less frequent with high‐potency drugs, such as sedation or hypotonia. The cut‐off between high‐ and low‐potency drugs is not clear, but attempts have been made to express their relationship in terms of dose equivalence. The most frequently applied concept is based on chlorpromazine equivalents according to <a href="./references#CD009268-bbs2-0070" title="DavisJM . Overview: maintenance therapy in psychiatry: I. Schizophrenia. American Journal of Psychiatry1975;132(12):1237‐45. ">Davis 1974</a> or <a href="./references#CD009268-bbs2-0090" title="HaaseHJ . Dosierung der Neuroleptika. Ein Leitfaden für Klinik und Praxis unter besonderer Berücksichtigung psychotisch Kranker. Erlangen: Perimed fachbuch‐verlagsgesellschaft, 1983. ">Haase 1983</a> and provides data about comparable doses of various antipsychotic drugs to achieve a therapeutic effect similar to 100 mg chlorpromazine. </p> </section> <section id="CD009268-sec-0027"> <h3 class="title" id="CD009268-sec-0027">Why it is important to do this review</h3> <p>Systematic reviews on the comparative efficacy of high‐potency versus low‐potency antipsychotic drugs are not available. Cochrane reviews on the effects of specific conventional antipsychotic drugs have been published, but they compared the effects of one antipsychotic drug versus any other antipsychotic drugs (e.g. <i>Pimozide versus any other antipsychotic drug</i>, <a href="./references#CD009268-bbs2-0084" title="FentonM , RathboneJ , ReillyJ , SultanaA . Thioridazine for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD001944.pub2] ">Fenton 2007</a>) and thus did not consider the important classification in high‐potency and low‐potency antipsychotics. Due to this lack of evidence, treatment guidelines make statements such as “all conventional antipsychotics if adequately dosed have comparable efficacy” (German national schizophrenia guideline (<a href="./references#CD009268-bbs2-0087" title="GaebelW , FalkaiP , WeinmannS . Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff, 2006. ">Gaebel 2006</a>, also <i>see</i> the guideline of the World Federations of Societies of Biological Psychiatry (<a href="./references#CD009268-bbs2-0082" title="FalkaiP , WobrockT , LiebermanJ . World Federation of Societies of Biological Psychiatry (WFSBP) ‐ Guidelines for biological treatment of schizophrenia, part 1: Acute treatment of schizophrenia. World Journal of Biological Psychiatry2005;6:132‐91. ">Falkai 2005</a>)).<br/> <br/> These guidelines contrast with the clinical impression that low‐potency conventional antipsychotic drugs are less efficacious than high‐potency conventional antipsychotic drugs. The clinical consequences in following these guidelines are considerable, because high‐potency and low‐potency antipsychotics differ clearly in side‐effects. High‐potency antipsychotics often produce extrapyramidal symptoms, low‐potency antipsychotics on the other hand have strong sedating properties and often also lead to hypotension. </p> <p>Conventional antipsychotic drugs are still the mainstay of treatment in countries that can not afford newer, expensive 'atypical' or 'second‐generation' antipsychotic drugs and even in some industrialised countries such as Germany, conventional antipsychotic medications still account for 50% of the market‐share (<a href="./references#CD009268-bbs2-0105" title="LohseMJ , LorenzenA , Müller‐OerlinghausenB . Psychotropic drugs [Psychopharmaka]. Arzneimittel Verordnungs Report2005:820‐64. ">Lohse 2005</a>). Recent studies about these more expensive second‐generation antipsychotics have also called into question their superiority (<a href="./references#CD009268-bbs2-0092" title="JonesPB , BarnesTRE , DaviesL . Randomized controlled trial of the effect on quality of life of second‐ vs first‐generation antipsychotic drugs in schizophrenia ‐ cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Archives of General Psychiatry2006;63:1079‐86. ">Jones 2006</a>; <a href="./references#CD009268-bbs2-0102" title="LeuchtS , CorvesC , ArbterD , EngelR , LiC , DavisJM . A meta‐analysis comparing second‐generation and first‐generation antipsychotics for schizophrenia. Lancet2009;373:31‐41. ">Leucht 2009a</a>; <a href="./references#CD009268-bbs2-0104" title="LiebermanJA , StroupTS , McEvoyJP . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine2005;353:1209‐23. ">Lieberman 2005</a>). Therefore, research on older conventional agents is essential and has been asked for (<a href="./references#CD009268-bbs2-0103" title="LeuchtS , CorvesC , ArbterD , EngelRR , LiC , DavisJM . Second‐generation versus first‐generation antipsychotic drugs for schizophrenia: a meta‐analysis. Lancet2009;373(9657):31‐41. ">Leucht 2009b</a>). </p> <p>For a list of related reviews, please <i>see</i><a href="#CD009268-tbl-0002">Table 1</a>. </p> <div class="table" id="CD009268-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Series of similar reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Title</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus first‐generation antipsychotics for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0076" title="DoldM , LiC , TardyM , LeuchtS . Haloperidol versus first generation antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD009831] ">Dold 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Perphenazine versus low‐potency antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0119" title="TardyM , LeuchtS , PotapovA , EngelR , HuhnM , KomossaK . Perphenazine versus low‐potency first generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2011, Issue 10. [DOI: 10.1002/14651858.CD009369] ">Tardy 2011b</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluphenazine versus low‐potency antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0120" title="TardyM , LeuchtS , PotapovA , EngelR , HuhnM , KomossaK . Fluphenazine versus low‐potency first generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2011, Issue 8. [DOI: 10.1002/14651858.CD009230] ">Tardy 2011c</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trifluoperazine versus low‐potency antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0121" title="TardyM , LeuchtS , PotapovA , EngelR , DoldM , KisslingW . Trifluoperazine versus low‐potency first generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2011, Issue 10. [DOI: 10.1002/14651858.CD009396] ">Tardy 2011d</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flupenthixol versus low‐potency antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0122" title="TardyM , LeuchtS , PotapovA , EngelR , DoldM , KisslingW . Flupenthixol versus low‐potency first generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2011, Issue 8. [DOI: 10.1002/14651858.CD009227] ">Tardy 2011e</a> </p> </td> </tr> </tbody> </table> </div> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009268-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009268-sec-0028"></div> <p>To review the effects of the high‐potency antipsychotic drug haloperidol versus low‐potency antipsychotic drugs. Haloperidol is sometimes perceived to be more efficacious than low‐potency antipsychotics and we tested this hypothesis in our review. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009268-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009268-sec-0029"></div> <section id="CD009268-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009268-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled (parallel group or cross‐over) trials that had a minimum follow‐up duration of three weeks. We included trials that were described as randomised or where randomisation was implied. We excluded quasi‐randomised trials, such as those that used alternation, an open list of random numbers, or any other method of recruitment where allocation to interventions was predictable. </p> </section> <section id="CD009268-sec-0032"> <h4 class="title">Types of participants</h4> <p>People with schizophrenia and schizophrenia‐like psychoses (schizophreniform and schizoaffective disorders). There is no clear evidence that the schizophrenia‐like psychoses are caused by fundamentally different disease processes or require different treatment approaches (<a href="./references#CD009268-bbs2-0068" title="CarpenterWT , BuchananRW . Schizophrenia. New England Journal of Medicine1994;330:681‐90. ">Carpenter 1994</a>). We included studies irrespective of the diagnostic criteria used. Diagnostic criteria, such as ICD 10 (International Classification of Diseases) or DSM‐IV (Diagnostic and Statistical Manual ‐ Version IV), are not routinely used in clinical practice and restricting inclusion to trials that used operationally defined diagnostic criteria would have reduced generalisation and representativeness. </p> <p>We were interested in making sure that information is as relevant to the current care of people with schizophrenia as possible so proposed to clearly highlight the current clinical state (acute, early post‐acute, partial remission, remission) as well as the stage (prodromal, first episode, early illness, persistent) and as to whether the studies primarily focused on people with particular problems (for example, negative symptoms, treatment‐resistant illnesses). </p> </section> <section id="CD009268-sec-0033"> <h4 class="title">Types of interventions</h4> <section id="CD009268-sec-0034"> <h5 class="title">1. Intervention: Haloperidol</h5> <p>Any dose of oral mode of administration (no depots, no short‐acting parenteral forms of administration).<br/> <br/> We a priori decided that haloperidol would be the intervention because it is sometimes perceived to be more efficacious than low‐potency drugs. Therefore, our hypothesis was that haloperidol is more efficacious and was thus chosen as the intervention drug. </p> </section> <section id="CD009268-sec-0035"> <h5 class="title">2. Low‐potency antipsychotic drugs</h5> <p>The control interventions were low‐potency conventional antipsychotic drugs, any oral form of administration and any dose. We used the dose equivalence tables by Davis (<a href="./references#CD009268-bbs2-0070" title="DavisJM . Overview: maintenance therapy in psychiatry: I. Schizophrenia. American Journal of Psychiatry1975;132(12):1237‐45. ">Davis 1974</a>) and/or Haase (<a href="./references#CD009268-bbs2-0090" title="HaaseHJ . Dosierung der Neuroleptika. Ein Leitfaden für Klinik und Praxis unter besonderer Berücksichtigung psychotisch Kranker. Erlangen: Perimed fachbuch‐verlagsgesellschaft, 1983. ">Haase 1983</a>) to define drugs as low‐potency with a chlorpromazine equivalence roughly equal or higher than chlorpromazine. The chlorpromazine equivalence dose of sulpiride is often estimated to be approximately 100. However, it has similar properties as amisulpride, which is an atypical antipsychotic and thus not within the scope of the review. Moreover, sulpiride does not cause a lot of sedation, which is an important characteristic of low‐potency antipsychotics. Therefore, we decided to cover sulpiride in another Cochrane review on haloperidol (<a href="./references#CD009268-bbs2-0076" title="DoldM , LiC , TardyM , LeuchtS . Haloperidol versus first generation antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD009831] ">Dold 2012</a>). </p> </section> </section> <section id="CD009268-sec-0036"> <h4 class="title">Types of outcome measures</h4> <section id="CD009268-sec-0037"> <h5 class="title">Primary outcomes</h5> <section id="CD009268-sec-0038"> <h6 class="title">1. Clinical response</h6> <p>Response to treatment as defined by the original studies</p> </section> </section> <section id="CD009268-sec-0039"> <h5 class="title">Secondary outcomes</h5> <section id="CD009268-sec-0040"> <h6 class="title">1. Mental state: symptoms of schizophrenia</h6> <p>1.1 Overall symptoms ‐ average score/change in mental state<br/> 1.2 Positive symptoms ‐ average score/change in positive symptoms<br/> 1.3 Negative symptoms ‐ average score/change in negative symptoms </p> </section> <section id="CD009268-sec-0041"> <h6 class="title">2. Global state: average score/change in global state</h6> </section> <section id="CD009268-sec-0042"> <h6 class="title">3. Relapse ‐ as defined by each of the studies</h6> </section> <section id="CD009268-sec-0043"> <h6 class="title">4. Leaving the study early</h6> <p>4.1 Acceptability of treatment ‐ leaving the study early due to any reason<br/> 4.2 Leaving the study early due to inefficacy of treatment<br/> 4.3 Leaving the study early due to side‐effects </p> </section> <section id="CD009268-sec-0044"> <h6 class="title">5. Service use</h6> <p>5.1 Rehospitalisation<br/> 5.2 Days in hospital<br/> 5.3 Healthy days </p> </section> <section id="CD009268-sec-0045"> <h6 class="title">6. Death</h6> <p>6.1 Death (all causes)<br/> 6.2 Suicide </p> </section> <section id="CD009268-sec-0046"> <h6 class="title">7. Adverse effects</h6> <p>7.1 At least one adverse effect<br/> 7.2 Extrapyramidal/movement disorders<br/> 7.3 Cardiac effects<br/> 7.4 Hypotension<br/> 7.5 Sedation<br/> 7.6 Weight gain<br/> 7.7 Other </p> </section> <section id="CD009268-sec-0047"> <h6 class="title">8. Quality of life</h6> </section> <section id="CD009268-sec-0048"> <h6 class="title">9. Participant's/carer`s satisfaction with care</h6> </section> <section id="CD009268-sec-0049"> <h6 class="title">10. Economic outcomes</h6> </section> </section> </section> </section> <section id="CD009268-sec-0050"> <h3 class="title">Search methods for identification of studies</h3> <p>No language restriction was applied within the limitations of the search tools.</p> <section id="CD009268-sec-0051"> <h4 class="title">Electronic searches</h4> <p>We searched the ‘Cochrane Schizophrenia Group Trials Register’ for relevant studies (July 2010) using the phrase: </p> <p>[(*haloperidol* in intervention of STUDY) OR (*haloperidol* in title, abstract and index terms of REFERENCE entered &gt;=01/05/10)] </p> <p>This register is compiled by systematic searches of major databases, handsearches and conference proceedings (<i>see</i><a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">Group Module</a>). </p> </section> <section id="CD009268-sec-0052"> <h4 class="title">Searching other resources</h4> <section id="CD009268-sec-0053"> <h5 class="title">1. Reference searching</h5> <p>We inspected the references of all identified studies for more trials.</p> </section> <section id="CD009268-sec-0054"> <h5 class="title">2. Previous reviews</h5> <p>We searched previous conventional reviews (<a href="./references#CD009268-bbs2-0071" title="DavisJM , BarterJT , KaneJM . Antipsychotic drugs. Comprehensive Textbook of Psychiatry. Williams and Wilkins, 1989. ">Davis 1989</a>; <a href="./references#CD009268-bbs2-0097" title="KleinDF , DavisJM . Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore: Williams and Wilkins, 1969. ">Klein 1969</a>). </p> </section> <section id="CD009268-sec-0055"> <h5 class="title">3. Personal contact</h5> <p>We contacted the first author of each included study for missing information and for the existence of further studies. </p> </section> <section id="CD009268-sec-0056"> <h5 class="title">4. Drug companies</h5> <p>We contacted the original manufacturer of haloperidol (Janssen) and asked them for further relevant studies and for missing information on identified studies. </p> </section> </section> </section> <section id="CD009268-sec-0057"> <h3 class="title" id="CD009268-sec-0057">Data collection and analysis</h3> <section id="CD009268-sec-0058"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MT, MH) independently inspected all abstracts identified in the searches. Disagreement was resolved by discussion and where doubt still remained, we acquired the full article for further inspection. Once the full articles were obtained, at least two review authors (MT, MH) independently decided whether the studies met the review criteria. If disagreement could not be resolved by discussion, we resolved it with a third review author (SL) or sought further information from the study authors. </p> </section> <section id="CD009268-sec-0059"> <h4 class="title">Data extraction and management</h4> <section id="CD009268-sec-0060"> <h5 class="title">1. Extraction</h5> <p>Two review authors (MT, MH) independently extracted data from <i>all</i> selected trials. Any disagreement was discussed, decisions documented and, if necessary, authors of studies were contacted for clarification. With remaining problems SL helped clarify issues and those final decisions were documented. Attempts were made to contact authors through an open‐ended request in order to obtain missing information or for clarification whenever necessary. </p> </section> <section id="CD009268-sec-0061"> <h5 class="title">2. Management</h5> <section id="CD009268-sec-0062"> <h6 class="title">2.1 Forms</h6> <p>We extracted data onto simple standard forms.</p> </section> <section id="CD009268-sec-0063"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if:<br/> a. the psychometric properties of the measuring instrument had been described in a peer‐reviewed journal (<a href="./references#CD009268-bbs2-0106" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); and<br/> b. the measuring instrument was not written or modified by one of the trialists for that particular trial. </p> </section> <section id="CD009268-sec-0064"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>There are advantages of both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided primarily to use endpoint data and only use change data if the former were not available. Endpoint and change data were combined in the analysis as we used mean differences (MD) rather than standardised mean differences (SMD) throughout (<a href="./references#CD009268-bbs2-0091" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>, <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Chapter 9.4.5.2 ). </p> </section> <section id="CD009268-sec-0065"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we aimed to apply the following standards to all data before inclusion: a) standard deviations (SD) and means were reported in the paper or obtainable from the authors; b) when a scale starts from the finite number zero, the SD, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution), (<a href="./references#CD009268-bbs2-0060" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313:1200. ">Altman 1996</a>); c) if a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS) <a href="./references#CD009268-bbs2-0095" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi‐Health Systems, 1986. ">Kay 1986</a>), which can have values from 30 to 210), the calculation described above was modified to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S‐S min), where S is the mean score and S min is the minimum score. Endpoint scores on scales often have a finite start and end point and these rules can be applied. Skewed data from studies of less than 200 participants would have been entered as other data within the <a href="./references#CD009268-sec-0186" title="">Data and analyses</a> section rather than into a statistical analysis. Skewed data pose less of a problem when looking at means if the sample size is large and data from studies with over 200 participants would have been entered into statistical syntheses.<br/> When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not and skewed change data were entered into statistical analysis. </p> </section> <section id="CD009268-sec-0066"> <h6 class="title">2.5 Common measure</h6> <p>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD009268-sec-0067"> <h6 class="title">2.6 Conversion of continuous to binary</h6> <p>Where possible, efforts were made to convert outcome measures to dichotomous data. This could be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It was generally assumed that if there had been a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD009268-bbs2-0111" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐12. ">Overall 1962</a>) or the PANSS (<a href="./references#CD009268-bbs2-0095" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi‐Health Systems, 1986. ">Kay 1986</a>), this could be considered as a clinically significant response (<a href="./references#CD009268-bbs2-0100" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . What does the PANSS mean?. Schizophrenia Research2005;79:231‐8. ">Leucht 2005a</a>; <a href="./references#CD009268-bbs2-0101" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry2005;187:366‐71. ">Leucht 2005b</a>). If data based on these thresholds were not available, we used the primary cut‐off presented by the original authors. </p> </section> <section id="CD009268-sec-0068"> <h6 class="title">2.7 Direction of graphs</h6> <p>Where possible, we entered data in such a way that the area to the left of the line of no effect indicates a favourable outcome for haloperidol. Where keeping to this made it impossible to avoid outcome titles with clumsy double‐negatives (e.g. 'Not improved'), we did report data where the left of the line indicates an unfavourable outcome. This is noted in the relevant graphs. </p> </section> <section id="CD009268-sec-0069"> <h6 class="title">2.8 'Summary of findings' table</h6> <p>We used the GRADE approach to interpret findings (<a href="./references#CD009268-bbs2-0114" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359‐83. ">Schünemann 2008</a>) and GRADE profiler (<a href="http://www.ims.cochrane.org/revman/gradepro" target="_blank">GRADE</a>) to import data from RevMan 5 (<a href="http://www.ims.cochrane.org/revman" target="_blank">Review Manager</a>) to create a 'Summary of findings' table. These tables provide outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes rated as important to patient‐care and decision making. We have selected the following long‐term main outcomes for inclusion in the summary of findings table. </p> <p>We anticipated including the following short or medium‐term outcomes in a 'Summary of findings' table. </p> <p> <ol id="CD009268-list-0001"> <li> <p>Response to treatment</p> </li> <li> <p>Leaving the study early due to any reason</p> </li> <li> <p>Adverse effect ‐ at least one adverse effect</p> </li> <li> <p>Adverse effects ‐ movement disorders ‐ at least one movement disorder</p> </li> <li> <p>Adverse effects ‐ sedation</p> </li> <li> <p>Death</p> </li> <li> <p>Quality of life</p> </li> </ol> </p> </section> </section> </section> <section id="CD009268-sec-0070"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Again working independently, two authors assessed risk of bias using the tool described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009268-bbs2-0091" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). This tool encourages consideration of how the sequence was generated, how allocation was concealed, the integrity of blinding at outcome, the completeness of outcome data, selective reporting and other biases. </p> <p>The risk of bias in each domain and overall were assessed and categorised into:</p> <p>A. Low risk of bias: plausible bias unlikely to seriously alter the results (categorised as 'Yes' in 'Risk of bias' table)<br/> B. High risk of bias: plausible bias that seriously weakens confidence in the results (categorised as 'No' in 'Risk of bias' table)<br/> C. Unclear risk of bias: plausible bias that raises some doubt about the results (categorised as 'Unclear' in 'Risk of bias' table) </p> <p>If the raters disagreed, the final rating was made by consensus with the involvement of another member of the review group. Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the studies to obtain further information. We reported non‐concurrence in quality assessment. </p> </section> <section id="CD009268-sec-0071"> <h4 class="title">Measures of treatment effect</h4> <section id="CD009268-sec-0072"> <h5 class="title">1. Dichotomous data</h5> <p>For binary outcomes we calculated a standard estimation of the random‐effects risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<a href="./references#CD009268-bbs2-0067" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie1999;54(4):405‐11. ">Boissel 1999</a>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<a href="./references#CD009268-bbs2-0072" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25‐28th; Cape Town, South Africa. Cape Town, 2000. ">Deeks 2000</a>). This misinterpretation then leads to an overestimate of the impression of the effect. Where possible, efforts were made to convert outcome measures to dichotomous data. This could be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It was generally assumed that if there had been a 50% reduction in a scale‐derived score such as the BPRS (<a href="./references#CD009268-bbs2-0111" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐12. ">Overall 1962</a>) or the PANSS (<a href="./references#CD009268-bbs2-0095" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi‐Health Systems, 1986. ">Kay 1986</a>), this could be considered as a clinically significant response (<a href="./references#CD009268-bbs2-0100" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . What does the PANSS mean?. Schizophrenia Research2005;79:231‐8. ">Leucht 2005a</a>; <a href="./references#CD009268-bbs2-0101" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry2005;187:366‐71. ">Leucht 2005b</a>). If data based on these thresholds were not available, we used the primary cut‐off presented by the original authors. </p> </section> <section id="CD009268-sec-0073"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes we estimated a mean difference (MD) between groups using the random‐effects model as this takes into account any differences between studies even if there is no statistically significant heterogeneity. We did not calculate standardised mean differences (SMD) measures. There was one exception to this rule, however. In the case of where scales were of such similarity to allow pooling we calculated the SMD and, whenever possible, transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD009268-sec-0074"> <h4 class="title">Unit of analysis issues</h4> <section id="CD009268-sec-0075"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a 'unit of analysis' error (<a href="./references#CD009268-bbs2-0075" title="DivineGW , BrownJT , FrazerLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7:623‐9. ">Divine 1992</a>) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<a href="./references#CD009268-bbs2-0066" title="BlandJM , KerrySM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600. ">Bland 1997</a>; <a href="./references#CD009268-bbs2-0088" title="GullifordMC , UkoumunneOC , ChinnS . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). </p> <p>Had we identified any cluster randomised trials and clustering had not been accounted for in primary studies, we planned to present data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. Where clustering had been incorporated into the analysis of primary studies, we would have presented these data as if from a non‐cluster randomised study, but adjusted for the clustering effect. If a cluster study had been appropriately analysed taking into account intra‐class correlation co‐efficient and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique, where the natural logarithm of the effect estimate (and standard errors) for all included trials for that outcome would be calculated and entered into <a href="http://www.ims.cochrane.org/revman" target="_blank">RevMan</a> along with the log of the effect estimate (and standard errors) from the cluster randomised trial(s). We would have used methods described in section 7.7.7.2 and 7.7.7.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009268-bbs2-0091" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>) to obtain standard errors. </p> </section> <section id="CD009268-sec-0076"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase the participants can differ systematically from their initial state despite a wash‐out phase. For the same reason, cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD009268-bbs2-0081" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31:140‐9. ">Elbourne 2002</a>). As both effects are very likely in schizophrenia, randomised cross‐over studies were eligible but we used only data up to the point of first cross‐over. </p> </section> <section id="CD009268-sec-0077"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>If we had included any studies involving more than two treatment arms, if relevant, the additional treatment arms would have been presented in comparisons. If data were binary these would simply have been added and combined within the two‐by‐two table. If data were continuous, we would have combined data following the formula in section <a href="http://books.google.co.uk/books?id=s11gCx4LS_EC%26pg=PT199%26lpg=PT199%26dq=7.7.3.8+combining+groups%26source=bl%26ots=FePxt5qxZI%26sig=8u2Dow36cB41x1tXqtfubVlBFVk%26hl=en%26ei=2IKXTOsylryMB-WIwekF%26sa=X%26oi=book_result%26ct=result%26resnum=3%26ved=0CBsQ6AEwAg#v=onepage%26q=7.7.3.8%20combining%20groups%26f=false" target="_blank">7.7.3.8</a>  (Combining groups) of the <i>Cochrane Handbook for Systematic Reviews of Interventions (</i><a href="./references#CD009268-bbs2-0091" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a><i>)</i>. Where the additional treatment arms were not relevant, the data would not have been reproduced. </p> </section> </section> <section id="CD009268-sec-0078"> <h4 class="title">Dealing with missing data</h4> <section id="CD009268-sec-0079"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD009268-bbs2-0128" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). The loss to follow‐up in randomised schizophrenia trials is often considerable calling the validity of the results into question. Nevertheless, it is unclear which degree of attrition leads to a high degree of bias. We did not exclude trials from outcomes on the basis of the percentage of participants completing them. We, however, used the 'Risk of bias' tool described above to indicate potential bias when more than 25% of the participants from the haloperidol group and low‐potency drug group left the studies prematurely (<a href="./references#CD009268-bbs2-0128" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>), when the reasons for attrition differed between the intervention and the control group, and when no appropriate imputation strategies were applied. </p> </section> <section id="CD009268-sec-0080"> <h5 class="title">2. Dichotomous data</h5> <p>Data were presented on a 'once‐randomised‐always‐analyse' basis, assuming an intention‐to‐treat (ITT) analysis. If the authors applied such a strategy, we used their results. If the original authors presented only the results of the per‐protocol or completer population, we assumed that those participants lost to follow‐up would have had the same percentage of events as those who remained in the study. </p> </section> <section id="CD009268-sec-0081"> <h5 class="title">3. Continuous data</h5> <section id="CD009268-sec-0082"> <h6 class="title">3.1 Attrition</h6> <p>Intention‐to‐treat (ITT) was used when available. We anticipated that in some studies, in order to do an ITT analysis, the method of last observation carried forward (LOCF) would be employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<a href="./references#CD009268-bbs2-0099" title="LeonAC , MallinckrodtCH , Chuang‐SteinC , ArchibaldDG , ArcherGE , ChartierK . Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry2006;59:1001‐5. ">Leon 2006</a>). Therefore, where LOCF data were used in the analysis, it was indicated in the review. </p> </section> <section id="CD009268-sec-0083"> <h6 class="title">3.2 Standard deviations</h6> <p>We first tried to obtain the missing values from the authors. If not available, where there were missing measures of variance for continuous data but an exact standard error (SE) and confidence interval were available for group means, and either 'P' value or 't' value were available for differences in mean, we calculated them according to the rules described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009268-bbs2-0091" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>): When only the SE is reported, standard deviations (SDs) are calculated by the formula SD = SE * square root (n). Chapters 7.7.3 and 16.1.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009268-bbs2-0091" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>) present detailed formulae for estimating SDs from P values, t or F values, confidence intervals, ranges or other statistics. If these formulae did not apply, we calculated the SDs according to a validated imputation method, which is based on the SDs of the other included studies (<a href="./references#CD009268-bbs2-0085" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(1):7‐10. ">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study's outcome and thus to lose information. We nevertheless examined the validity of the imputations in a sensitivity analysis excluding imputed values. </p> </section> </section> </section> <section id="CD009268-sec-0084"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD009268-sec-0085"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies without any comparison group to judge clinical heterogeneity. </p> <p>We simply inspected all studies for clearly outlying situations or people which we had not predicted would arise and discussed them fully, if such situations or participants arose.. </p> </section> <section id="CD009268-sec-0086"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise and discussed them if they were evident. </p> </section> <section id="CD009268-sec-0087"> <h5 class="title">3. Statistical</h5> <section id="CD009268-sec-0088"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD009268-sec-0089"> <h6 class="title">3.2 Employing the I<sup>2</sup> statistic </h6> <p>Heterogeneity between studies was investigated by considering the I<sup>2</sup> method alongside the Chi<sup>2</sup> 'P' value. The I<sup>2</sup> provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD009268-bbs2-0091" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). The importance of the observed value of I<sup>2</sup> depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. 'P' value from Chi<sup>2</sup> test, or a confidence interval for I<sup>2</sup>). </p> <p>An I<sup>2</sup> estimate of 50% to 90% accompanied by a statistically significant Chi<sup>2</sup> statistic, may represent substantial heterogeneity (Section 9.5.2 <i>Cochrane Handbook for Systematic Reviews of Interventions</i> ‐ <a href="./references#CD009268-bbs2-0091" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>) and reasons for heterogeneity were explored. If the inconsistency was high and clear reasons were found, data were presented separately. </p> </section> </section> </section> <section id="CD009268-sec-0090"> <h4 class="title">Assessment of reporting biases</h4> <section id="CD009268-sec-0091"> <h5 class="title">1. Protocol versus full study</h5> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results. These are described in section 10.1 of the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD009268-bbs2-0091" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). If necessary, we tried to locate protocols of included randomised trials. If the protocol was available, outcomes in the protocol and in the published report were compared. If the protocol was not available, outcomes listed in the methods section of the trial report were compared with actually reported results. </p> </section> <section id="CD009268-sec-0092"> <h5 class="title">2. Funnel plot</h5> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD009268-bbs2-0080" title="EggerM , Davey‐SmithG , SchneiderM , MinderCSO . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;13:629‐34. ">Egger 1997</a>). These are again described in Section 10 of the <i>Cochrane Handbook for Systematic reviews of Interventions</i> (<a href="./references#CD009268-bbs2-0091" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We did not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar sizes. In addition to the usual inspection of funnel plots, we used the trim‐and‐fill method by Duval and Tweedy (<a href="./references#CD009268-bbs2-0079" title="DuvalS , TweedieR . Trim and fill: A simple funnel‐plot‐based method of testing and adjusting for publication bias in meta‐analysis. Biometrics2000;56(2):455‐63. ">Duval 2000</a>) to examine whether missing studies would have changed the mean effect size to an important extent. </p> </section> </section> <section id="CD009268-sec-0093"> <h4 class="title">Data synthesis</h4> <p>We employed a random‐effects model for analyses (<a href="./references#CD009268-bbs2-0073" title="Der‐SimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7:177‐88. ">Der‐Simonian 1986</a>). We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This does seem true to us and the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. Therefore, the random‐effects model is usually more conservative in terms of statistical significance, although as a disadvantage it puts added weight onto smaller studies, which can either inflate or deflate the effect size. We examined in a secondary analysis whether using a fixed‐effect model markedly changed the results of the primary outcome. </p> </section> <section id="CD009268-sec-0094"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD009268-sec-0095"> <h5 class="title">1. Subgroup analysis</h5> <p>All subgroup analyses were applied only to the primary outcome.</p> <section id="CD009268-sec-0096"> <h6 class="title">1.1 Different low‐potency drugs</h6> <p>Subgrouping was performed by comparing haloperidol with each single low‐potency antipsychotic separately. </p> </section> <section id="CD009268-sec-0097"> <h6 class="title">1.2 Clinical state, stage or problem</h6> <p>We tried to report data on subgroups of people in the same clinical state, stage and with similar problems. </p> </section> </section> <section id="CD009268-sec-0098"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>If inconsistency was high, this was reported. First, we investigated whether data had been entered correctly. Second, if data had been correct, the graph was visually inspected and outlying studies were successively removed to see if heterogeneity was restored. For this review we decided that should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, data were presented. If not, data were not pooled and issues discussed. We know of no supporting research for this 10% cut‐off but are investigating use of <a href="http://books.google.co.uk/books?id=jrOivWoZwr8C%26pg=PA127%26dq=prediction+intervals%26hl=en%26ei=V4iXTKaiIciVswbP0uVa%26sa=X%26oi=book_result%26ct=result%26resnum=1%26ved=0CCgQ6AEwAA#v=onepage%26q=prediction%20intervals%26f=false" target="_blank">prediction intervals</a> as an alternative to this unsatisfactory state. </p> <p>When unanticipated clinical or methodological heterogeneity were obvious, we simply stated hypotheses regarding these for future reviews or versions of this review. We did not anticipate undertaking analyses relating to these. </p> </section> </section> <section id="CD009268-sec-0099"> <h4 class="title">Sensitivity analysis</h4> <section id="CD009268-sec-0100"> <h5 class="title">1. Implication of randomisation</h5> <p>We aimed to include trials in a sensitivity analysis if they were described in some way as to imply randomisation. For the primary outcome we included these studies and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then all data were employed from these studies. </p> </section> <section id="CD009268-sec-0101"> <h5 class="title">2. Implication of non double‐blind trials</h5> <p>We aimed to include trials in a sensitivity analysis if participants and treating psychiatrists were not blinded. For the primary outcome we included these studies and if there was no substantive difference when the non double‐blind studies were added to the double‐blind studies, then all data were employed from these studies. </p> </section> <section id="CD009268-sec-0102"> <h5 class="title">3. Assessment of dosage</h5> <p>We aimed to include trials in a sensitivity analysis if doses between haloperidol and low‐potency antipsychotics were clearly discrepant by our judgement based on the chlorpromazine equivalence tables (<a href="./references#CD009268-bbs2-0070" title="DavisJM . Overview: maintenance therapy in psychiatry: I. Schizophrenia. American Journal of Psychiatry1975;132(12):1237‐45. ">Davis 1974</a>; <a href="./references#CD009268-bbs2-0090" title="HaaseHJ . Dosierung der Neuroleptika. Ein Leitfaden für Klinik und Praxis unter besonderer Berücksichtigung psychotisch Kranker. Erlangen: Perimed fachbuch‐verlagsgesellschaft, 1983. ">Haase 1983</a>; <a href="./references#CD009268-bbs2-0061" title="AndreasenNC , PresslerM , NopoulosP , MillerD , HoBC . Antipsychotic drug equivalents and dose‐years: A standardized method for comparing exposure to different drugs. Biological Psychiatry2010;67:255‐62. ">Andreasen 2010</a>). If there was no substantive difference when studies with discrepant doses were added, then we used all data from these studies. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009268-sec-0103" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009268-sec-0103"></div> <section id="CD009268-sec-0104"> <h3 class="title">Description of studies</h3> <p>For substantive description of studies please <i>see</i><a href="./references#CD009268-sec-0194" title="">Characteristics of included studies</a> and <a href="./references#CD009268-sec-0195" title="">Characteristics of excluded studies</a> tables. </p> <section id="CD009268-sec-0105"> <h4 class="title">Results of the search</h4> <p>The search strategy in the "Cochrane Schizophrenia Group Trials Register" generated 2239 reports of which 73 publications on 58 studies were closely inspected (<a href="#CD009268-fig-0001">Figure 1</a>). Seventeen studies (877 participants) met the inclusion criteria. No further studies were identified by reference search or by contacting the major manufacturer of haloperidol. </p> <div class="figure" id="CD009268-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009268-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD009268-sec-0106"> <h4 class="title">Included studies</h4> <section id="CD009268-sec-0107"> <h5 class="title">1. Length of trials</h5> <p>Of the included studies, nine had durations of up to one month (<a href="./references#CD009268-bbs2-0001" title="BiY . A relation study of the extrapyramidal symptoms, serum prolactin levels and clinical response during treatment of antipsychotics. Chinese Journal of Nervous and Mental Diseases1994;20(2):70‐3. ">Bi 1994</a>; <a href="./references#CD009268-bbs2-0002" title="BlinO , AzorinJM , BouhoursP . Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. Journal of Clinical Psychopharmacology1996; Vol. 16, issue 1:38‐44. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol and risperidone in 62 schizophrenic patients. Clinical Pharmacology and Therapeutics. France, 1992; Vol. 51, issue 2:189. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol, and risperidone in 62 schizophrenic patients. Psychopharmacology1992:31‐2. BlinO , AzorinJM , BouhoursP . Comparison of anxiolytic properties of levomepromazine, haloperidol and risperidone in schizophrenic patients. Biological Psychiatry. France, 1991; Vol. 29:388. BlinO , AzorinJM , BouhoursP , FondaraiJ . Anxiolytic profiles of risperidone, haloperidol, and levomepromazine in schizophrenia: a factorial and regression analysis. Proceedings of the 9th World Congress of Psychiatry; 1993 Jun 6‐12; Rio de Janeiro, Brazil. France, 1993:24. BlinO , AzorinJM , BouhoursPh , FondaraiJ . Comparison of risperidone, haloperidol and levomepromazine in schizophrenia: a factorial analysis and discriminant function analysis. Clinical Neuropharmacology1992; Vol. 15, issue Suppl 1. Pt B:169B. ">Blin 1996</a>; <a href="./references#CD009268-bbs2-0006" title="FoxW , GobbleIF , ClosM . A clinical comparison of trifluperidol, haloperidol and chlorpromazine. Current Therapeutic Research1964;6(6):409‐15. ">Fox 1964</a>; <a href="./references#CD009268-bbs2-0007" title="GallantDM , BishopM , Guerrero‐FigueroaR . Effects of two butyrophenone compounds on acute schizophrenic patients: speculation on the neurophysiologic sites of action. International Journal of Neuropsychiatry1967;3(1):53‐60. ">Gallant 1967</a>; <a href="./references#CD009268-bbs2-0008" title="KlimkeA , KlieserE , LehmannE , MieleL . Initial improvement as a criterion for drug choice in acute schizophrenia. Pharmacopsychiatry1993;26:25‐9. ">Klimke 1993</a>; <a href="./references#CD009268-bbs2-0010" title="NishizonoM . A comparative trial of zotepine, chlorpromazine and haloperidol in schizophrenic patients. Neuropsychopharmacology1994;10:30. ">Nishizono 1994</a>; <a href="./references#CD009268-bbs2-0013" title="SchmidtLG , SchüsslerG , KappesCV , Müller‐OerlinghausenB . Comparison of higher‐dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients [Vergleich einer höher dosierten Haloperidol‐Therapie mt einer Perazin‐Standard‐Therapie bei akut‐schizophrenen Patienten]. Nervenarzt1982;53(9):530‐6. ">Schmidt 1982</a>; <a href="./references#CD009268-bbs2-0015" title="ShalevA , HermeshH , RothbergJ , MunitzH . Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica1993; Vol. 87, issue 2:86‐91. ">Shalev 1993</a>; <a href="./references#CD009268-bbs2-0017" title="WhiteK , BuskJ , EatonE , GomezG , RazaniJ , SloaneRB . Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine. International Pharmacopsychiatry1981; Vol. 16, issue 1:34‐8. ">White 1981</a>). Two studies lasted six weeks (<a href="./references#CD009268-bbs2-0003" title="BorisonRL , SinhaD , HaverstockS , McLarnonMC , DiamondBI . Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double‐blind, placebo‐controlled trial. Psychopharmacology Bulletin1989; Vol. 25, issue 2:190‐3. ">Borison 1989</a>; <a href="./references#CD009268-bbs2-0005" title="DufresneRL , ValentinoD , KassDJ . Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacology Bulletin1993; Vol. 29, issue 2:249‐55. ">Dufresne 1993</a>) and six studies lasted between seven weeks and three months (<a href="./references#CD009268-bbs2-0004" title="ClarkML . Haloperidol versus chlorpromazine versus placebo. Psychopharmacology Bulletin1969; Vol. 5, issue 3:57‐9. ">Clark 1969</a>; <a href="./references#CD009268-bbs2-0009" title="McCreadieRG , MacDonaldIM . High dosage haloperidol in chronic schizophrenia. British Journal of Psychiatry1977; Vol. 131:310‐6. ">McCreadie 1977</a>; <a href="./references#CD009268-bbs2-0011" title="PrasadL , TownleyMC . Haloperidol and thioridazine in treatment of chronic schizophrenics. Diseases of the Nervous System1966;27(11):722‐6. ">Prasad 1966</a>; <a href="./references#CD009268-bbs2-0012" title="RompelH , SegalH . A comparison of the relative efficacy of serenace and chlorpromazine in the treatment of chronic schizophrenics. Journal of International Medical Research1978; Vol. 6, issue 2:126‐32. [MEDLINE: 344086] ">Rompel 1978</a>; <a href="./references#CD009268-bbs2-0014" title="SerafetinidesEA , ClarkML . Psychological effects of single dose antipsychotic medication. Biological Psychiatry1973; Vol. 7, issue 3:263‐7. SerafetinidesEA , CollinsS , ClarkML . Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease1972; Vol. 154, issue 1:31‐42. ">Serafetinides 1972</a>; <a href="./references#CD009268-bbs2-0016" title="WestonMJ , BentleyR , UnwinA , MorrisM , HarperMA . A comparative trial of haloperidol and thioridazine: management of chronic schizophrenia. Australian and New Zealand Journal of Psychiatry1973; Vol. 7, issue 1:52‐7. ">Weston 1973</a>). Thus, all studies fell into the short‐term category. </p> </section> <section id="CD009268-sec-0108"> <h5 class="title">2. Participants</h5> <p>In seven studies, participants were diagnosed according to clinical criteria (<a href="./references#CD009268-bbs2-0004" title="ClarkML . Haloperidol versus chlorpromazine versus placebo. Psychopharmacology Bulletin1969; Vol. 5, issue 3:57‐9. ">Clark 1969</a>, <a href="./references#CD009268-bbs2-0006" title="FoxW , GobbleIF , ClosM . A clinical comparison of trifluperidol, haloperidol and chlorpromazine. Current Therapeutic Research1964;6(6):409‐15. ">Fox 1964</a>; <a href="./references#CD009268-bbs2-0007" title="GallantDM , BishopM , Guerrero‐FigueroaR . Effects of two butyrophenone compounds on acute schizophrenic patients: speculation on the neurophysiologic sites of action. International Journal of Neuropsychiatry1967;3(1):53‐60. ">Gallant 1967</a>; <a href="./references#CD009268-bbs2-0011" title="PrasadL , TownleyMC . Haloperidol and thioridazine in treatment of chronic schizophrenics. Diseases of the Nervous System1966;27(11):722‐6. ">Prasad 1966</a>; <a href="./references#CD009268-bbs2-0012" title="RompelH , SegalH . A comparison of the relative efficacy of serenace and chlorpromazine in the treatment of chronic schizophrenics. Journal of International Medical Research1978; Vol. 6, issue 2:126‐32. [MEDLINE: 344086] ">Rompel 1978</a>; <a href="./references#CD009268-bbs2-0014" title="SerafetinidesEA , ClarkML . Psychological effects of single dose antipsychotic medication. Biological Psychiatry1973; Vol. 7, issue 3:263‐7. SerafetinidesEA , CollinsS , ClarkML . Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease1972; Vol. 154, issue 1:31‐42. ">Serafetinides 1972</a>; <a href="./references#CD009268-bbs2-0016" title="WestonMJ , BentleyR , UnwinA , MorrisM , HarperMA . A comparative trial of haloperidol and thioridazine: management of chronic schizophrenia. Australian and New Zealand Journal of Psychiatry1973; Vol. 7, issue 1:52‐7. ">Weston 1973</a>). Three studies used the Diagnostic and Statistical Manual Version III (DSM‐III) (<a href="./references#CD009268-bbs2-0062" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM III). Washington DC: American Psychiatric Association, 1980. ">APA 1980</a>) (<a href="./references#CD009268-bbs2-0003" title="BorisonRL , SinhaD , HaverstockS , McLarnonMC , DiamondBI . Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double‐blind, placebo‐controlled trial. Psychopharmacology Bulletin1989; Vol. 25, issue 2:190‐3. ">Borison 1989</a>; <a href="./references#CD009268-bbs2-0005" title="DufresneRL , ValentinoD , KassDJ . Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacology Bulletin1993; Vol. 29, issue 2:249‐55. ">Dufresne 1993</a>; <a href="./references#CD009268-bbs2-0015" title="ShalevA , HermeshH , RothbergJ , MunitzH . Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica1993; Vol. 87, issue 2:86‐91. ">Shalev 1993</a>) and one study the Diagnostic and Statistical Manual Version III Revised (DSM‐III‐R) (<a href="./references#CD009268-bbs2-0063" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd edition‐ Revised (DSM‐III‐R). Washington, DC: American Psychiatric Association, 1987. ">APA 1987</a>) (<a href="./references#CD009268-bbs2-0002" title="BlinO , AzorinJM , BouhoursP . Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. Journal of Clinical Psychopharmacology1996; Vol. 16, issue 1:38‐44. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol and risperidone in 62 schizophrenic patients. Clinical Pharmacology and Therapeutics. France, 1992; Vol. 51, issue 2:189. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol, and risperidone in 62 schizophrenic patients. Psychopharmacology1992:31‐2. BlinO , AzorinJM , BouhoursP . Comparison of anxiolytic properties of levomepromazine, haloperidol and risperidone in schizophrenic patients. Biological Psychiatry. France, 1991; Vol. 29:388. BlinO , AzorinJM , BouhoursP , FondaraiJ . Anxiolytic profiles of risperidone, haloperidol, and levomepromazine in schizophrenia: a factorial and regression analysis. Proceedings of the 9th World Congress of Psychiatry; 1993 Jun 6‐12; Rio de Janeiro, Brazil. France, 1993:24. BlinO , AzorinJM , BouhoursPh , FondaraiJ . Comparison of risperidone, haloperidol and levomepromazine in schizophrenia: a factorial analysis and discriminant function analysis. Clinical Neuropharmacology1992; Vol. 15, issue Suppl 1. Pt B:169B. ">Blin 1996</a>). One study used the Feighner´s criteria (<a href="./references#CD009268-bbs2-0083" title="FeighnerJP , RobinsE , GuzeSB , WoodruffRA , WinokurG , MunozR . Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry1972;26:57‐63. ">Feighner 1972</a>) (<a href="./references#CD009268-bbs2-0017" title="WhiteK , BuskJ , EatonE , GomezG , RazaniJ , SloaneRB . Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine. International Pharmacopsychiatry1981; Vol. 16, issue 1:34‐8. ">White 1981</a>) and one Schneiderian first rank symptoms (<a href="./references#CD009268-bbs2-0113" title="SchneiderK . Clinical Psychopathology. New York: Grune and Stratton, 1959. ">Schneider 1959</a>) (<a href="./references#CD009268-bbs2-0009" title="McCreadieRG , MacDonaldIM . High dosage haloperidol in chronic schizophrenia. British Journal of Psychiatry1977; Vol. 131:310‐6. ">McCreadie 1977</a>). Two studies used International Classification of Diseases, ninth revision (ICD‐9) (<a href="./references#CD009268-bbs2-0126" title="World Health Organization. The Ninth Revision of the International Classification of Diseases and Related Health Problems (ICD‐9). Geneva: World Health Organization, 1978. ">WHO 1978</a>) (<a href="./references#CD009268-bbs2-0008" title="KlimkeA , KlieserE , LehmannE , MieleL . Initial improvement as a criterion for drug choice in acute schizophrenia. Pharmacopsychiatry1993;26:25‐9. ">Klimke 1993</a>; <a href="./references#CD009268-bbs2-0013" title="SchmidtLG , SchüsslerG , KappesCV , Müller‐OerlinghausenB . Comparison of higher‐dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients [Vergleich einer höher dosierten Haloperidol‐Therapie mt einer Perazin‐Standard‐Therapie bei akut‐schizophrenen Patienten]. Nervenarzt1982;53(9):530‐6. ">Schmidt 1982</a>) and one ICD‐10 (<a href="./references#CD009268-bbs2-0127" title="World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD‐10). Geneva: World Health Organization, 1992. ">WHO 1992</a>) (<a href="./references#CD009268-bbs2-0010" title="NishizonoM . A comparative trial of zotepine, chlorpromazine and haloperidol in schizophrenic patients. Neuropsychopharmacology1994;10:30. ">Nishizono 1994</a>). One study (<a href="./references#CD009268-bbs2-0001" title="BiY . A relation study of the extrapyramidal symptoms, serum prolactin levels and clinical response during treatment of antipsychotics. Chinese Journal of Nervous and Mental Diseases1994;20(2):70‐3. ">Bi 1994</a>) diagnosed participants according to the Research Diagnositic Criteria (RDC) (<a href="./references#CD009268-bbs2-0118" title="SpitzerRL , RobinsE . Research diagnostic criteria: rationale and reliability. Archives of General Psychiatry1978;35(6):773‐82. ">Spitzer 1978</a>) and the Chinese classification of mental disorders (CCMD‐2). </p> <p>The mean age was 39.1 years (reported by 13 studies) and the mean age at onset was 28.3 years. The mean duration of illness was 11.3 years (as indicated by seven studies) and the mean number of previous hospitalisations was three (based on four studies). Four studies reported information on severity of illness at baseline (<a href="./references#CD009268-bbs2-0003" title="BorisonRL , SinhaD , HaverstockS , McLarnonMC , DiamondBI . Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double‐blind, placebo‐controlled trial. Psychopharmacology Bulletin1989; Vol. 25, issue 2:190‐3. ">Borison 1989</a>; <a href="./references#CD009268-bbs2-0005" title="DufresneRL , ValentinoD , KassDJ . Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacology Bulletin1993; Vol. 29, issue 2:249‐55. ">Dufresne 1993</a>; <a href="./references#CD009268-bbs2-0008" title="KlimkeA , KlieserE , LehmannE , MieleL . Initial improvement as a criterion for drug choice in acute schizophrenia. Pharmacopsychiatry1993;26:25‐9. ">Klimke 1993</a>; <a href="./references#CD009268-bbs2-0017" title="WhiteK , BuskJ , EatonE , GomezG , RazaniJ , SloaneRB . Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine. International Pharmacopsychiatry1981; Vol. 16, issue 1:34‐8. ">White 1981</a>), with scores between 35 and 59.9 on the Brief Psychiatric Rating Scale (BPRS) (<a href="./references#CD009268-bbs2-0111" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐12. ">Overall 1962</a>). </p> </section> <section id="CD009268-sec-0109"> <h5 class="title">3. Setting</h5> <p>Thirteen studies were conducted in hospitals (<a href="./references#CD009268-bbs2-0002" title="BlinO , AzorinJM , BouhoursP . Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. Journal of Clinical Psychopharmacology1996; Vol. 16, issue 1:38‐44. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol and risperidone in 62 schizophrenic patients. Clinical Pharmacology and Therapeutics. France, 1992; Vol. 51, issue 2:189. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol, and risperidone in 62 schizophrenic patients. Psychopharmacology1992:31‐2. BlinO , AzorinJM , BouhoursP . Comparison of anxiolytic properties of levomepromazine, haloperidol and risperidone in schizophrenic patients. Biological Psychiatry. France, 1991; Vol. 29:388. BlinO , AzorinJM , BouhoursP , FondaraiJ . Anxiolytic profiles of risperidone, haloperidol, and levomepromazine in schizophrenia: a factorial and regression analysis. Proceedings of the 9th World Congress of Psychiatry; 1993 Jun 6‐12; Rio de Janeiro, Brazil. France, 1993:24. BlinO , AzorinJM , BouhoursPh , FondaraiJ . Comparison of risperidone, haloperidol and levomepromazine in schizophrenia: a factorial analysis and discriminant function analysis. Clinical Neuropharmacology1992; Vol. 15, issue Suppl 1. Pt B:169B. ">Blin 1996</a>; <a href="./references#CD009268-bbs2-0004" title="ClarkML . Haloperidol versus chlorpromazine versus placebo. Psychopharmacology Bulletin1969; Vol. 5, issue 3:57‐9. ">Clark 1969</a>; <a href="./references#CD009268-bbs2-0006" title="FoxW , GobbleIF , ClosM . A clinical comparison of trifluperidol, haloperidol and chlorpromazine. Current Therapeutic Research1964;6(6):409‐15. ">Fox 1964</a>; <a href="./references#CD009268-bbs2-0007" title="GallantDM , BishopM , Guerrero‐FigueroaR . Effects of two butyrophenone compounds on acute schizophrenic patients: speculation on the neurophysiologic sites of action. International Journal of Neuropsychiatry1967;3(1):53‐60. ">Gallant 1967</a>; <a href="./references#CD009268-bbs2-0008" title="KlimkeA , KlieserE , LehmannE , MieleL . Initial improvement as a criterion for drug choice in acute schizophrenia. Pharmacopsychiatry1993;26:25‐9. ">Klimke 1993</a>; <a href="./references#CD009268-bbs2-0009" title="McCreadieRG , MacDonaldIM . High dosage haloperidol in chronic schizophrenia. British Journal of Psychiatry1977; Vol. 131:310‐6. ">McCreadie 1977</a>; <a href="./references#CD009268-bbs2-0011" title="PrasadL , TownleyMC . Haloperidol and thioridazine in treatment of chronic schizophrenics. Diseases of the Nervous System1966;27(11):722‐6. ">Prasad 1966</a>; <a href="./references#CD009268-bbs2-0012" title="RompelH , SegalH . A comparison of the relative efficacy of serenace and chlorpromazine in the treatment of chronic schizophrenics. Journal of International Medical Research1978; Vol. 6, issue 2:126‐32. [MEDLINE: 344086] ">Rompel 1978</a>; <a href="./references#CD009268-bbs2-0013" title="SchmidtLG , SchüsslerG , KappesCV , Müller‐OerlinghausenB . Comparison of higher‐dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients [Vergleich einer höher dosierten Haloperidol‐Therapie mt einer Perazin‐Standard‐Therapie bei akut‐schizophrenen Patienten]. Nervenarzt1982;53(9):530‐6. ">Schmidt 1982</a>; <a href="./references#CD009268-bbs2-0014" title="SerafetinidesEA , ClarkML . Psychological effects of single dose antipsychotic medication. Biological Psychiatry1973; Vol. 7, issue 3:263‐7. SerafetinidesEA , CollinsS , ClarkML . Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease1972; Vol. 154, issue 1:31‐42. ">Serafetinides 1972</a>; <a href="./references#CD009268-bbs2-0015" title="ShalevA , HermeshH , RothbergJ , MunitzH . Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica1993; Vol. 87, issue 2:86‐91. ">Shalev 1993</a>; <a href="./references#CD009268-bbs2-0016" title="WestonMJ , BentleyR , UnwinA , MorrisM , HarperMA . A comparative trial of haloperidol and thioridazine: management of chronic schizophrenia. Australian and New Zealand Journal of Psychiatry1973; Vol. 7, issue 1:52‐7. ">Weston 1973</a>; <a href="./references#CD009268-bbs2-0017" title="WhiteK , BuskJ , EatonE , GomezG , RazaniJ , SloaneRB . Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine. International Pharmacopsychiatry1981; Vol. 16, issue 1:34‐8. ">White 1981</a>). Four studies (<a href="./references#CD009268-bbs2-0001" title="BiY . A relation study of the extrapyramidal symptoms, serum prolactin levels and clinical response during treatment of antipsychotics. Chinese Journal of Nervous and Mental Diseases1994;20(2):70‐3. ">Bi 1994</a>; <a href="./references#CD009268-bbs2-0003" title="BorisonRL , SinhaD , HaverstockS , McLarnonMC , DiamondBI . Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double‐blind, placebo‐controlled trial. Psychopharmacology Bulletin1989; Vol. 25, issue 2:190‐3. ">Borison 1989</a>; <a href="./references#CD009268-bbs2-0005" title="DufresneRL , ValentinoD , KassDJ . Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacology Bulletin1993; Vol. 29, issue 2:249‐55. ">Dufresne 1993</a>; <a href="./references#CD009268-bbs2-0010" title="NishizonoM . A comparative trial of zotepine, chlorpromazine and haloperidol in schizophrenic patients. Neuropsychopharmacology1994;10:30. ">Nishizono 1994</a>) did not report on setting. </p> </section> <section id="CD009268-sec-0110"> <h5 class="title">4. Study size</h5> <p><a href="./references#CD009268-bbs2-0003" title="BorisonRL , SinhaD , HaverstockS , McLarnonMC , DiamondBI . Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double‐blind, placebo‐controlled trial. Psychopharmacology Bulletin1989; Vol. 25, issue 2:190‐3. ">Borison 1989</a> was the smallest study, randomising only 16 participants. Twelve studies (<a href="./references#CD009268-bbs2-0001" title="BiY . A relation study of the extrapyramidal symptoms, serum prolactin levels and clinical response during treatment of antipsychotics. Chinese Journal of Nervous and Mental Diseases1994;20(2):70‐3. ">Bi 1994</a>; <a href="./references#CD009268-bbs2-0004" title="ClarkML . Haloperidol versus chlorpromazine versus placebo. Psychopharmacology Bulletin1969; Vol. 5, issue 3:57‐9. ">Clark 1969</a>; <a href="./references#CD009268-bbs2-0005" title="DufresneRL , ValentinoD , KassDJ . Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacology Bulletin1993; Vol. 29, issue 2:249‐55. ">Dufresne 1993</a>; <a href="./references#CD009268-bbs2-0006" title="FoxW , GobbleIF , ClosM . A clinical comparison of trifluperidol, haloperidol and chlorpromazine. Current Therapeutic Research1964;6(6):409‐15. ">Fox 1964</a>; <a href="./references#CD009268-bbs2-0007" title="GallantDM , BishopM , Guerrero‐FigueroaR . Effects of two butyrophenone compounds on acute schizophrenic patients: speculation on the neurophysiologic sites of action. International Journal of Neuropsychiatry1967;3(1):53‐60. ">Gallant 1967</a>; <a href="./references#CD009268-bbs2-0009" title="McCreadieRG , MacDonaldIM . High dosage haloperidol in chronic schizophrenia. British Journal of Psychiatry1977; Vol. 131:310‐6. ">McCreadie 1977</a>; <a href="./references#CD009268-bbs2-0011" title="PrasadL , TownleyMC . Haloperidol and thioridazine in treatment of chronic schizophrenics. Diseases of the Nervous System1966;27(11):722‐6. ">Prasad 1966</a>; <a href="./references#CD009268-bbs2-0012" title="RompelH , SegalH . A comparison of the relative efficacy of serenace and chlorpromazine in the treatment of chronic schizophrenics. Journal of International Medical Research1978; Vol. 6, issue 2:126‐32. [MEDLINE: 344086] ">Rompel 1978</a>; <a href="./references#CD009268-bbs2-0013" title="SchmidtLG , SchüsslerG , KappesCV , Müller‐OerlinghausenB . Comparison of higher‐dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients [Vergleich einer höher dosierten Haloperidol‐Therapie mt einer Perazin‐Standard‐Therapie bei akut‐schizophrenen Patienten]. Nervenarzt1982;53(9):530‐6. ">Schmidt 1982</a>; <a href="./references#CD009268-bbs2-0014" title="SerafetinidesEA , ClarkML . Psychological effects of single dose antipsychotic medication. Biological Psychiatry1973; Vol. 7, issue 3:263‐7. SerafetinidesEA , CollinsS , ClarkML . Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease1972; Vol. 154, issue 1:31‐42. ">Serafetinides 1972</a>; <a href="./references#CD009268-bbs2-0015" title="ShalevA , HermeshH , RothbergJ , MunitzH . Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica1993; Vol. 87, issue 2:86‐91. ">Shalev 1993</a>; <a href="./references#CD009268-bbs2-0017" title="WhiteK , BuskJ , EatonE , GomezG , RazaniJ , SloaneRB . Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine. International Pharmacopsychiatry1981; Vol. 16, issue 1:34‐8. ">White 1981</a>) randomised between 20 and 40 participants. Four studies randomised more than 40 participants, <a href="./references#CD009268-bbs2-0002" title="BlinO , AzorinJM , BouhoursP . Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. Journal of Clinical Psychopharmacology1996; Vol. 16, issue 1:38‐44. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol and risperidone in 62 schizophrenic patients. Clinical Pharmacology and Therapeutics. France, 1992; Vol. 51, issue 2:189. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol, and risperidone in 62 schizophrenic patients. Psychopharmacology1992:31‐2. BlinO , AzorinJM , BouhoursP . Comparison of anxiolytic properties of levomepromazine, haloperidol and risperidone in schizophrenic patients. Biological Psychiatry. France, 1991; Vol. 29:388. BlinO , AzorinJM , BouhoursP , FondaraiJ . Anxiolytic profiles of risperidone, haloperidol, and levomepromazine in schizophrenia: a factorial and regression analysis. Proceedings of the 9th World Congress of Psychiatry; 1993 Jun 6‐12; Rio de Janeiro, Brazil. France, 1993:24. BlinO , AzorinJM , BouhoursPh , FondaraiJ . Comparison of risperidone, haloperidol and levomepromazine in schizophrenia: a factorial analysis and discriminant function analysis. Clinical Neuropharmacology1992; Vol. 15, issue Suppl 1. Pt B:169B. ">Blin 1996</a> (41 participants), <a href="./references#CD009268-bbs2-0008" title="KlimkeA , KlieserE , LehmannE , MieleL . Initial improvement as a criterion for drug choice in acute schizophrenia. Pharmacopsychiatry1993;26:25‐9. ">Klimke 1993</a> (50 participants), <a href="./references#CD009268-bbs2-0016" title="WestonMJ , BentleyR , UnwinA , MorrisM , HarperMA . A comparative trial of haloperidol and thioridazine: management of chronic schizophrenia. Australian and New Zealand Journal of Psychiatry1973; Vol. 7, issue 1:52‐7. ">Weston 1973</a> (86 participants) and <a href="./references#CD009268-bbs2-0010" title="NishizonoM . A comparative trial of zotepine, chlorpromazine and haloperidol in schizophrenic patients. Neuropsychopharmacology1994;10:30. ">Nishizono 1994</a> as the largest study with 109 participants. </p> </section> <section id="CD009268-sec-0111"> <h5 class="title">5. Interventions</h5> <p>In most studies flexible doses of antipsychotic drugs could be prescribed. The dose range for haloperidol was between 2 mg/day and 100 mg/day. Eight studies (<a href="./references#CD009268-bbs2-0001" title="BiY . A relation study of the extrapyramidal symptoms, serum prolactin levels and clinical response during treatment of antipsychotics. Chinese Journal of Nervous and Mental Diseases1994;20(2):70‐3. ">Bi 1994</a>; <a href="./references#CD009268-bbs2-0004" title="ClarkML . Haloperidol versus chlorpromazine versus placebo. Psychopharmacology Bulletin1969; Vol. 5, issue 3:57‐9. ">Clark 1969</a>; <a href="./references#CD009268-bbs2-0006" title="FoxW , GobbleIF , ClosM . A clinical comparison of trifluperidol, haloperidol and chlorpromazine. Current Therapeutic Research1964;6(6):409‐15. ">Fox 1964</a>; <a href="./references#CD009268-bbs2-0007" title="GallantDM , BishopM , Guerrero‐FigueroaR . Effects of two butyrophenone compounds on acute schizophrenic patients: speculation on the neurophysiologic sites of action. International Journal of Neuropsychiatry1967;3(1):53‐60. ">Gallant 1967</a>; <a href="./references#CD009268-bbs2-0009" title="McCreadieRG , MacDonaldIM . High dosage haloperidol in chronic schizophrenia. British Journal of Psychiatry1977; Vol. 131:310‐6. ">McCreadie 1977</a>; <a href="./references#CD009268-bbs2-0010" title="NishizonoM . A comparative trial of zotepine, chlorpromazine and haloperidol in schizophrenic patients. Neuropsychopharmacology1994;10:30. ">Nishizono 1994</a>; <a href="./references#CD009268-bbs2-0012" title="RompelH , SegalH . A comparison of the relative efficacy of serenace and chlorpromazine in the treatment of chronic schizophrenics. Journal of International Medical Research1978; Vol. 6, issue 2:126‐32. [MEDLINE: 344086] ">Rompel 1978</a>; <a href="./references#CD009268-bbs2-0014" title="SerafetinidesEA , ClarkML . Psychological effects of single dose antipsychotic medication. Biological Psychiatry1973; Vol. 7, issue 3:263‐7. SerafetinidesEA , CollinsS , ClarkML . Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease1972; Vol. 154, issue 1:31‐42. ">Serafetinides 1972</a>) used chlorpromazine as the comparator antipsychotic with doses between 50 to 1800 mg/day. Two studies (<a href="./references#CD009268-bbs2-0002" title="BlinO , AzorinJM , BouhoursP . Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. Journal of Clinical Psychopharmacology1996; Vol. 16, issue 1:38‐44. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol and risperidone in 62 schizophrenic patients. Clinical Pharmacology and Therapeutics. France, 1992; Vol. 51, issue 2:189. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol, and risperidone in 62 schizophrenic patients. Psychopharmacology1992:31‐2. BlinO , AzorinJM , BouhoursP . Comparison of anxiolytic properties of levomepromazine, haloperidol and risperidone in schizophrenic patients. Biological Psychiatry. France, 1991; Vol. 29:388. BlinO , AzorinJM , BouhoursP , FondaraiJ . Anxiolytic profiles of risperidone, haloperidol, and levomepromazine in schizophrenia: a factorial and regression analysis. Proceedings of the 9th World Congress of Psychiatry; 1993 Jun 6‐12; Rio de Janeiro, Brazil. France, 1993:24. BlinO , AzorinJM , BouhoursPh , FondaraiJ . Comparison of risperidone, haloperidol and levomepromazine in schizophrenia: a factorial analysis and discriminant function analysis. Clinical Neuropharmacology1992; Vol. 15, issue Suppl 1. Pt B:169B. ">Blin 1996</a>; <a href="./references#CD009268-bbs2-0015" title="ShalevA , HermeshH , RothbergJ , MunitzH . Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica1993; Vol. 87, issue 2:86‐91. ">Shalev 1993</a>) used levomepromazine with doses range between 50 to 379 mg/day. One study (<a href="./references#CD009268-bbs2-0017" title="WhiteK , BuskJ , EatonE , GomezG , RazaniJ , SloaneRB . Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine. International Pharmacopsychiatry1981; Vol. 16, issue 1:34‐8. ">White 1981</a>) used 100 to 800 mg/day mesoridazine. Two studies (<a href="./references#CD009268-bbs2-0008" title="KlimkeA , KlieserE , LehmannE , MieleL . Initial improvement as a criterion for drug choice in acute schizophrenia. Pharmacopsychiatry1993;26:25‐9. ">Klimke 1993</a>; <a href="./references#CD009268-bbs2-0013" title="SchmidtLG , SchüsslerG , KappesCV , Müller‐OerlinghausenB . Comparison of higher‐dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients [Vergleich einer höher dosierten Haloperidol‐Therapie mt einer Perazin‐Standard‐Therapie bei akut‐schizophrenen Patienten]. Nervenarzt1982;53(9):530‐6. ">Schmidt 1982</a>) used 300 to 900 mg/day perazine and four studies (<a href="./references#CD009268-bbs2-0003" title="BorisonRL , SinhaD , HaverstockS , McLarnonMC , DiamondBI . Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double‐blind, placebo‐controlled trial. Psychopharmacology Bulletin1989; Vol. 25, issue 2:190‐3. ">Borison 1989</a>; <a href="./references#CD009268-bbs2-0005" title="DufresneRL , ValentinoD , KassDJ . Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacology Bulletin1993; Vol. 29, issue 2:249‐55. ">Dufresne 1993</a>; <a href="./references#CD009268-bbs2-0011" title="PrasadL , TownleyMC . Haloperidol and thioridazine in treatment of chronic schizophrenics. Diseases of the Nervous System1966;27(11):722‐6. ">Prasad 1966</a>; <a href="./references#CD009268-bbs2-0016" title="WestonMJ , BentleyR , UnwinA , MorrisM , HarperMA . A comparative trial of haloperidol and thioridazine: management of chronic schizophrenia. Australian and New Zealand Journal of Psychiatry1973; Vol. 7, issue 1:52‐7. ">Weston 1973</a>) used thioridazine with doses between 60 and 800 mg/day. </p> </section> <section id="CD009268-sec-0112"> <h5 class="title">6. Outcomes</h5> <section id="CD009268-sec-0113"> <h6 class="title">6.1 Response to treatment</h6> <p>Our primary outcome was response to treatment as defined by the original studies. An at least 20% reduction of the Positive and Negative Syndrome Scale (PANSS) total score from baseline was used as the threshold of clinically significant response by <a href="./references#CD009268-bbs2-0002" title="BlinO , AzorinJM , BouhoursP . Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. Journal of Clinical Psychopharmacology1996; Vol. 16, issue 1:38‐44. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol and risperidone in 62 schizophrenic patients. Clinical Pharmacology and Therapeutics. France, 1992; Vol. 51, issue 2:189. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol, and risperidone in 62 schizophrenic patients. Psychopharmacology1992:31‐2. BlinO , AzorinJM , BouhoursP . Comparison of anxiolytic properties of levomepromazine, haloperidol and risperidone in schizophrenic patients. Biological Psychiatry. France, 1991; Vol. 29:388. BlinO , AzorinJM , BouhoursP , FondaraiJ . Anxiolytic profiles of risperidone, haloperidol, and levomepromazine in schizophrenia: a factorial and regression analysis. Proceedings of the 9th World Congress of Psychiatry; 1993 Jun 6‐12; Rio de Janeiro, Brazil. France, 1993:24. BlinO , AzorinJM , BouhoursPh , FondaraiJ . Comparison of risperidone, haloperidol and levomepromazine in schizophrenia: a factorial analysis and discriminant function analysis. Clinical Neuropharmacology1992; Vol. 15, issue Suppl 1. Pt B:169B. ">Blin 1996</a>. <a href="./references#CD009268-bbs2-0005" title="DufresneRL , ValentinoD , KassDJ . Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacology Bulletin1993; Vol. 29, issue 2:249‐55. ">Dufresne 1993</a> defined response as an at least 20% reduction on the BPRS. A 50% reduction of the BPRS total score was used as a response cut‐off by <a href="./references#CD009268-bbs2-0010" title="NishizonoM . A comparative trial of zotepine, chlorpromazine and haloperidol in schizophrenic patients. Neuropsychopharmacology1994;10:30. ">Nishizono 1994</a>. </p> <p>Four further studies (<a href="./references#CD009268-bbs2-0001" title="BiY . A relation study of the extrapyramidal symptoms, serum prolactin levels and clinical response during treatment of antipsychotics. Chinese Journal of Nervous and Mental Diseases1994;20(2):70‐3. ">Bi 1994</a>; <a href="./references#CD009268-bbs2-0003" title="BorisonRL , SinhaD , HaverstockS , McLarnonMC , DiamondBI . Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double‐blind, placebo‐controlled trial. Psychopharmacology Bulletin1989; Vol. 25, issue 2:190‐3. ">Borison 1989</a>; <a href="./references#CD009268-bbs2-0008" title="KlimkeA , KlieserE , LehmannE , MieleL . Initial improvement as a criterion for drug choice in acute schizophrenia. Pharmacopsychiatry1993;26:25‐9. ">Klimke 1993</a>; <a href="./references#CD009268-bbs2-0017" title="WhiteK , BuskJ , EatonE , GomezG , RazaniJ , SloaneRB . Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine. International Pharmacopsychiatry1981; Vol. 16, issue 1:34‐8. ">White 1981</a>) also based response on the BPRS, but did not give detailed response criteria. <a href="./references#CD009268-bbs2-0004" title="ClarkML . Haloperidol versus chlorpromazine versus placebo. Psychopharmacology Bulletin1969; Vol. 5, issue 3:57‐9. ">Clark 1969</a> based response both on the BPRS as well as the Clinical Global Impression Scale (CGI), but did not indicate the cut‐offs. The CGI was used by <a href="./references#CD009268-bbs2-0013" title="SchmidtLG , SchüsslerG , KappesCV , Müller‐OerlinghausenB . Comparison of higher‐dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients [Vergleich einer höher dosierten Haloperidol‐Therapie mt einer Perazin‐Standard‐Therapie bei akut‐schizophrenen Patienten]. Nervenarzt1982;53(9):530‐6. ">Schmidt 1982</a> and <a href="./references#CD009268-bbs2-0014" title="SerafetinidesEA , ClarkML . Psychological effects of single dose antipsychotic medication. Biological Psychiatry1973; Vol. 7, issue 3:263‐7. SerafetinidesEA , CollinsS , ClarkML . Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease1972; Vol. 154, issue 1:31‐42. ">Serafetinides 1972</a>. All other studies based response on clinical judgement (<a href="./references#CD009268-bbs2-0006" title="FoxW , GobbleIF , ClosM . A clinical comparison of trifluperidol, haloperidol and chlorpromazine. Current Therapeutic Research1964;6(6):409‐15. ">Fox 1964</a>; <a href="./references#CD009268-bbs2-0007" title="GallantDM , BishopM , Guerrero‐FigueroaR . Effects of two butyrophenone compounds on acute schizophrenic patients: speculation on the neurophysiologic sites of action. International Journal of Neuropsychiatry1967;3(1):53‐60. ">Gallant 1967</a><a href="./references#CD009268-bbs2-0009" title="McCreadieRG , MacDonaldIM . High dosage haloperidol in chronic schizophrenia. British Journal of Psychiatry1977; Vol. 131:310‐6. ">McCreadie 1977</a>; <a href="./references#CD009268-bbs2-0011" title="PrasadL , TownleyMC . Haloperidol and thioridazine in treatment of chronic schizophrenics. Diseases of the Nervous System1966;27(11):722‐6. ">Prasad 1966</a>; <a href="./references#CD009268-bbs2-0012" title="RompelH , SegalH . A comparison of the relative efficacy of serenace and chlorpromazine in the treatment of chronic schizophrenics. Journal of International Medical Research1978; Vol. 6, issue 2:126‐32. [MEDLINE: 344086] ">Rompel 1978</a>; <a href="./references#CD009268-bbs2-0015" title="ShalevA , HermeshH , RothbergJ , MunitzH . Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica1993; Vol. 87, issue 2:86‐91. ">Shalev 1993</a>; <a href="./references#CD009268-bbs2-0016" title="WestonMJ , BentleyR , UnwinA , MorrisM , HarperMA . A comparative trial of haloperidol and thioridazine: management of chronic schizophrenia. Australian and New Zealand Journal of Psychiatry1973; Vol. 7, issue 1:52‐7. ">Weston 1973</a>). </p> <p>Of the 17 included studies, 13 studies reported useable data for this primary outcome (<a href="./references#CD009268-bbs2-0001" title="BiY . A relation study of the extrapyramidal symptoms, serum prolactin levels and clinical response during treatment of antipsychotics. Chinese Journal of Nervous and Mental Diseases1994;20(2):70‐3. ">Bi 1994</a>; <a href="./references#CD009268-bbs2-0002" title="BlinO , AzorinJM , BouhoursP . Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. Journal of Clinical Psychopharmacology1996; Vol. 16, issue 1:38‐44. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol and risperidone in 62 schizophrenic patients. Clinical Pharmacology and Therapeutics. France, 1992; Vol. 51, issue 2:189. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol, and risperidone in 62 schizophrenic patients. Psychopharmacology1992:31‐2. BlinO , AzorinJM , BouhoursP . Comparison of anxiolytic properties of levomepromazine, haloperidol and risperidone in schizophrenic patients. Biological Psychiatry. France, 1991; Vol. 29:388. BlinO , AzorinJM , BouhoursP , FondaraiJ . Anxiolytic profiles of risperidone, haloperidol, and levomepromazine in schizophrenia: a factorial and regression analysis. Proceedings of the 9th World Congress of Psychiatry; 1993 Jun 6‐12; Rio de Janeiro, Brazil. France, 1993:24. BlinO , AzorinJM , BouhoursPh , FondaraiJ . Comparison of risperidone, haloperidol and levomepromazine in schizophrenia: a factorial analysis and discriminant function analysis. Clinical Neuropharmacology1992; Vol. 15, issue Suppl 1. Pt B:169B. ">Blin 1996</a>; <a href="./references#CD009268-bbs2-0005" title="DufresneRL , ValentinoD , KassDJ . Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacology Bulletin1993; Vol. 29, issue 2:249‐55. ">Dufresne 1993</a>; <a href="./references#CD009268-bbs2-0006" title="FoxW , GobbleIF , ClosM . A clinical comparison of trifluperidol, haloperidol and chlorpromazine. Current Therapeutic Research1964;6(6):409‐15. ">Fox 1964</a>; <a href="./references#CD009268-bbs2-0007" title="GallantDM , BishopM , Guerrero‐FigueroaR . Effects of two butyrophenone compounds on acute schizophrenic patients: speculation on the neurophysiologic sites of action. International Journal of Neuropsychiatry1967;3(1):53‐60. ">Gallant 1967</a>; <a href="./references#CD009268-bbs2-0009" title="McCreadieRG , MacDonaldIM . High dosage haloperidol in chronic schizophrenia. British Journal of Psychiatry1977; Vol. 131:310‐6. ">McCreadie 1977</a>; <a href="./references#CD009268-bbs2-0010" title="NishizonoM . A comparative trial of zotepine, chlorpromazine and haloperidol in schizophrenic patients. Neuropsychopharmacology1994;10:30. ">Nishizono 1994</a>; <a href="./references#CD009268-bbs2-0011" title="PrasadL , TownleyMC . Haloperidol and thioridazine in treatment of chronic schizophrenics. Diseases of the Nervous System1966;27(11):722‐6. ">Prasad 1966</a>; <a href="./references#CD009268-bbs2-0012" title="RompelH , SegalH . A comparison of the relative efficacy of serenace and chlorpromazine in the treatment of chronic schizophrenics. Journal of International Medical Research1978; Vol. 6, issue 2:126‐32. [MEDLINE: 344086] ">Rompel 1978</a>; <a href="./references#CD009268-bbs2-0013" title="SchmidtLG , SchüsslerG , KappesCV , Müller‐OerlinghausenB . Comparison of higher‐dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients [Vergleich einer höher dosierten Haloperidol‐Therapie mt einer Perazin‐Standard‐Therapie bei akut‐schizophrenen Patienten]. Nervenarzt1982;53(9):530‐6. ">Schmidt 1982</a>; <a href="./references#CD009268-bbs2-0014" title="SerafetinidesEA , ClarkML . Psychological effects of single dose antipsychotic medication. Biological Psychiatry1973; Vol. 7, issue 3:263‐7. SerafetinidesEA , CollinsS , ClarkML . Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease1972; Vol. 154, issue 1:31‐42. ">Serafetinides 1972</a>; <a href="./references#CD009268-bbs2-0015" title="ShalevA , HermeshH , RothbergJ , MunitzH . Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica1993; Vol. 87, issue 2:86‐91. ">Shalev 1993</a>; <a href="./references#CD009268-bbs2-0016" title="WestonMJ , BentleyR , UnwinA , MorrisM , HarperMA . A comparative trial of haloperidol and thioridazine: management of chronic schizophrenia. Australian and New Zealand Journal of Psychiatry1973; Vol. 7, issue 1:52‐7. ">Weston 1973</a>). </p> </section> <section id="CD009268-sec-0114"> <h6 class="title">6.2 Mental and global state</h6> <p>Average scores in mental state were assessed with the BPRS (<a href="./references#CD009268-bbs2-0111" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐12. ">Overall 1962</a>), the PANSS <a href="./references#CD009268-bbs2-0095" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi‐Health Systems, 1986. ">Kay 1986</a>), and the CGI scale (<a href="./references#CD009268-bbs2-0089" title="GuyW . Clinical Global Impressions Scale. ECDEU Assessment Manual for Psychopharmacology (DOTES: Dosage Record and Treatment Emergent Symptom Scale). National Institute of Mental Health, 1976. ">Guy 1976</a>). Altogether five studies provided data on these continuous outcome measures (<a href="./references#CD009268-bbs2-0001" title="BiY . A relation study of the extrapyramidal symptoms, serum prolactin levels and clinical response during treatment of antipsychotics. Chinese Journal of Nervous and Mental Diseases1994;20(2):70‐3. ">Bi 1994</a>; <a href="./references#CD009268-bbs2-0002" title="BlinO , AzorinJM , BouhoursP . Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. Journal of Clinical Psychopharmacology1996; Vol. 16, issue 1:38‐44. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol and risperidone in 62 schizophrenic patients. Clinical Pharmacology and Therapeutics. France, 1992; Vol. 51, issue 2:189. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol, and risperidone in 62 schizophrenic patients. Psychopharmacology1992:31‐2. BlinO , AzorinJM , BouhoursP . Comparison of anxiolytic properties of levomepromazine, haloperidol and risperidone in schizophrenic patients. Biological Psychiatry. France, 1991; Vol. 29:388. BlinO , AzorinJM , BouhoursP , FondaraiJ . Anxiolytic profiles of risperidone, haloperidol, and levomepromazine in schizophrenia: a factorial and regression analysis. Proceedings of the 9th World Congress of Psychiatry; 1993 Jun 6‐12; Rio de Janeiro, Brazil. France, 1993:24. BlinO , AzorinJM , BouhoursPh , FondaraiJ . Comparison of risperidone, haloperidol and levomepromazine in schizophrenia: a factorial analysis and discriminant function analysis. Clinical Neuropharmacology1992; Vol. 15, issue Suppl 1. Pt B:169B. ">Blin 1996</a>; <a href="./references#CD009268-bbs2-0003" title="BorisonRL , SinhaD , HaverstockS , McLarnonMC , DiamondBI . Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double‐blind, placebo‐controlled trial. Psychopharmacology Bulletin1989; Vol. 25, issue 2:190‐3. ">Borison 1989</a>; <a href="./references#CD009268-bbs2-0009" title="McCreadieRG , MacDonaldIM . High dosage haloperidol in chronic schizophrenia. British Journal of Psychiatry1977; Vol. 131:310‐6. ">McCreadie 1977</a>; <a href="./references#CD009268-bbs2-0017" title="WhiteK , BuskJ , EatonE , GomezG , RazaniJ , SloaneRB . Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine. International Pharmacopsychiatry1981; Vol. 16, issue 1:34‐8. ">White 1981</a>). </p> </section> <section id="CD009268-sec-0115"> <h6 class="title">6.3 Relapse</h6> <p>Only five studies (<a href="./references#CD009268-bbs2-0003" title="BorisonRL , SinhaD , HaverstockS , McLarnonMC , DiamondBI . Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double‐blind, placebo‐controlled trial. Psychopharmacology Bulletin1989; Vol. 25, issue 2:190‐3. ">Borison 1989</a>; <a href="./references#CD009268-bbs2-0008" title="KlimkeA , KlieserE , LehmannE , MieleL . Initial improvement as a criterion for drug choice in acute schizophrenia. Pharmacopsychiatry1993;26:25‐9. ">Klimke 1993</a>; <a href="./references#CD009268-bbs2-0009" title="McCreadieRG , MacDonaldIM . High dosage haloperidol in chronic schizophrenia. British Journal of Psychiatry1977; Vol. 131:310‐6. ">McCreadie 1977</a>; <a href="./references#CD009268-bbs2-0013" title="SchmidtLG , SchüsslerG , KappesCV , Müller‐OerlinghausenB . Comparison of higher‐dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients [Vergleich einer höher dosierten Haloperidol‐Therapie mt einer Perazin‐Standard‐Therapie bei akut‐schizophrenen Patienten]. Nervenarzt1982;53(9):530‐6. ">Schmidt 1982</a>; <a href="./references#CD009268-bbs2-0014" title="SerafetinidesEA , ClarkML . Psychological effects of single dose antipsychotic medication. Biological Psychiatry1973; Vol. 7, issue 3:263‐7. SerafetinidesEA , CollinsS , ClarkML . Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease1972; Vol. 154, issue 1:31‐42. ">Serafetinides 1972</a>) reported relapse rates with various definitions. </p> </section> <section id="CD009268-sec-0116"> <h6 class="title">6.4 Leaving the study early</h6> <p>The number of participants leaving the study early were recorded for the categories any reason, adverse events and lack of efficacy. Eleven studies (<a href="./references#CD009268-bbs2-0001" title="BiY . A relation study of the extrapyramidal symptoms, serum prolactin levels and clinical response during treatment of antipsychotics. Chinese Journal of Nervous and Mental Diseases1994;20(2):70‐3. ">Bi 1994</a>; <a href="./references#CD009268-bbs2-0002" title="BlinO , AzorinJM , BouhoursP . Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. Journal of Clinical Psychopharmacology1996; Vol. 16, issue 1:38‐44. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol and risperidone in 62 schizophrenic patients. Clinical Pharmacology and Therapeutics. France, 1992; Vol. 51, issue 2:189. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol, and risperidone in 62 schizophrenic patients. Psychopharmacology1992:31‐2. BlinO , AzorinJM , BouhoursP . Comparison of anxiolytic properties of levomepromazine, haloperidol and risperidone in schizophrenic patients. Biological Psychiatry. France, 1991; Vol. 29:388. BlinO , AzorinJM , BouhoursP , FondaraiJ . Anxiolytic profiles of risperidone, haloperidol, and levomepromazine in schizophrenia: a factorial and regression analysis. Proceedings of the 9th World Congress of Psychiatry; 1993 Jun 6‐12; Rio de Janeiro, Brazil. France, 1993:24. BlinO , AzorinJM , BouhoursPh , FondaraiJ . Comparison of risperidone, haloperidol and levomepromazine in schizophrenia: a factorial analysis and discriminant function analysis. Clinical Neuropharmacology1992; Vol. 15, issue Suppl 1. Pt B:169B. ">Blin 1996</a>; <a href="./references#CD009268-bbs2-0003" title="BorisonRL , SinhaD , HaverstockS , McLarnonMC , DiamondBI . Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double‐blind, placebo‐controlled trial. Psychopharmacology Bulletin1989; Vol. 25, issue 2:190‐3. ">Borison 1989</a>; <a href="./references#CD009268-bbs2-0004" title="ClarkML . Haloperidol versus chlorpromazine versus placebo. Psychopharmacology Bulletin1969; Vol. 5, issue 3:57‐9. ">Clark 1969</a>; <a href="./references#CD009268-bbs2-0005" title="DufresneRL , ValentinoD , KassDJ . Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacology Bulletin1993; Vol. 29, issue 2:249‐55. ">Dufresne 1993</a>; <a href="./references#CD009268-bbs2-0008" title="KlimkeA , KlieserE , LehmannE , MieleL . Initial improvement as a criterion for drug choice in acute schizophrenia. Pharmacopsychiatry1993;26:25‐9. ">Klimke 1993</a>; <a href="./references#CD009268-bbs2-0009" title="McCreadieRG , MacDonaldIM . High dosage haloperidol in chronic schizophrenia. British Journal of Psychiatry1977; Vol. 131:310‐6. ">McCreadie 1977</a>; <a href="./references#CD009268-bbs2-0011" title="PrasadL , TownleyMC . Haloperidol and thioridazine in treatment of chronic schizophrenics. Diseases of the Nervous System1966;27(11):722‐6. ">Prasad 1966</a>; <a href="./references#CD009268-bbs2-0013" title="SchmidtLG , SchüsslerG , KappesCV , Müller‐OerlinghausenB . Comparison of higher‐dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients [Vergleich einer höher dosierten Haloperidol‐Therapie mt einer Perazin‐Standard‐Therapie bei akut‐schizophrenen Patienten]. Nervenarzt1982;53(9):530‐6. ">Schmidt 1982</a>; <a href="./references#CD009268-bbs2-0014" title="SerafetinidesEA , ClarkML . Psychological effects of single dose antipsychotic medication. Biological Psychiatry1973; Vol. 7, issue 3:263‐7. SerafetinidesEA , CollinsS , ClarkML . Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease1972; Vol. 154, issue 1:31‐42. ">Serafetinides 1972</a>; <a href="./references#CD009268-bbs2-0016" title="WestonMJ , BentleyR , UnwinA , MorrisM , HarperMA . A comparative trial of haloperidol and thioridazine: management of chronic schizophrenia. Australian and New Zealand Journal of Psychiatry1973; Vol. 7, issue 1:52‐7. ">Weston 1973</a>) reported on leaving the study early due to any reason and leaving the study early due to adverse events. Ten studies (<a href="./references#CD009268-bbs2-0001" title="BiY . A relation study of the extrapyramidal symptoms, serum prolactin levels and clinical response during treatment of antipsychotics. Chinese Journal of Nervous and Mental Diseases1994;20(2):70‐3. ">Bi 1994</a>; <a href="./references#CD009268-bbs2-0002" title="BlinO , AzorinJM , BouhoursP . Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. Journal of Clinical Psychopharmacology1996; Vol. 16, issue 1:38‐44. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol and risperidone in 62 schizophrenic patients. Clinical Pharmacology and Therapeutics. France, 1992; Vol. 51, issue 2:189. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol, and risperidone in 62 schizophrenic patients. Psychopharmacology1992:31‐2. BlinO , AzorinJM , BouhoursP . Comparison of anxiolytic properties of levomepromazine, haloperidol and risperidone in schizophrenic patients. Biological Psychiatry. France, 1991; Vol. 29:388. BlinO , AzorinJM , BouhoursP , FondaraiJ . Anxiolytic profiles of risperidone, haloperidol, and levomepromazine in schizophrenia: a factorial and regression analysis. Proceedings of the 9th World Congress of Psychiatry; 1993 Jun 6‐12; Rio de Janeiro, Brazil. France, 1993:24. BlinO , AzorinJM , BouhoursPh , FondaraiJ . Comparison of risperidone, haloperidol and levomepromazine in schizophrenia: a factorial analysis and discriminant function analysis. Clinical Neuropharmacology1992; Vol. 15, issue Suppl 1. Pt B:169B. ">Blin 1996</a>; <a href="./references#CD009268-bbs2-0003" title="BorisonRL , SinhaD , HaverstockS , McLarnonMC , DiamondBI . Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double‐blind, placebo‐controlled trial. Psychopharmacology Bulletin1989; Vol. 25, issue 2:190‐3. ">Borison 1989</a>; <a href="./references#CD009268-bbs2-0004" title="ClarkML . Haloperidol versus chlorpromazine versus placebo. Psychopharmacology Bulletin1969; Vol. 5, issue 3:57‐9. ">Clark 1969</a>; <a href="./references#CD009268-bbs2-0008" title="KlimkeA , KlieserE , LehmannE , MieleL . Initial improvement as a criterion for drug choice in acute schizophrenia. Pharmacopsychiatry1993;26:25‐9. ">Klimke 1993</a>; <a href="./references#CD009268-bbs2-0009" title="McCreadieRG , MacDonaldIM . High dosage haloperidol in chronic schizophrenia. British Journal of Psychiatry1977; Vol. 131:310‐6. ">McCreadie 1977</a>; <a href="./references#CD009268-bbs2-0011" title="PrasadL , TownleyMC . Haloperidol and thioridazine in treatment of chronic schizophrenics. Diseases of the Nervous System1966;27(11):722‐6. ">Prasad 1966</a>; <a href="./references#CD009268-bbs2-0013" title="SchmidtLG , SchüsslerG , KappesCV , Müller‐OerlinghausenB . Comparison of higher‐dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients [Vergleich einer höher dosierten Haloperidol‐Therapie mt einer Perazin‐Standard‐Therapie bei akut‐schizophrenen Patienten]. Nervenarzt1982;53(9):530‐6. ">Schmidt 1982</a>; <a href="./references#CD009268-bbs2-0014" title="SerafetinidesEA , ClarkML . Psychological effects of single dose antipsychotic medication. Biological Psychiatry1973; Vol. 7, issue 3:263‐7. SerafetinidesEA , CollinsS , ClarkML . Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease1972; Vol. 154, issue 1:31‐42. ">Serafetinides 1972</a>; <a href="./references#CD009268-bbs2-0016" title="WestonMJ , BentleyR , UnwinA , MorrisM , HarperMA . A comparative trial of haloperidol and thioridazine: management of chronic schizophrenia. Australian and New Zealand Journal of Psychiatry1973; Vol. 7, issue 1:52‐7. ">Weston 1973</a>) reported data on leaving the study early due to inefficacy. </p> </section> <section id="CD009268-sec-0117"> <h6 class="title">6.5 Service use</h6> <p>None of the included studies reported data on this outcome.</p> </section> <section id="CD009268-sec-0118"> <h6 class="title">6.6. Adverse effects</h6> <p>Scales that provided usable data are described below.</p> <p><i>6.6.1 Abnormal Involuntary Movement Scale ‐ AIMS</i> (<a href="./references#CD009268-bbs2-0089" title="GuyW . Clinical Global Impressions Scale. ECDEU Assessment Manual for Psychopharmacology (DOTES: Dosage Record and Treatment Emergent Symptom Scale). National Institute of Mental Health, 1976. ">Guy 1976</a>) </p> <p>This scale has been used to assess tardive dyskinesia, a long‐term, drug‐induced movement disorder and short‐term movement disorders such as tremor. A high score indicates severe dyskinesia (score from zero to four). </p> <p><i>6.6.2 Asberg Rating Scale of side‐effects</i> (<a href="./references#CD009268-bbs2-0064" title="AsbergM , CronholmB , SjöckvistF , TuckD . Correlation of subjective side effects with plasma concentrations of nortriptyline. British Medical Journal1970;4:18‐21. ">Asberg 1970</a>) </p> <p>This 10‐item scale, with a scoring system of zero to four for each item, measures drug‐induced parkinsonism, a short‐term drug‐induced movement disorder. A low score indicates low levels of parkinsonism. </p> <p><i>6.6.3 Extrapyramidal Symptom Rating Scale ‐ ESRS</i> (<a href="./references#CD009268-bbs2-0069" title="ChouinardG , Ross‐ChouinardA , AnnableL , JonesBD . Extrapyramidal Symptom Rating Scale. Canadian Journal of Neurological Sciences1980;7:233‐9. ">Chouinard 1980</a>) </p> <p>This scale assess four types of medication induced extrapyramidal side‐effects: parkinsonism, akathisia, dystonia, and tardive dyskinesia. Low scores indicate low levels of these side‐effects. </p> <p><i>6.6.4 Reversible Extrapyramidal Symptom Rating Scale ‐ ERS</i> (<a href="./references#CD009268-bbs2-0074" title="DiMascioA , BernardoDC . A controlled trial of amantadine in drug‐induced extrapyramidal disorders. Archives of General Psychiatry1976;33:599‐602. ">DiMascio 1976</a>) </p> <p>This 10‐item scale, with a scoring system of zero to four for each item, measures drug‐induced parkinsonism, a short‐term drug‐induced movement disorder. A low score indicates low levels of parkinsonism. </p> <p><i>6.6.5 Simpson Angus Scale ‐ SAS</i> (<a href="./references#CD009268-bbs2-0116" title="SimpsonEN , AngusJWF . A rating scale for extrapyramidal side‐effects. Acta Psychiatrica Scandinavica Supplementum1970;212:11‐9. ">Simpson 1970</a>) </p> <p>This 10‐item scale, with a scoring system of zero to four for each item, measures drug‐induced parkinsonism, a short‐term drug‐induced movement disorder. A low score indicates low levels of extrapyramidal side‐effects. </p> <p>6.6.6 <i>Treatment Emergent Symptom Rating Scale ‐ TESS</i> (<a href="./references#CD009268-bbs2-0109" title="National Institute of Mental Health. Special feature: rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacological Bulletin1985;21(4):714‐1124. ">NIMH 1985</a>) </p> <p>This six‐item scale measures various medication side‐effects, it was developed by the National Institute of Mental Health. </p> <p><i>6.6.7 Other adverse effects</i> </p> <p>The following adverse events were reported in a dichotomous manner in terms of the number of participants with such a side‐effect: 'at least one adverse event', at least one movement disorder, akathisia, dyskinesia, dystonia, rigor, tremor, use of antiparkinson medication, hypotension, sedation, weight gain, allergic reactions, amenorrhoea, ankle oedema, asthenia, blurring of vision, confusion, constipation, dizziness, drooling, dry mouth, excitement, galactorrhoea, headache, loss of associated movement, micturition disturbances, nausea, oculogyric crisis, orthostatic symptoms, palpitations, photosensitivity, prolactin increase, rash, repercussions on sexual life, somnolence, sleep disturbances, sweating, syncope, tongue changes, urinary retention, weight loss. None of the included studies reported data on the following predefined important adverse effects: death, suicide and cardiac effects. </p> </section> <section id="CD009268-sec-0119"> <h6 class="title">6.7 Quality of life and participant´s/carer´s satisfaction with care</h6> <p>None of the included studies reported data on this outcome.</p> </section> <section id="CD009268-sec-0120"> <h6 class="title">6.8 Economic outcomes</h6> <p>None of the included studies reported data on this outcome.</p> </section> </section> </section> <section id="CD009268-sec-0121"> <h4 class="title">Excluded studies</h4> <p>Forty‐one studies were excluded from the analysis. Fifteen were not randomised (<a href="./references#CD009268-bbs2-0018" title="AzimaH , Durost , ArthursD . The effect of R‐1625 (haloperidol) in mental syndromes: a multiblind study. American Journal of Psychiatry1960; Vol. 117:546‐7. ">Azima 1960</a>; <a href="./references#CD009268-bbs2-0020" title="BlumRA , LivingstonPB , ShaderRI . Changes in cognition, attention and language in acute schizophrenia. Diseases of the Nervous System1969; Vol. 30, issue 1:31‐6. ">Blum 1969</a>; <a href="./references#CD009268-bbs2-0027" title="EitanN , LevinY , Ben ArtziE , LevyA , NeumannM . Effects of antipsychotic drugs on memory functions of schizophrenic patients. Acta Psychiatrica Scandinavica1992; Vol. 85, issue 1:74‐6. ">Eitan 1992</a>; <a href="./references#CD009268-bbs2-0030" title="GerlachJ , SimmelsgaardH . Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine. Psychopharmacology1978; Vol. 59, issue 2:105‐12. ">Gerlach 1978</a>; <a href="./references#CD009268-bbs2-0031" title="GillisJS . The effects of selected antipsychotic drugs of human judgment. Current Therapeutic Research, Clinical and Experimental1977; Vol. 21, issue 2:224‐32. ">Gillis 1977</a>; <a href="./references#CD009268-bbs2-0036" title="HayanoT , KadomaeS , KikuokaM , ImadeT , IkomaY , NakataniY , et al. Pharmacometrics of double‐blind test of two drugs, haloperidol and sultopride (barnetil(R); MS‐5024), on the schizophrenic patients. Journal of the Wakayama Medical Society1989; Vol. 40, issue 4:607‐20. ">Hayano 1989</a>; <a href="./references#CD009268-bbs2-0038" title="HorodnickiJM , CzekalskiS , JaremaM , KubasiewiczA , PobochaJ , WdowiakJ . Comparison of the effects of chlorprothixene and haloperidol on hypothalamic function in patients with paranoid schizophrenia [Porownanie wplywu chloroprotyksenu i haloperidolu na czynnosc podwzgorza u chorych na schizofrenie paranoidalna]. Psychiatria Polska1985; Vol. 19, issue 3:181‐7. ">Horodnicki 1985</a>; <a href="./references#CD009268-bbs2-0040" title="LiuK , LLungFW . Difference in prolaction response of schizophrenic patients to equivalent doses of haloperidol, remoxipride and sulpiride. Kao Hsiung I Hsueh Ko Hsueh Tsa Chih Kaohsiung (Journal of Medical Sciences)1996; Vol. 12, issue 12:685‐90. ">Liu 1996</a>; <a href="./references#CD009268-bbs2-0042" title="MechriA , FendriC , Ben OthmanL , MekhininiA , KerkeniA , GahaL . Effect of first generation antipsychotic treatment on oxidative stress markers in schizophrenia. European Neuropsychopharmacology2006; Vol. 16, issue Suppl 4:S438. ">Mechri 2006</a>; <a href="./references#CD009268-bbs2-0043" title="MinamiH , MiyaharaA , MurasakiO , NakanishiT , OgawaH , OhkuboT , et al. Prediction of response to chlorpromazine and haloperidol after test dose. Proceedings of the 17th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1990 Sep 10‐14; Kyoto, Japan1990:215. ">Minami 1990</a>; <a href="./references#CD009268-bbs2-0045" title="MoriA , KazamatsuriH , KanenoS , KamijimaK , KariyaT , MurasakiM , et al. A double‐blind comparison of emonapride with haloperidol in the treatment of schizophrenia. Proceedings of the 17th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1990 Sep 10‐14; Kyoto, Japan1990:296. ">Mori 1990</a>; <a href="./references#CD009268-bbs2-0053" title="SinghMM . Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Diseases of the Nervous System1976; Vol. 37:191‐6. SinghMM , KaySR . A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Theoretical implications for potency differences among neuroleptics. Psychopharmacology1975; Vol. 43, issue 2:103‐13. SinghMM , KaySR . A longitudinal therapeutic comparison between two prototypic neuroleptics (haloperidol and chlorpromazine) in matched groups of schizophrenics. Nontherapeutic interactions with trihexyphenidyl. Theoretical implications for potency differences. Psychopharmacology1975; Vol. 43, issue 2:115‐21. SinghMM , KaySR . Therapeutic reversal with benztropine in schizophrenics: practical and theoretical significance. Journal of Nervous and Mental Disease1975; Vol. 160, issue 4:258‐66. ">Singh 1975</a>; <a href="./references#CD009268-bbs2-0056" title="TerminskaK , MrowiecW . Comparison of influence of perazine, fluphenazine, trifluoroperazine, chloropromazine and haloperidol on primary and deficit schizophrenic symptoms in patients first hospitalized because of paranoid schizophrenia [Badanie porownawcze wplywu perazyny, flufenazyny, trifluoroperazyny, chloropromazny i haloperydolu na objawy pierwotne i deficytowe pierwszego zachorowania na schizofrenie paranoidalna]. Psychiatria Polska1989; Vol. 23, issue 1:24‐30. ">Terminska 1989</a>; <a href="./references#CD009268-bbs2-0057" title="WangYC , CuoJH , ChenJS . The relation of qeeg with the therapeutic effect of antipsychotic drugs. Modern Rehabilitation2000; Vol. 4, issue 11:12‐3. ">Wang 2000</a>; <a href="./references#CD009268-bbs2-0058" title="ZuoningJ , Huang ShuZheng , Qin YingFu , YamamotoM . Comparative clinical study of nemonapride, a benzamide compound with dopamine D‐2‐like receptor blocking activity, and haloperidol in schizophrenic patients. Research Communications in Biological Psychology and Psychiatry1999; Vol. 24, issue 1‐2:35‐46. ">Zuoning 1999</a>). <a href="./references#CD009268-bbs2-0033" title="GonierT , SchieleBC , VestreND . A comparison of haloperidol and thioridazine HC1 in chronic treatment‐resistant schizophrenics. Behavioral Neuropsychiatry1970;2(3):47‐50. ">Gonier 1970</a> randomised participants, but later described that randomisation did not work. <a href="./references#CD009268-bbs2-0026" title="DubinWR , WaxmanHM , WeissKJ , RamchandaniD , Tavani‐PetroneC . Rapid tranquilization: the efficacy of oral concentrate. Journal of Clinical Psychiatry1985; Vol. 46, issue 11:475‐8. ">Dubin 1985</a> and <a href="./references#CD009268-bbs2-0035" title="HarrisMJ , PantonD , CaligiuriMP , KrullAJ , Tran JohnsonTK , JesteDV . High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics. Psychopharmacology Bulletin1992; Vol. 28, issue 1:87‐92. ">Harris 1992</a> included participants with diagnoses other than schizophrenia. Altogether, 12 studies compared haloperidol against medications not relevant for this review, because they were not low‐potency first‐generation antipsychotics. Of these, seven compared haloperidol with sulpiride (<a href="./references#CD009268-bbs2-0021" title="CassanoGB , CastrogiovanniP , ContiL . The computer diagnosis in a multicenter study of psychoactive agents. Psychopharmacology Bulletin1976; Vol. 12, issue 2:22‐4. CassanoGB , CastrogiovanniP , ContiL , BonolloL . Sulpiride versus haloperidol in schizophrenia: a double‐blind comparative trial. Current Therapeutic Research1975; Vol. 17, issue 2:189‐201. CastrogiovanniP , CassanoGB , ContiL , MagginiC , BonolloL , SarteschiP . An automated diagnostic process (PDA) in clinical psychopharmacology. An exemplification of its use in a sulpiride versus haloperidol comparative trial. International Pharmacopsychiatry1976; Vol. 11, issue 2:74‐83. ">Cassano 1975</a>; <a href="./references#CD009268-bbs2-0034" title='GuazzelliM , BarracchiaE , BertolinoA , BertolinolA , CasacchiaM , CiapparelliA , et al. Clinical effects of l‐sulpiride vs haloperidol in acutely relapsed chronic schizophrenics: therapeutic efficacy on "disorganization"?. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 Sep 30 ‐ Oct 4; Venice, Italy1995. '>Guazzelli 1995</a>; <a href="./references#CD009268-bbs2-0044" title="MoriA , KazamatsuriH , KanenoS , KamijimaK , KariyaT , MurasakiM , et al. A double‐blind comparison of a new benzamide compound YM 09151 with haloperidol in the treatment of schizophrenia. Rinsho Hyoka (Clinical Evaluation)1989; Vol. 17, issue 3‐4:349‐77. ">Mori 1989</a>; <a href="./references#CD009268-bbs2-0046" title="GerlachJ , BehnkeK , HeltbergJ , Munk‐AndersonE , NielsenH . Sulpiride and haloperidol in schizophrenia: a double‐blind cross‐over study of therapeutic effect, side effects and plasma concentrations. British Journal of Psychiatry1985; Vol. 147:283‐8. Munk‐AndersenE , BehnkeK , HeltbergJ , NielsenH . Sulpiride versus haloperidol in the treatment of schizophrenia. A short preliminary report [Sulpirid versus haloperidol i behandling af skizofreni. En kort, praeliminaer rapport]. Nordisk Psykiatrisk Tidsskrift1984; Vol. 38, issue 4:223‐8. Munk‐AndersenEM , BehnkeK , HeltbergJ , NielsenH , GerlachJ . Sulpiride versus haloperidol, a clinical trial in schizophrenia. A preliminary report. Acta Psychiatrica Scandinavica Supplementum1984; Vol. 311:31‐41. ">Munk‐Andersen 1984</a>; <a href="./references#CD009268-bbs2-0048" title="OkudaO , AkaueY , OkishioY . The efficacy of sulpiride in the treatment of schizophrenia by the double‐blind method. Yakuri To Chiryo1979; Vol. 7, issue 2:439‐58. ">Okuda 1979</a>; <a href="./references#CD009268-bbs2-0050" title="Rama RaoV , BaileyJ , BishopM , CoppenA . A clinical and pharmacodynamic evaluation of sulpiride. Psychopharmacology1981; Vol. 73, issue 1:77‐80. ">Rama 1981</a>; <a href="./references#CD009268-bbs2-0051" title="RopertR , PayanC , AllardS . Sultopride versus haloperidol for the treatment of acute psychosis. Results of a multicenter double‐blind controlled trial [Sultopride versus haloperidol dans le traitement des etats psychotiques aigus]. Annales de Psychiatrie1989; Vol. 4, issue 1:92‐8. ">Ropert 1989</a>); two studies used placebo as a comparator (<a href="./references#CD009268-bbs2-0023" title="CrowTJ , MacMillanJF , JohnsonAL , JohnstoneEC . A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry1986; Vol. 148, issue 2:120‐7. [MEDLINE: 2870753] JohnstoneEC , CrowJ , JohnsonAL , MacMillanJF . The northwick park study of first episodes of schizophrenia. British Journal of Psychiatry1986;148:115‐20. ">Crow 1986</a>; <a href="./references#CD009268-bbs2-0029" title="GarryJW , LeonardTJ . Haloperidol: a controlled trial in chronic schizophrenia. Journal of Mental Science1962; Vol. 108:105‐7. ">Garry 1962</a>); <a href="./references#CD009268-bbs2-0032" title="GiordanaJY , FrenayS . Comparative study of pipotiazine (in its non‐esterified form) and of haloperidol in acute or subacute psychotic states [Etude comparative de la pipothiazine (dans sa forme non esterifiee) et de l'haloperidol au cours d'etats psychotiques aigus et subaigus]. Psychologie Medicale1984;16(10):1803‐15. ">Giordana 1984</a> compared with pipotiazine; <a href="./references#CD009268-bbs2-0047" title="NahunekK , SvestkaJ , CeskovaE , RysanekR . Blind comparison of oxyprothepin and haloperidol in six‐week treatment periods in schizophrenia. Activitas Nervosa Superior1982; Vol. 24, issue 4:219‐20. ">Nahunek 1982</a> with oxyprothepine and placebo; and <a href="./references#CD009268-bbs2-0054" title="SmithRC , BaumgartnerR , BurdA , RavichandranGK , MauldinM . Haloperidol and thioridazine drug levels and clinical response in schizophrenia: comparison of gas‐liquid chromatography and adioreceptor drug level assays. Psychopharmacology Bulletin. United States, 1985; Vol. 21, issue 1:52‐8. ">Smith 1985</a> compared different haloperidol dosages without a comparator drug. <a href="./references#CD009268-bbs2-0025" title="deLimaMS , deJesusMJ , BreierA , CostaAM , deSenaEP , HotopfM . Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first‐generation antipsychotics. Journal of Clinical Psychiatry. United States, 2005; Vol. 66, issue 7:831‐8. ">de Lima 2005</a> and <a href="./references#CD009268-bbs2-0049" title="Palma WenzelMI , ParadaR , OsorioC , DorrA , BauerS . Flupentixol decanoate versus other neuroleptics in chronic schizophrenia [Decanoato de flupentixol versus otros neurolepticos en esquizofrenicos cronicos]. Revista Chilena de Neuropsiquiatria1997; Vol. 35, issue 1:29‐35. ">Palma 1997</a> did not have results for each single drug separately. Nine studies met all the inclusion criteria, however, they did not present any usable data (<a href="./references#CD009268-bbs2-0019" title="BagneCA , LewisRF . Evaluating the effects of drugs on behavior and quality of life: an alternative strategy for clinical trials. Journal of Consulting and Clinical Psychology1992; Vol. 60:225‐39. ">Bagne 1992</a>; <a href="./references#CD009268-bbs2-0022" title="CosarB , CandansayarS , TanerE , IsikE . Comparison of efficacy of clozapine, sulpiride, chlorpromazine and haloperidol in chronic schizophrenic patients therapy. European Neuropsychopharmacology1999; Vol. 9:S287. ">Cosar 1999</a>; <a href="./references#CD009268-bbs2-0024" title="DaviesLM , LewisS , JonesPB , BarnesTR , GaughranF , HayhurstK , et al. CUtLASS team. Cost‐effectiveness of first‐ versus second‐generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. British Journal of Psychiatry. United Kingdom, 2007; Vol. 191, issue July:14‐22. JonesPB , BatnesTR , DaviesL , DunnG , LloydH , HayhurstKP , et al. Randomized controlled trial of the effect on quality of life of second‐ vs first‐generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry. United States, 2006; Vol. 63, issue 10:1079‐87. ">Davies 2007</a>; <a href="./references#CD009268-bbs2-0028" title="FuxM , BelmakerRH . A controlled comparative study of chlorprothixene vs. haloperidol in chronic schizophrenia. Israel Journal of Psychiatry and Related Sciences1991; Vol. 28, issue 1:37‐40. ">Fux 1991</a>; <a href="./references#CD009268-bbs2-0037" title="HoganTP , AwadAG . Subjective response to neuroleptics and outcome in schizophrenia: a re‐examination comparing two measures. Psychological Medicine1992; Vol. 22, issue 2:347‐52. ">Hogan 1992</a>; <a href="./references#CD009268-bbs2-0039" title="LempérièreT , DelayJ , PichotP , PiretJ . A comparison of the effects of four major antipsychotic drugs (chlorpromazine, thioproperazine, prochlorpremazine and haloperidol) for paraniod schizophrenia [Comparaison de l'action de quatre neuroleptiques majeurs (chlorpromazine, thiopropérazine, prochlorprémazine ethalopéridol) dans les formes paranoides de la schizophrénie]. Neuro‐Psychopharmacology1962;3:89‐93. ">Lempérière 1962</a>; <a href="./references#CD009268-bbs2-0041" title="MarjerrisonG , BowmanR , KeoghRP . A comparison of chlorprothixene and haloperidol in acute schizophrenia. Canadian Psychiatric Association Journal1971; Vol. 16, issue 6:533‐6. ">Marjerrison 1971</a>; <a href="./references#CD009268-bbs2-0052" title="ShvartsburdA , SajadiC , MortonV , MirabiM , GordonJ , SmithRC . Blood levels of haloperidol and thioridazine during maintenance neuroleptic treatment of schizophrenic outpatients. Journal of Clinical Psychopharmacology1984; Vol. 4, issue 4:194‐8. ">Shvartsburd 1984</a>; <a href="./references#CD009268-bbs2-0055" title="TejaJS , GreyWH , ClumJM , WarrenC . Tranquilizers or anti‐depressanrs for chronic schizophrenics: a long term study. Australian and New Zealand Journal of Psychiatry1975;9:241‐7. ">Teja 1975</a>). </p> </section> </section> <section id="CD009268-sec-0122"> <h3 class="title">Risk of bias in included studies</h3> <p>For graphical representations of our judgements of risk of bias please refer to <a href="#CD009268-fig-0002">Figure 2</a> and <a href="#CD009268-fig-0003">Figure 3</a>. Full details of judgements are seen in the 'Risk of bias' tables. </p> <div class="figure" id="CD009268-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009268-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD009268-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009268-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009268-sec-0123"> <h4 class="title">Allocation</h4> <p>In all studies, random sequence generation was unclear. Among these, 14 studies were described as randomised without providing further details about random sequence generation. Three further studies did not provide any information about sequence generation, but they were double‐blind, therefore we assumed randomisation (<a href="./references#CD009268-bbs2-0004" title="ClarkML . Haloperidol versus chlorpromazine versus placebo. Psychopharmacology Bulletin1969; Vol. 5, issue 3:57‐9. ">Clark 1969</a>; <a href="./references#CD009268-bbs2-0011" title="PrasadL , TownleyMC . Haloperidol and thioridazine in treatment of chronic schizophrenics. Diseases of the Nervous System1966;27(11):722‐6. ">Prasad 1966</a>; <a href="./references#CD009268-bbs2-0017" title="WhiteK , BuskJ , EatonE , GomezG , RazaniJ , SloaneRB . Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine. International Pharmacopsychiatry1981; Vol. 16, issue 1:34‐8. ">White 1981</a>). </p> <p>Only one of the 17 included randomised studies provided details on allocation concealment (<a href="./references#CD009268-bbs2-0015" title="ShalevA , HermeshH , RothbergJ , MunitzH . Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica1993; Vol. 87, issue 2:86‐91. ">Shalev 1993</a>). Therefore, it was unclear for all the other studies whether adequate allocation concealment methods were used. </p> </section> <section id="CD009268-sec-0124"> <h4 class="title">Blinding</h4> <p><a href="./references#CD009268-bbs2-0001" title="BiY . A relation study of the extrapyramidal symptoms, serum prolactin levels and clinical response during treatment of antipsychotics. Chinese Journal of Nervous and Mental Diseases1994;20(2):70‐3. ">Bi 1994</a>, <a href="./references#CD009268-bbs2-0015" title="ShalevA , HermeshH , RothbergJ , MunitzH . Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica1993; Vol. 87, issue 2:86‐91. ">Shalev 1993</a> and <a href="./references#CD009268-bbs2-0010" title="NishizonoM . A comparative trial of zotepine, chlorpromazine and haloperidol in schizophrenic patients. Neuropsychopharmacology1994;10:30. ">Nishizono 1994</a> were probably open studies and were thus rated to have a high risk of bias in terms of blinding. One study was rated with a high risk of bias (<a href="./references#CD009268-bbs2-0009" title="McCreadieRG , MacDonaldIM . High dosage haloperidol in chronic schizophrenia. British Journal of Psychiatry1977; Vol. 131:310‐6. ">McCreadie 1977</a>), because psychiatrists could guess correctly in eight participants out of 20 which antipsychotic they had been given. Six studies were described as double‐blind but did not provide even a minimal description of the blinding methods. These studies were rated as unclear with regards to blinding (<a href="./references#CD009268-bbs2-0002" title="BlinO , AzorinJM , BouhoursP . Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. Journal of Clinical Psychopharmacology1996; Vol. 16, issue 1:38‐44. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol and risperidone in 62 schizophrenic patients. Clinical Pharmacology and Therapeutics. France, 1992; Vol. 51, issue 2:189. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol, and risperidone in 62 schizophrenic patients. Psychopharmacology1992:31‐2. BlinO , AzorinJM , BouhoursP . Comparison of anxiolytic properties of levomepromazine, haloperidol and risperidone in schizophrenic patients. Biological Psychiatry. France, 1991; Vol. 29:388. BlinO , AzorinJM , BouhoursP , FondaraiJ . Anxiolytic profiles of risperidone, haloperidol, and levomepromazine in schizophrenia: a factorial and regression analysis. Proceedings of the 9th World Congress of Psychiatry; 1993 Jun 6‐12; Rio de Janeiro, Brazil. France, 1993:24. BlinO , AzorinJM , BouhoursPh , FondaraiJ . Comparison of risperidone, haloperidol and levomepromazine in schizophrenia: a factorial analysis and discriminant function analysis. Clinical Neuropharmacology1992; Vol. 15, issue Suppl 1. Pt B:169B. ">Blin 1996</a>; <a href="./references#CD009268-bbs2-0003" title="BorisonRL , SinhaD , HaverstockS , McLarnonMC , DiamondBI . Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double‐blind, placebo‐controlled trial. Psychopharmacology Bulletin1989; Vol. 25, issue 2:190‐3. ">Borison 1989</a>; <a href="./references#CD009268-bbs2-0004" title="ClarkML . Haloperidol versus chlorpromazine versus placebo. Psychopharmacology Bulletin1969; Vol. 5, issue 3:57‐9. ">Clark 1969</a>; <a href="./references#CD009268-bbs2-0006" title="FoxW , GobbleIF , ClosM . A clinical comparison of trifluperidol, haloperidol and chlorpromazine. Current Therapeutic Research1964;6(6):409‐15. ">Fox 1964</a>; <a href="./references#CD009268-bbs2-0013" title="SchmidtLG , SchüsslerG , KappesCV , Müller‐OerlinghausenB . Comparison of higher‐dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients [Vergleich einer höher dosierten Haloperidol‐Therapie mt einer Perazin‐Standard‐Therapie bei akut‐schizophrenen Patienten]. Nervenarzt1982;53(9):530‐6. ">Schmidt 1982</a>; <a href="./references#CD009268-bbs2-0017" title="WhiteK , BuskJ , EatonE , GomezG , RazaniJ , SloaneRB . Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine. International Pharmacopsychiatry1981; Vol. 16, issue 1:34‐8. ">White 1981</a>). Seven studies provided at least some description of the blinding process. Five studies described that they used identical capsules and were rated to have a low risk of bias (<a href="./references#CD009268-bbs2-0005" title="DufresneRL , ValentinoD , KassDJ . Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacology Bulletin1993; Vol. 29, issue 2:249‐55. ">Dufresne 1993</a>; <a href="./references#CD009268-bbs2-0007" title="GallantDM , BishopM , Guerrero‐FigueroaR . Effects of two butyrophenone compounds on acute schizophrenic patients: speculation on the neurophysiologic sites of action. International Journal of Neuropsychiatry1967;3(1):53‐60. ">Gallant 1967</a>; <a href="./references#CD009268-bbs2-0011" title="PrasadL , TownleyMC . Haloperidol and thioridazine in treatment of chronic schizophrenics. Diseases of the Nervous System1966;27(11):722‐6. ">Prasad 1966</a>; <a href="./references#CD009268-bbs2-0014" title="SerafetinidesEA , ClarkML . Psychological effects of single dose antipsychotic medication. Biological Psychiatry1973; Vol. 7, issue 3:263‐7. SerafetinidesEA , CollinsS , ClarkML . Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease1972; Vol. 154, issue 1:31‐42. ">Serafetinides 1972</a>; <a href="./references#CD009268-bbs2-0016" title="WestonMJ , BentleyR , UnwinA , MorrisM , HarperMA . A comparative trial of haloperidol and thioridazine: management of chronic schizophrenia. Australian and New Zealand Journal of Psychiatry1973; Vol. 7, issue 1:52‐7. ">Weston 1973</a>). <a href="./references#CD009268-bbs2-0008" title="KlimkeA , KlieserE , LehmannE , MieleL . Initial improvement as a criterion for drug choice in acute schizophrenia. Pharmacopsychiatry1993;26:25‐9. ">Klimke 1993</a> made an explicit statement about blinding and was therefore also rated to have a low risk of bias. <a href="./references#CD009268-bbs2-0012" title="RompelH , SegalH . A comparison of the relative efficacy of serenace and chlorpromazine in the treatment of chronic schizophrenics. Journal of International Medical Research1978; Vol. 6, issue 2:126‐32. [MEDLINE: 344086] ">Rompel 1978</a> was single‐blind study. It seems that nurses know the treatment, but they were not allowed to tell raters and patients. Therefore, there might have been a performance bias, but no detection bias. </p> </section> <section id="CD009268-sec-0125"> <h4 class="title">Incomplete outcome data</h4> <p>In four studies risk of bias for incomplete outcome data was rated as adequate (<a href="./references#CD009268-bbs2-0006" title="FoxW , GobbleIF , ClosM . A clinical comparison of trifluperidol, haloperidol and chlorpromazine. Current Therapeutic Research1964;6(6):409‐15. ">Fox 1964</a>; <a href="./references#CD009268-bbs2-0007" title="GallantDM , BishopM , Guerrero‐FigueroaR . Effects of two butyrophenone compounds on acute schizophrenic patients: speculation on the neurophysiologic sites of action. International Journal of Neuropsychiatry1967;3(1):53‐60. ">Gallant 1967</a>; <a href="./references#CD009268-bbs2-0011" title="PrasadL , TownleyMC . Haloperidol and thioridazine in treatment of chronic schizophrenics. Diseases of the Nervous System1966;27(11):722‐6. ">Prasad 1966</a>; <a href="./references#CD009268-bbs2-0017" title="WhiteK , BuskJ , EatonE , GomezG , RazaniJ , SloaneRB . Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine. International Pharmacopsychiatry1981; Vol. 16, issue 1:34‐8. ">White 1981</a>). Four studies provided insufficient information to permit judgement about incomplete outcome data and were rated as unclear (<a href="./references#CD009268-bbs2-0001" title="BiY . A relation study of the extrapyramidal symptoms, serum prolactin levels and clinical response during treatment of antipsychotics. Chinese Journal of Nervous and Mental Diseases1994;20(2):70‐3. ">Bi 1994</a>; <a href="./references#CD009268-bbs2-0010" title="NishizonoM . A comparative trial of zotepine, chlorpromazine and haloperidol in schizophrenic patients. Neuropsychopharmacology1994;10:30. ">Nishizono 1994</a>; <a href="./references#CD009268-bbs2-0013" title="SchmidtLG , SchüsslerG , KappesCV , Müller‐OerlinghausenB . Comparison of higher‐dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients [Vergleich einer höher dosierten Haloperidol‐Therapie mt einer Perazin‐Standard‐Therapie bei akut‐schizophrenen Patienten]. Nervenarzt1982;53(9):530‐6. ">Schmidt 1982</a>; <a href="./references#CD009268-bbs2-0016" title="WestonMJ , BentleyR , UnwinA , MorrisM , HarperMA . A comparative trial of haloperidol and thioridazine: management of chronic schizophrenia. Australian and New Zealand Journal of Psychiatry1973; Vol. 7, issue 1:52‐7. ">Weston 1973</a>). <a href="./references#CD009268-bbs2-0016" title="WestonMJ , BentleyR , UnwinA , MorrisM , HarperMA . A comparative trial of haloperidol and thioridazine: management of chronic schizophrenia. Australian and New Zealand Journal of Psychiatry1973; Vol. 7, issue 1:52‐7. ">Weston 1973</a> described that there were no drop‐outs in the haloperidol group, yet there were two participants missing from global assessment. It is not clear what happened with these two participants.<br/> <br/> Nine studies were rated to have a high risk of bias. Of these, six studies had an attrition rate between 10% and 25% and most of these studies only analysed study completers (<a href="./references#CD009268-bbs2-0003" title="BorisonRL , SinhaD , HaverstockS , McLarnonMC , DiamondBI . Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double‐blind, placebo‐controlled trial. Psychopharmacology Bulletin1989; Vol. 25, issue 2:190‐3. ">Borison 1989</a>; <a href="./references#CD009268-bbs2-0004" title="ClarkML . Haloperidol versus chlorpromazine versus placebo. Psychopharmacology Bulletin1969; Vol. 5, issue 3:57‐9. ">Clark 1969</a>; <a href="./references#CD009268-bbs2-0005" title="DufresneRL , ValentinoD , KassDJ . Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacology Bulletin1993; Vol. 29, issue 2:249‐55. ">Dufresne 1993</a>; <a href="./references#CD009268-bbs2-0009" title="McCreadieRG , MacDonaldIM . High dosage haloperidol in chronic schizophrenia. British Journal of Psychiatry1977; Vol. 131:310‐6. ">McCreadie 1977</a>; <a href="./references#CD009268-bbs2-0012" title="RompelH , SegalH . A comparison of the relative efficacy of serenace and chlorpromazine in the treatment of chronic schizophrenics. Journal of International Medical Research1978; Vol. 6, issue 2:126‐32. [MEDLINE: 344086] ">Rompel 1978</a>; <a href="./references#CD009268-bbs2-0014" title="SerafetinidesEA , ClarkML . Psychological effects of single dose antipsychotic medication. Biological Psychiatry1973; Vol. 7, issue 3:263‐7. SerafetinidesEA , CollinsS , ClarkML . Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease1972; Vol. 154, issue 1:31‐42. ">Serafetinides 1972</a>). Two studies had a high attrition rate of &gt; 25% and drop‐outs were not equally distributed between groups (<a href="./references#CD009268-bbs2-0002" title="BlinO , AzorinJM , BouhoursP . Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. Journal of Clinical Psychopharmacology1996; Vol. 16, issue 1:38‐44. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol and risperidone in 62 schizophrenic patients. Clinical Pharmacology and Therapeutics. France, 1992; Vol. 51, issue 2:189. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol, and risperidone in 62 schizophrenic patients. Psychopharmacology1992:31‐2. BlinO , AzorinJM , BouhoursP . Comparison of anxiolytic properties of levomepromazine, haloperidol and risperidone in schizophrenic patients. Biological Psychiatry. France, 1991; Vol. 29:388. BlinO , AzorinJM , BouhoursP , FondaraiJ . Anxiolytic profiles of risperidone, haloperidol, and levomepromazine in schizophrenia: a factorial and regression analysis. Proceedings of the 9th World Congress of Psychiatry; 1993 Jun 6‐12; Rio de Janeiro, Brazil. France, 1993:24. BlinO , AzorinJM , BouhoursPh , FondaraiJ . Comparison of risperidone, haloperidol and levomepromazine in schizophrenia: a factorial analysis and discriminant function analysis. Clinical Neuropharmacology1992; Vol. 15, issue Suppl 1. Pt B:169B. ">Blin 1996</a>; <a href="./references#CD009268-bbs2-0008" title="KlimkeA , KlieserE , LehmannE , MieleL . Initial improvement as a criterion for drug choice in acute schizophrenia. Pharmacopsychiatry1993;26:25‐9. ">Klimke 1993</a>). Another reason for high risk of bias was incomplete reporting of the exact number of drop‐outs for each drug group (<a href="./references#CD009268-bbs2-0015" title="ShalevA , HermeshH , RothbergJ , MunitzH . Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica1993; Vol. 87, issue 2:86‐91. ">Shalev 1993</a>). </p> </section> <section id="CD009268-sec-0126"> <h4 class="title">Selective reporting</h4> <p>We judged six studies to be free of selective reporting (<a href="./references#CD009268-bbs2-0002" title="BlinO , AzorinJM , BouhoursP . Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. Journal of Clinical Psychopharmacology1996; Vol. 16, issue 1:38‐44. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol and risperidone in 62 schizophrenic patients. Clinical Pharmacology and Therapeutics. France, 1992; Vol. 51, issue 2:189. BlinO , AzorinJM , BouhoursP . Anxiolytic profiles of levomepromazine, haloperidol, and risperidone in 62 schizophrenic patients. Psychopharmacology1992:31‐2. BlinO , AzorinJM , BouhoursP . Comparison of anxiolytic properties of levomepromazine, haloperidol and risperidone in schizophrenic patients. Biological Psychiatry. France, 1991; Vol. 29:388. BlinO , AzorinJM , BouhoursP , FondaraiJ . Anxiolytic profiles of risperidone, haloperidol, and levomepromazine in schizophrenia: a factorial and regression analysis. Proceedings of the 9th World Congress of Psychiatry; 1993 Jun 6‐12; Rio de Janeiro, Brazil. France, 1993:24. BlinO , AzorinJM , BouhoursPh , FondaraiJ . Comparison of risperidone, haloperidol and levomepromazine in schizophrenia: a factorial analysis and discriminant function analysis. Clinical Neuropharmacology1992; Vol. 15, issue Suppl 1. Pt B:169B. ">Blin 1996</a>; <a href="./references#CD009268-bbs2-0003" title="BorisonRL , SinhaD , HaverstockS , McLarnonMC , DiamondBI . Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double‐blind, placebo‐controlled trial. Psychopharmacology Bulletin1989; Vol. 25, issue 2:190‐3. ">Borison 1989</a>; <a href="./references#CD009268-bbs2-0009" title="McCreadieRG , MacDonaldIM . High dosage haloperidol in chronic schizophrenia. British Journal of Psychiatry1977; Vol. 131:310‐6. ">McCreadie 1977</a>; <a href="./references#CD009268-bbs2-0012" title="RompelH , SegalH . A comparison of the relative efficacy of serenace and chlorpromazine in the treatment of chronic schizophrenics. Journal of International Medical Research1978; Vol. 6, issue 2:126‐32. [MEDLINE: 344086] ">Rompel 1978</a>; <a href="./references#CD009268-bbs2-0015" title="ShalevA , HermeshH , RothbergJ , MunitzH . Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica1993; Vol. 87, issue 2:86‐91. ">Shalev 1993</a>; <a href="./references#CD009268-bbs2-0017" title="WhiteK , BuskJ , EatonE , GomezG , RazaniJ , SloaneRB . Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine. International Pharmacopsychiatry1981; Vol. 16, issue 1:34‐8. ">White 1981</a>). Three studies did not provide enough information to permit a reasonable judgement and were rated as unclear (<a href="./references#CD009268-bbs2-0001" title="BiY . A relation study of the extrapyramidal symptoms, serum prolactin levels and clinical response during treatment of antipsychotics. Chinese Journal of Nervous and Mental Diseases1994;20(2):70‐3. ">Bi 1994</a>; <a href="./references#CD009268-bbs2-0010" title="NishizonoM . A comparative trial of zotepine, chlorpromazine and haloperidol in schizophrenic patients. Neuropsychopharmacology1994;10:30. ">Nishizono 1994</a>; <a href="./references#CD009268-bbs2-0016" title="WestonMJ , BentleyR , UnwinA , MorrisM , HarperMA . A comparative trial of haloperidol and thioridazine: management of chronic schizophrenia. Australian and New Zealand Journal of Psychiatry1973; Vol. 7, issue 1:52‐7. ">Weston 1973</a>).<br/> <br/> We judged eight studies to have a high risk of bias. The following seven studies did not report sufficiently on predefined outcomes: <a href="./references#CD009268-bbs2-0004" title="ClarkML . Haloperidol versus chlorpromazine versus placebo. Psychopharmacology Bulletin1969; Vol. 5, issue 3:57‐9. ">Clark 1969</a>; <a href="./references#CD009268-bbs2-0005" title="DufresneRL , ValentinoD , KassDJ . Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacology Bulletin1993; Vol. 29, issue 2:249‐55. ">Dufresne 1993</a>; <a href="./references#CD009268-bbs2-0006" title="FoxW , GobbleIF , ClosM . A clinical comparison of trifluperidol, haloperidol and chlorpromazine. Current Therapeutic Research1964;6(6):409‐15. ">Fox 1964</a>; <a href="./references#CD009268-bbs2-0007" title="GallantDM , BishopM , Guerrero‐FigueroaR . Effects of two butyrophenone compounds on acute schizophrenic patients: speculation on the neurophysiologic sites of action. International Journal of Neuropsychiatry1967;3(1):53‐60. ">Gallant 1967</a>; <a href="./references#CD009268-bbs2-0011" title="PrasadL , TownleyMC . Haloperidol and thioridazine in treatment of chronic schizophrenics. Diseases of the Nervous System1966;27(11):722‐6. ">Prasad 1966</a>; <a href="./references#CD009268-bbs2-0013" title="SchmidtLG , SchüsslerG , KappesCV , Müller‐OerlinghausenB . Comparison of higher‐dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients [Vergleich einer höher dosierten Haloperidol‐Therapie mt einer Perazin‐Standard‐Therapie bei akut‐schizophrenen Patienten]. Nervenarzt1982;53(9):530‐6. ">Schmidt 1982</a>; <a href="./references#CD009268-bbs2-0014" title="SerafetinidesEA , ClarkML . Psychological effects of single dose antipsychotic medication. Biological Psychiatry1973; Vol. 7, issue 3:263‐7. SerafetinidesEA , CollinsS , ClarkML . Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease1972; Vol. 154, issue 1:31‐42. ">Serafetinides 1972</a>. One study presented results only for subgroups or independently of treatment condition (<a href="./references#CD009268-bbs2-0008" title="KlimkeA , KlieserE , LehmannE , MieleL . Initial improvement as a criterion for drug choice in acute schizophrenia. Pharmacopsychiatry1993;26:25‐9. ">Klimke 1993</a>). </p> </section> <section id="CD009268-sec-0127"> <h4 class="title">Other potential sources of bias</h4> <p>Fourteen studies were free of other potential sources of bias and in three studies this was unclear (<a href="./references#CD009268-bbs2-0004" title="ClarkML . Haloperidol versus chlorpromazine versus placebo. Psychopharmacology Bulletin1969; Vol. 5, issue 3:57‐9. ">Clark 1969</a>; <a href="./references#CD009268-bbs2-0010" title="NishizonoM . A comparative trial of zotepine, chlorpromazine and haloperidol in schizophrenic patients. Neuropsychopharmacology1994;10:30. ">Nishizono 1994</a>; <a href="./references#CD009268-bbs2-0017" title="WhiteK , BuskJ , EatonE , GomezG , RazaniJ , SloaneRB . Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine. International Pharmacopsychiatry1981; Vol. 16, issue 1:34‐8. ">White 1981</a>). </p> </section> </section> <section id="CD009268-sec-0128"> <h3 class="title" id="CD009268-sec-0128">Effects of interventions</h3> <p>See: <a href="./full#CD009268-tbl-0001"><b>Summary of findings for the main comparison</b> HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS for schizophrenia</a> </p> <p>For dichotomous data, we calculated risk ratios (RR) and for continuous data, we calculated mean differences (MD), both with 95% confidence intervals (CI). </p> <section id="CD009268-sec-0129"> <h4 class="title">1. Haloperidol versus low‐potency antipsychotic drugs</h4> <section id="CD009268-sec-0130"> <h5 class="title">1.1 Response to treatment</h5> <p>There was no significant difference between haloperidol and low‐potency antipsychotics in terms of response to treatment as defined by the original studies (haloperidol 40%, low‐potency antipsychotics 36%, 14 RCTs, n = 574, RR 1.11, CI 0.86 to 1.44, <a href="./references#CD009268-fig-0005" title="">Analysis 1.1</a>). </p> </section> <section id="CD009268-sec-0131"> <h5 class="title">1.2 Mental state</h5> <p>There was no significant difference between groups for total BPRS scoring (4 RCTs, n = 133, MD ‐0.09, CI ‐2.15 to 1.96, <a href="./references#CD009268-fig-0006" title="">Analysis 1.2</a>) or PANSS scores (1 RCT, n = 41, MD ‐4.00, CI ‐20.69 to 12.69, <a href="./references#CD009268-fig-0007" title="">Analysis 1.3</a>). </p> <p>Subscores of PANSS positive symptom reduction were also not significant (1 RCT, n = 41, MD ‐1.00, CI ‐6.77 to 4.77), neither were negative symptom scores (1 RCT, n = 41, MD ‐0.10, CI ‐5.20 to 5.00, <a href="./references#CD009268-fig-0007" title="">Analysis 1.3</a>). </p> </section> <section id="CD009268-sec-0132"> <h5 class="title">1.3 Global state</h5> <p>We found no significant difference in CGI scores between drugs (3 RCTs, n = 117, MD 0.09, CI ‐0.31 to 0.50, <a href="./references#CD009268-fig-0008" title="">Analysis 1.4</a>). </p> </section> <section id="CD009268-sec-0133"> <h5 class="title">1.4 Relapse</h5> <p>There was no significant difference between drugs (haloperidol 7%, low‐potency drug 14%, 5 RCTs, n = 141, RR 0.64, CI 0.26 to 1.57, <a href="./references#CD009268-fig-0009" title="">Analysis 1.5</a>). </p> </section> <section id="CD009268-sec-0134"> <h5 class="title">1.5 Leaving the study early</h5> <p>There was no significant difference in the number of participants leaving the study early due to any reason (haloperidol 13%, low‐potency antipsychotics 17%, 11 RCTs, n = 408, RR 0.82, CI 0.38 to 1.77, <a href="./references#CD009268-fig-0010" title="">Analysis 1.6</a>). Similar findings were evident for the reason of leaving because of adverse effects (haloperidol 2%, low‐potency antipsychotics 7%, 11 RCTs, n = 408, RR 0.44, CI 0.16 to 1.20) or inefficacy of treatment (haloperidol 4.3%, low‐potency antipsychotics 8%, 10 RCTs, n = 378, RR 0.63, CI 0.31 to 1.29). </p> </section> <section id="CD009268-sec-0135"> <h5 class="title">1.6 Adverse effects</h5> <section id="CD009268-sec-0136"> <h6 class="title">1.6.1 General</h6> <p>There was no significant difference for the general outcome of 'at least one adverse effect' (haloperidol 70%, low‐potency antipsychotics 35%, 5 RCTs, n = 158, RR 1.97, CI 0.69 to 5.66, <a href="./references#CD009268-fig-0011" title="">Analysis 1.7</a>). </p> </section> <section id="CD009268-sec-0137"> <h6 class="title">1.6.2 Specific ‐ movement disorder</h6> <p>When it came to movement disorders (<a href="./references#CD009268-fig-0012" title="">Analysis 1.8</a>), there was a significant difference in favour of low‐potency antipsychotics for the outcome of 'at least one movement disorder adverse effect' (haloperidol 72%, low‐potency antipsychotics 41%, 5 RCTs, n = 170, RR 1.64, CI 1.22 to 2.21). </p> <p>There was no significant difference for 'akathisia' (haloperidol 34%, low‐potency antipsychotics 27%, 4 RCTs, n = 160, RR 1.27, CI 0.56 to 2.90) or dyskinesia (haloperidol 16%, low‐potency antipsychotics 5%, 1 RCT, n = 38, RR 3.00, CI 0.34 to 26.33). For dystonia, there was a significant difference in favour of low‐potency antipsychotics (haloperidol 23%, low‐potency antipsychotics 4%, 5 RCTs, n = 193, RR 4.71, CI 1.95 to 11.36) but not for 'loss of associated movement', (haloperidol 7%, low‐potency antipsychotics 0%, 1 RCT, n = 86, RR 7.33,CI 0.39 to 137.68), oculogyric crisis (haloperidol 2%, low‐potency antipsychotics 0%, 1 RCT, n = 86, RR 3.14, CI 0.13 to 74.98), or 'rigor' (haloperidol 25%, low‐potency antipsychotics 0%, 1 RCT, n = 16, RR 5.00, CI 0.28 to 90.18). For tremor, there was no significant difference (haloperidol 50%, low‐potency antipsychotics 49%, 2 RCTs, n = 127, RR 2.17, CI 0.16 to 29.13) but for the less specific 'use of antiparkinson medication' there was (haloperidol 64%, low‐potency antipsychotics 25%, 6 RCTs, n = 165, RR 2.88, CI 1.19 to 7.00). There was, however, significant heterogeneity of the study results (P &lt; .01, I<sup>2</sup> = 67%), but the antiparkinson medication rates were always lower in the low‐potency drug group than in the haloperidol group. Thus, the heterogeneity expresses a difference in the magnitude of the superiority rather than in the direction of the effect which is less problematic. </p> <p>For rating scales, there was there a significant difference in favour of low‐potency antipsychotic drugs (2 RCTs, n = 78, MD 2.01, CI 1.35 to 2.68, <a href="./references#CD009268-fig-0013" title="">Analysis 1.9</a>). </p> </section> <section id="CD009268-sec-0138"> <h6 class="title">1.6.3 Specific ‐ others</h6> <section id="CD009268-sec-0139"> <p><b>a. Allergy</b></p> <p>There was no significant difference for 'allergic reactions' (haloperidol 2%, low‐potency antipsychotics 0%, 1 RCT, n = 86, RR 3.14, CI 0.13 to 74.98, <a href="./references#CD009268-fig-0014" title="">Analysis 1.10</a>) and for 'rash' (haloperidol 5%, low‐potency antipsychotics 0%, 1 RCT, n = 38, RR 3.00, CI 0.13 to 69.31). Based on a single study, there was a significant difference in favour of haloperidol for 'tongue reactions' (haloperidol 26%, low‐potency antipsychotics 52%, 1 RCT, n = 86, RR 0.50, CI 0.28 to 0.90 NNH 4 CI 2‐17). </p> </section> <section id="CD009268-sec-0140"> <p><b>b. Anticholinergic</b></p> <p>There was no significant difference for 'blurring of vision' (haloperidol 15%, low‐potency antipsychotics 19%, 2 RCTs, n = 124, RR 0.78, CI 0.35 to 1.70), constipation (haloperidol 17%, low‐potency antipsychotics 9%, 3 RCTs, n = 155, RR 1.53, CI 0.21 to 11.20), drooling (haloperidol 5%, low‐potency antipsychotics 2%, 1 RCT, n = 86, RR 2.10, CI 0.20 to 22.26), dry mouth (haloperidol 37%, low‐potency antipsychotics 46%, 4 RCTs, n = 195, RR 0.85, CI 0.63 to 1.15), micturition disturbances (haloperidol 0%, low‐potency antipsychotics 10%, 1 RCT, n = 41, RR 0.21, CI 0.01 to 4.11), repercussions on sexual life (haloperidol 0%, low‐potency antipsychotics 10%, 1 RCT, n = 41, RR 0.21, CI 0.01 to 4.11), sweating (haloperidol 15%, low‐potency antipsychotics 5%, 1 RCT, n = 41, RR 3.15, CI 0.36 to 27.83) or urinary retention (haloperidol 0%, low‐potency antipsychotics 0%, 1 RCT, n = 86, RR not estimable). </p> </section> <section id="CD009268-sec-0141"> <p><b>c. Cardiovascular</b></p> <p>There was no significant difference for 'ankle oedema' (haloperidol 0%, low‐potency antipsychotics 0%, 1 RCT, n = 28, RR not estimable), palpitations (haloperidol 10%, low‐potency antipsychotics 33%, 1 RCT, n = 41, RR 0.30, CI 0.07 to 1.28), or syncope (haloperidol 0%, low‐potency antipsychotics 7%, 1 RCT, n = 86, RR 0.15, CI 0.01 to 2.81). There was a significant difference in favour of haloperidol for dizziness (haloperidol 19%, low‐potency antipsychotics 54%, 2 RCTs, n = 127, RR 0.36, CI 0.21 to 0.62), and orthostatic symptoms (haloperidol 25%, low‐potency antipsychotics 71%, 1 RCT, n = 41, RR 0.35, CI 0.16 to 0.78). There was a trend in favour haloperidol in terms of hypotension but the difference was not statistically significant (haloperidol 2%, low‐potency antipsychotics 46%, 6 RCTs, n = 251, RR 0.32, CI 0.10 to 1.07). </p> </section> <section id="CD009268-sec-0142"> <p><b>d. Central nervous system</b></p> <p>There was a trend in favour of low‐potency antipsychotics for 'asthenia' but the difference was not statistically significant (haloperidol 60%, low‐potency antipsychotics 29%, 1 RCT, n = 41, RR 2.10, CI 0.98 to 4.51). There was no significant difference for 'confusion' (haloperidol 6%, low‐potency antipsychotics 0%, 1 RCT, n = 30, RR 2.65, CI 0.12 to 60.21), excitement (haloperidol 0%, low‐potency antipsychotics 0%, 1 RCT, n = 28, RR not estimable), headache (haloperidol 11%, low‐potency antipsychotics 4%, 2 RCTs, n = 127, RR 2.67, CI 0.50 to 14.19), nausea (haloperidol 7%, low‐potency antipsychotics 5%, 1 RCT, n = 86, RR 1.57, CI 0.28 to 8.94), photosensitivity (haloperidol 32%, low‐potency antipsychotics 32%, 3 RCTs, n = 134, RR 0.41, CI 0.05 to 3.39), somnolence (haloperidol 47%, low‐potency antipsychotics 53%, 5 RCTs, n = 224, RR 0.91, CI 0.49 to 1.72), and sleep disturbances (haloperidol 30%, low‐potency antipsychotics 5%, 1 RCT, n = 41, RR 6.30, CI 0.83 to 47.80). There was a significant difference in favour of haloperidol in terms of sedation (haloperidol 14%, low‐potency antipsychotics 41%, 2 RCTs, n = 44, RR 0.30, CI 0.11 to 0.82). </p> </section> <section id="CD009268-sec-0143"> <p><b>e. Hormonal</b></p> <p>For amenorrhoea there was no significant difference (haloperidol 0%, low‐potency antipsychotics 0%, 1 RCT, n = 86, RR not estimable). </p> </section> <section id="CD009268-sec-0144"> <p><b>f. Metabolic</b></p> <p>There was a significant difference in the number of participants with weight gain in favour of haloperidol (haloperidol 5%, low‐potency antipsychotics 29%, 3 RCTs, n = 88, RR 0.22, CI 0.06 to 0.81). There was no significant difference regarding weight loss (haloperidol 40%, low‐potency antipsychotics 40%, 2 RCTs, n = 68, RR 0.60, CI 0.06 to 6.06). </p> </section> </section> <section id="CD009268-sec-0145"> <h6 class="title">1.13 Missing outcomes</h6> <p>There were no data on potentially important outcomes such as death, hospital admission, cost, satisfaction with care, quality of life or employment. </p> </section> </section> </section> <section id="CD009268-sec-0146"> <h4 class="title">2. Subgroup analyses</h4> <p>All subgroup analyses were conducted only on the primary outcome response to treatment as defined by the original studies. </p> <section id="CD009268-sec-0147"> <h5 class="title">2.1 Different low‐potency drugs</h5> <p>Seven studies compared haloperidol with chlorpromazine and did not find a significant difference in the primary outcome response to treatment (haloperidol 39%, chlorpromazine 27%, 7 RCTs, n = 290, RR 1.31, CI 0.97 to 1.77). The comparisons with levomepromazine (haloperidol 55%, levomepromazine 64%, 2 RCTs, n = 80, RR 0.86, CI 0.50 to 1.49), perazine (haloperidol 60%, perazine 53%, 1 RCT, n = 32, RR 1.13, CI 0.62 to 2.08) and thioridazine (haloperidol 32%, thioridazine 37%, 3 RCTs, n = 156, RR 0.78, CI 0.31 to 1.97) also did not find any significant difference of these low‐potency first‐generation antipsychotic drugs compared with haloperidol. </p> </section> <section id="CD009268-sec-0148"> <h5 class="title">2.2 Clinical state, stage or problem</h5> <p>Two studies included only participants who were treatment‐resistant and did not show a superiority of haloperidol compared with low‐potency antipsychotics (drug 50%, low‐potency antipsychotics 61%, 2 RCTs, n = 59, RR 0.91, CI 0.38 to 2.17). There was no significant difference compared with the rest of the studies (test for subgroup differences: Chi² = 0.27, df = 1 (P = 0.60), I² = 0%). </p> </section> </section> <section id="CD009268-sec-0149"> <h4 class="title">3. Sensitivity analyses</h4> <p>All sensitivity analyses were conducted only on the primary outcome "response to treatment as defined by the original studies". </p> <section id="CD009268-sec-0150"> <h5 class="title">3.1 Fixed‐effect model</h5> <p>When a fixed‐effect model was applied, haloperidol was again not significantly different from low‐potency drugs (haloperidol 40%, low‐potency 37%, 13 RCTs, n = 558, RR 1.11, CI 0.91 to 1.36). </p> </section> <section id="CD009268-sec-0151"> <h5 class="title">3.2 Exclusion of studies for which randomisation was implied because they were double‐blind</h5> <p>There was one study which was not explicitly described as randomised (<a href="./references#CD009268-bbs2-0011" title="PrasadL , TownleyMC . Haloperidol and thioridazine in treatment of chronic schizophrenics. Diseases of the Nervous System1966;27(11):722‐6. ">Prasad 1966</a>). Excluding this study did not change overall results. Haloperidol was still not significantly different from the low‐potency drugs (haloperidol 40%, low‐potency 37%, 12 RCTs, n = 518 RR 1.09, CI 0.82 to 1.44). </p> </section> <section id="CD009268-sec-0152"> <h5 class="title">3.3 Exclusion of studies which were not blinded</h5> <p>There were two studies which were probably open (<a href="./references#CD009268-bbs2-0001" title="BiY . A relation study of the extrapyramidal symptoms, serum prolactin levels and clinical response during treatment of antipsychotics. Chinese Journal of Nervous and Mental Diseases1994;20(2):70‐3. ">Bi 1994</a>; <a href="./references#CD009268-bbs2-0010" title="NishizonoM . A comparative trial of zotepine, chlorpromazine and haloperidol in schizophrenic patients. Neuropsychopharmacology1994;10:30. ">Nishizono 1994</a>). Excluding these two studies did not change overall results (haloperidol 43%, low‐potency 39%, 11 RCTs, n = 412, RR 1.11, CI 0.80 to 1.54). </p> </section> <section id="CD009268-sec-0153"> <h5 class="title">3.4 Investigation of heterogeneity</h5> <p>There was one outlying study (<a href="./references#CD009268-bbs2-0005" title="DufresneRL , ValentinoD , KassDJ . Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacology Bulletin1993; Vol. 29, issue 2:249‐55. ">Dufresne 1993</a>). Excluding this study removed heterogeneity, but did not change the overall results (haloperidol 42%, low‐potency antipsychotics 35%, 12 RCTs, n = 528, RR 1.13, CI 0.93 to 1.39). </p> </section> <section id="CD009268-sec-0154"> <h5 class="title">3.4 Assessment of dosage</h5> <p>There were no clearly discrepant doses between haloperidol and low‐potency antipsychotics in the included studies, therefore this sensitivity analysis was not performed. </p> </section> </section> <section id="CD009268-sec-0155"> <h4 class="title">4. Other results</h4> <section id="CD009268-sec-0156"> <h5 class="title">4.1 Publication bias</h5> <p>The funnel plot of the primary outcome response to treatment as defined by the original studies was slightly asymmetrical (<i>see</i><a href="#CD009268-fig-0004">Figure 4</a>), however only two studies were not within the scope of the funnel plot. Duval's and Tweedy's (<a href="./references#CD009268-bbs2-0079" title="DuvalS , TweedieR . Trim and fill: A simple funnel‐plot‐based method of testing and adjusting for publication bias in meta‐analysis. Biometrics2000;56(2):455‐63. ">Duval 2000</a>) trim‐and‐fill method also did not suggest a publication bias, because the point estimate did not change much (RR 1.02, CI 0.77‐1.34). </p> <div class="figure" id="CD009268-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, outcome: 1.1 Response to treatment." data-id="CD009268-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, outcome: 1.1 Response to treatment. </p> </div> </div> </div> </section> <section id="CD009268-sec-0157"> <h5 class="title">4.2 'Summary of findings' table</h5> <p>The results of the outcomes clinically significant response, leaving the study early, at least one adverse effect, at least one movement disorder, sedation, death and quality of life were inspected in the 'Summary of findings' table. Based on this tool, we considered the quality of the results for the outcomes sedation to be moderate, for response to treatment, leaving the study due to any reason and at least one movement disorder to be low and at least one adverse effect to be very poor. Moreover, no data on the outcome death as well as quality of life were available. The judgements derived from this instrument were used for the discussion section of the review (<i>see</i><a href="#CD009268-sec-0158">Discussion</a> ‐ <a href="#CD009268-sec-0159">Summary of main results</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009268-sec-0158" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009268-sec-0158"></div> <section id="CD009268-sec-0159"> <h3 class="title" id="CD009268-sec-0159">Summary of main results</h3> <section id="CD009268-sec-0160"> <h4 class="title">1. General</h4> <p>Conventional antipsychotic drugs are still used in the treatment of schizophrenia, both in poorer as well as in richer countries. This review compared haloperidol with low‐potency antipsychotics, including 17 trials with 877 participants. No superiority of haloperidol versus low‐potency antipsychotics or vice versa was found for the primary outcome 'response to treatment'. This finding is in line with the statements of treatment guidelines that low‐potency drugs are as efficacious as high‐potency antipsychotics such as haloperidol (e.g. <a href="./references#CD009268-bbs2-0082" title="FalkaiP , WobrockT , LiebermanJ . World Federation of Societies of Biological Psychiatry (WFSBP) ‐ Guidelines for biological treatment of schizophrenia, part 1: Acute treatment of schizophrenia. World Journal of Biological Psychiatry2005;6:132‐91. ">Falkai 2005</a>). This finding contrasts with a clinical impression that low‐potency conventional antipsychotic drugs are less efficacious than high‐potency conventional antipsychotic drugs. However, this review has general limitations. The included studies were old and small, and all studies except one (<a href="./references#CD009268-bbs2-0010" title="NishizonoM . A comparative trial of zotepine, chlorpromazine and haloperidol in schizophrenic patients. Neuropsychopharmacology1994;10:30. ">Nishizono 1994</a>), randomised fewer than 100 participants. Current studies for registration of new antipsychotics usually include several hundreds of participants (e.g. <a href="./references#CD009268-bbs2-0094" title="KaneJM , MackleM , Snow‐AdamiL , ZhaoJ , SzegediA , PanagidesJ . A randomized placebo‐controlled trial of asenapine for the prevention of relapse of schizophrenia after long‐term treatment. Journal of Clinical Psychiatry2011;72(3):349‐55. ">Kane 2011</a>). Also, for studies conducted in the 1960s and 1970s operationalised diagnostic criteria such as DSM‐III or its more recent versions were not available. The studies often did not report on the primary outcome response to treatment, used different cut‐offs of rating scale reductions to define it, and the methods of sequence generation and blinding were often poorly reported. Important outcomes such as hospital admission, death, quality of life, employment, cost of care, have not been reported at all. All in all, the data obtained are not ideal for making conclusions about the relative tolerability and efficacy of antipsychotics with differing potency, which is also reflected by the low quality of most outcomes in the 'Summary of findings' table (<i>see</i><a href="./full#CD009268-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD009268-sec-0161"> <h4 class="title">2. Treatment effects</h4> <section id="CD009268-sec-0162"> <h5 class="title">2.1 Response to treatment</h5> <p>The overall results of the outcome response to treatment do not suggest any difference in efficacy between haloperidol and low‐potency antipsychotic drugs. This applies to the primary dichotomous outcome as well as continuous measures, although data on the latter were scarce. This result supports early narrative work, which was not based on meta‐analytic methods (<a href="./references#CD009268-bbs2-0071" title="DavisJM , BarterJT , KaneJM . Antipsychotic drugs. Comprehensive Textbook of Psychiatry. Williams and Wilkins, 1989. ">Davis 1989</a>; <a href="./references#CD009268-bbs2-0097" title="KleinDF , DavisJM . Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore: Williams and Wilkins, 1969. ">Klein 1969</a>), and does not confirm the clinical perception that low‐potency antipsychotic drugs are less efficacious than haloperidol. However, the criteria and cut‐offs used for the primary outcome 'response to treatment' varied, although <a href="./references#CD009268-bbs2-0086" title="FurukawaTA , AkechiT , WagenpfeilS , LeuchtS . Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials. Schizophrenia Research2011;126:212‐9. ">Furukawa 2011</a> showed that this is not so much of a problem as long as relative risks and odds ratios are used as effect sizes. </p> </section> <section id="CD009268-sec-0163"> <h5 class="title">2.2 Leaving the study early</h5> <p>There was no significant difference between haloperidol and low‐potency antipsychotics in the outcome leaving the studies early due to any reason. As 'leaving the studies early for any reason' combines inefficacy of treatment and overall tolerability, it suggests that haloperidol and low‐potency antipsychotics are not different in their overall acceptability for people with schizophrenia. We also found no significant difference for leaving the study early due to adverse events as well as leaving early due to inefficacy. However, only 11 studies with 400 participants reported data on these outcomes, which is relatively little and more data would be needed to strengthen this interpretation. </p> </section> <section id="CD009268-sec-0164"> <h5 class="title">2.3 Adverse effects</h5> <p>In those studies that reported on adverse events, high‐potency antipsychotics produced more movement disorders in terms of at least one movement disorder, dystonia and use of antiparkinson medication. Low‐potency antipsychotics produced significantly more dizziness, orthostatic symptoms, sedation and weight gain, but only a few studies reported data on these important outcomes. Weight gain can have particularly serious consequences, such as diabetes and associated mortality, and it can also have a negative effect on treatment adherence. The findings on adverse effects are in line with today's knowledge that high‐potency and low‐potency antipsychotics have different affinities and binding properties to dopamine and other receptors, and that they thus differ in the nature of adverse events (<a href="./references#CD009268-bbs2-0093" title="KaneJM . Schizophrenia. New England Journal of Medicine1996;334:34‐41. ">Kane 1996</a>). </p> </section> <section id="CD009268-sec-0165"> <h5 class="title">2.4 Missing outcomes</h5> <p>None of the included studies reported on service use, death, quality of life, participants'/carers' satisfaction with care or economic outcomes. These outcomes may be more important for afflicted people and policy makers than conventional measures of efficacy and tolerability. It is therefore disappointing that they are not available. </p> </section> <section id="CD009268-sec-0166"> <h5 class="title">3. Publication bias</h5> <p>The funnel plot of the primary outcome response to treatment as defined by the original studies was slightly asymmetrical (<i>see</i><a href="#CD009268-fig-0004">Figure 4</a>), so it is possible that unpublished studies we are not aware of exist. However, Egger´s test (<a href="./references#CD009268-bbs2-0080" title="EggerM , Davey‐SmithG , SchneiderM , MinderCSO . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;13:629‐34. ">Egger 1997</a>) was not significant (intercept 1.11, P value 0.24, df 11) and when Duval's and Tweedy's (<a href="./references#CD009268-bbs2-0079" title="DuvalS , TweedieR . Trim and fill: A simple funnel‐plot‐based method of testing and adjusting for publication bias in meta‐analysis. Biometrics2000;56(2):455‐63. ">Duval 2000</a>) trim‐and‐fill method was used, the relative risk did not change much. However, both are imperfect methods to test for unpublished studies, therefore, a publication bias can not be ruled out with certainty. </p> </section> <section id="CD009268-sec-0167"> <h5 class="title">4. Subgroup analyses and investigation of heterogeneity</h5> <p>The effects of haloperidol versus each single low‐potency antipsychotic drug did not show significant differences between groups, but the results are clearly limited by the small number of trials assigned to each single low‐potency drug. There was also no difference in effects between studies with treatment‐resistant participants and the remaining studies. When the one study that accounted for heterogeneity was excluded, haloperidol was still not different from low‐potency antipsychotics in terms of clinically important response to treatment. </p> </section> <section id="CD009268-sec-0168"> <h5 class="title">5. Sensitivity analyses</h5> <p>The exclusion of studies that were not described as randomised or double‐blind did not change the overall results of the primary outcome. Also, the results of the primary outcome were not different when a fixed‐effect model instead of a random‐effects model was applied. Therefore, the results were robust towards the sensitivity analyses. </p> </section> </section> </section> <section id="CD009268-sec-0169"> <h3 class="title" id="CD009268-sec-0169">Overall completeness and applicability of evidence</h3> <section id="CD009268-sec-0170"> <h4 class="title">1. Completeness</h4> <p>Of the 17 included studies, 13 studies reported sufficient data for the primary outcome response to treatment. Therefore, we believe that the evidence on the primary outcome is quite complete. Nevertheless, several limitations, which are relevant for the conclusions of this systematic review, must be considered. The classification of high‐ and low‐potency antipsychotics is not clear cut and there were not data on all low‐potency antipsychotics. For example, there were no data for low‐potency antipsychotics such as mesoridazine, chlorprothixene or promazine, so that the overall evidence of the effectiveness of haloperidol compared with low‐potency antipsychotics is incomplete. The evidence on adverse events is particularly incomplete, as none of the included studies reported predefined adverse events such as death, suicide or cardiac effects, and for example, only three studies reported on weight gain. Finally, all studies fell in to the short‐term category. The long‐term effects are thus unclear. </p> </section> <section id="CD009268-sec-0171"> <h4 class="title">2. Applicability</h4> <p>Half of the studies were from the 1960s and 1970s and diagnosed participants according to clinical criteria, because at that time operationalised diagnostic criteria such as DSM‐III or its more recent versions were not available. Thus it is possible that those older studies included participants who nowadays would have another diagnosis than schizophrenia. The application of the findings for people diagnosed with schizophrenia nowadays must therefore be made with caution. Furthermore, most of the included studies were characterised by small sample sizes (&lt; 100 participants). It has been estimated that approximately 1000 participants need to be included in psychiatric meta‐analyses for the results to be robust (<a href="./references#CD009268-bbs2-0123" title="TrikalinosTA , ChurchillR , FerriM , LeuchtS , TuunainenA , WahlbeckK , IoannidisJP , EU‐PSI project. Effect sizes in cumulative meta‐analyses of mental health randomized trials evolved over time. Journal of Clinical Epidemiology2004;57(11):1124‐30. ">Trikalinos 2004</a>). However, this meta‐analyses included altogether only 677 participants and the primary outcome response to treatment was based on only 574 participants. </p> </section> </section> <section id="CD009268-sec-0172"> <h3 class="title" id="CD009268-sec-0172">Quality of the evidence</h3> <p>None of the included studies described the exact randomisation and allocation concealment methods and had to be rated as unclear in this regard. Most of the included studies were described as double‐blind but did not report many details on the methods and success of blinding. Lack of blinding is not necessarily a problem for objective outcomes, but problematic for subjective outcomes such as response to treatment or side‐effects. One could also argue that studies could also have unblinded by differences in side‐effects. We feel that the authors who used identical capsules probably did what they could, but we would recommend that the success of blinding should be verified in future trials. Most of the studies were not free of selective reporting because they failed to report on previously defined outcomes or on standard deviations for continuous outcomes. Incomplete outcome data and selective reporting can have an influence on the estimates of effect. There were also studies which did not report on the number of patients involved in the group or reported results independent of the treatment condition. Thus, a quarter of the included studies could not be used for the main outcome and even less so for other outcomes such as adverse events. In summary, the overall quality of the studies according to these criteria was rather low (also <i>see</i><a href="./full#CD009268-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD009268-sec-0173"> <h3 class="title" id="CD009268-sec-0173">Potential biases in the review process</h3> <p>We pooled all low‐potency antipsychotics in one group for all outcomes except for the primary outcome response to treatment, for which we also performed a subgroup analysis of each single low‐potency antipsychotic drug. However, the number of studies available for each individual drug was so small that analyses of most results would not have been meaningful and the "high‐potency versus low‐potency antipsychotic" classification is frequently used. Moreover, the search was based on Cochrane Schizophrenia Trials Register and the last search date was 2010, so it is possible that there are unpublished trials that we are not aware of. There is a possibility of publication bias, although the funnel plot may also be slightly asymmetrical due to other factors. </p> <p>We decided post‐hoc to include all outcomes reported by a study, not only the predefined outcomes. This change to the protocol was made on the basis that other outcomes (e.g. non‐prespecified adverse effects) might be important as well and did not affect review authors´ biases. </p> </section> <section id="CD009268-sec-0174"> <h3 class="title" id="CD009268-sec-0174">Agreements and disagreements with other studies or reviews</h3> <p>We are not aware of other reviews on the efficacy of haloperidol versus low‐potency antipsychotic drugs. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009268-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/urn:x-wiley:14651858:media:CD009268:CD009268-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_t/tCD009268-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009268-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/full#CD009268-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009268-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/urn:x-wiley:14651858:media:CD009268:CD009268-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_t/tCD009268-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009268-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/full#CD009268-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009268-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/urn:x-wiley:14651858:media:CD009268:CD009268-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_t/tCD009268-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009268-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/full#CD009268-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009268-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/urn:x-wiley:14651858:media:CD009268:CD009268-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_t/tCD009268-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, outcome: 1.1 Response to treatment." data-id="CD009268-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, outcome: 1.1 Response to treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/full#CD009268-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009268-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/urn:x-wiley:14651858:media:CD009268:CD009268-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_t/tCD009268-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 1 Response to treatment." data-id="CD009268-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 1 Response to treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/references#CD009268-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009268-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/urn:x-wiley:14651858:media:CD009268:CD009268-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_t/tCD009268-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 2 Mental state: 1a. General ‐ overall symptoms ‐ average endpoint score/change (BPRS, high = poor)." data-id="CD009268-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 2 Mental state: 1a. General ‐ overall symptoms ‐ average endpoint score/change (BPRS, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/references#CD009268-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009268-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/urn:x-wiley:14651858:media:CD009268:CD009268-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_t/tCD009268-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 3 Mental state: 1b. General ‐ overall symptoms ‐ average endpoint score/change (PANSS, high = poor)." data-id="CD009268-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 3 Mental state: 1b. General ‐ overall symptoms ‐ average endpoint score/change (PANSS, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/references#CD009268-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009268-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/urn:x-wiley:14651858:media:CD009268:CD009268-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_t/tCD009268-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 4 Global state: Average endpoint score/change (CGI, high = poor)." data-id="CD009268-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 4 Global state: Average endpoint score/change (CGI, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/references#CD009268-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009268-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/urn:x-wiley:14651858:media:CD009268:CD009268-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_t/tCD009268-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 5 Relapse." data-id="CD009268-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 5 Relapse. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/references#CD009268-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009268-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/urn:x-wiley:14651858:media:CD009268:CD009268-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_t/tCD009268-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 6 Leaving the study early." data-id="CD009268-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 6 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/references#CD009268-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009268-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/urn:x-wiley:14651858:media:CD009268:CD009268-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_t/tCD009268-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 7 Adverse effects: 1. General ‐ at least one adverse effect." data-id="CD009268-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 7 Adverse effects: 1. General ‐ at least one adverse effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/references#CD009268-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009268-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/urn:x-wiley:14651858:media:CD009268:CD009268-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_t/tCD009268-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 8 Adverse effects: 2a. Specific ‐ movement disorders." data-id="CD009268-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 8 Adverse effects: 2a. Specific ‐ movement disorders. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/references#CD009268-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009268-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/urn:x-wiley:14651858:media:CD009268:CD009268-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_t/tCD009268-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 9 Adverse effects: 2b. Specific ‐ movement disorders ‐ average endpoint score/change (ESRS, high = poor)." data-id="CD009268-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 9 Adverse effects: 2b. Specific ‐ movement disorders ‐ average endpoint score/change (ESRS, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/references#CD009268-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009268-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/urn:x-wiley:14651858:media:CD009268:CD009268-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_t/tCD009268-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 10 Adverse effects: 3. Others." data-id="CD009268-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS, Outcome 10 Adverse effects: 3. Others. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/references#CD009268-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009268-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/urn:x-wiley:14651858:media:CD009268:CD009268-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_t/tCD009268-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis, Outcome 1 Response to treatment ‐ each low‐potency antipsychotic separately." data-id="CD009268-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis, Outcome 1 Response to treatment ‐ each low‐potency antipsychotic separately. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/references#CD009268-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009268-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/urn:x-wiley:14651858:media:CD009268:CD009268-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_t/tCD009268-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis, Outcome 2 Response to treatment ‐ treatment resistance." data-id="CD009268-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis, Outcome 2 Response to treatment ‐ treatment resistance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/references#CD009268-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009268-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/urn:x-wiley:14651858:media:CD009268:CD009268-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_t/tCD009268-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis, Outcome 1 Response to treatment ‐ fixed‐effect model." data-id="CD009268-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis, Outcome 1 Response to treatment ‐ fixed‐effect model. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/references#CD009268-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009268-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/urn:x-wiley:14651858:media:CD009268:CD009268-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_t/tCD009268-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis, Outcome 2 Response to treatment ‐ exclusion of studies in which randomisation was assumed from blinding." data-id="CD009268-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis, Outcome 2 Response to treatment ‐ exclusion of studies in which randomisation was assumed from blinding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/references#CD009268-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009268-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/urn:x-wiley:14651858:media:CD009268:CD009268-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_t/tCD009268-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis, Outcome 3 Response to treatment ‐ exclusion of non double‐blind studies." data-id="CD009268-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis, Outcome 3 Response to treatment ‐ exclusion of non double‐blind studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/references#CD009268-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009268-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/urn:x-wiley:14651858:media:CD009268:CD009268-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_t/tCD009268-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis, Outcome 4 Response to treatment ‐ exclusion of outlier study leading to heterogeneity (Dufresne 1993)." data-id="CD009268-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis, Outcome 4 Response to treatment ‐ exclusion of outlier study leading to heterogeneity (Dufresne 1993). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/references#CD009268-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/media/CDSR/CD009268/image_n/nCD009268-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD009268-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Comparisons suggested by excluded studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Excluded study tag</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Current relevant Cochrane review</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amitriptyline for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0055" title="TejaJS , GreyWH , ClumJM , WarrenC . Tranquilizers or anti‐depressanrs for chronic schizophrenics: a long term study. Australian and New Zealand Journal of Psychiatry1975;9:241‐7. ">Teja 1975</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0125" title="WhiteheadC , MossS , CardnoA , LewisG , FurtadoVA . Antidepressants for people with both schizophrenia and depression. Cochrane Database of Systematic Reviews2002, Issue 2. [DOI: 10.1002/14651858.CD002305] ">Whitehead 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antipsychotic (various) withdrawal versus continuation for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0023" title="CrowTJ , MacMillanJF , JohnsonAL , JohnstoneEC . A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry1986; Vol. 148, issue 2:120‐7. [MEDLINE: 2870753] JohnstoneEC , CrowJ , JohnsonAL , MacMillanJF . The northwick park study of first episodes of schizophrenia. British Journal of Psychiatry1986;148:115‐20. ">Crow 1986</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Benztropine plus antipsychotic combinations for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0053" title="SinghMM . Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Diseases of the Nervous System1976; Vol. 37:191‐6. SinghMM , KaySR . A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Theoretical implications for potency differences among neuroleptics. Psychopharmacology1975; Vol. 43, issue 2:103‐13. SinghMM , KaySR . A longitudinal therapeutic comparison between two prototypic neuroleptics (haloperidol and chlorpromazine) in matched groups of schizophrenics. Nontherapeutic interactions with trihexyphenidyl. Theoretical implications for potency differences. Psychopharmacology1975; Vol. 43, issue 2:115‐21. SinghMM , KaySR . Therapeutic reversal with benztropine in schizophrenics: practical and theoretical significance. Journal of Nervous and Mental Disease1975; Vol. 160, issue 4:258‐66. ">Singh 1975</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol dose for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0054" title="SmithRC , BaumgartnerR , BurdA , RavichandranGK , MauldinM . Haloperidol and thioridazine drug levels and clinical response in schizophrenia: comparison of gas‐liquid chromatography and adioreceptor drug level assays. Psychopharmacology Bulletin. United States, 1985; Vol. 21, issue 1:52‐8. ">Smith 1985</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0077" title="DonnellyL , RathboneJ , Adams CliveE . Haloperidol dose for the acute phase of schizophrenia. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD001951.pub2] ">Donnelly 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus mid/high‐potency antipsychotic drugs for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0032" title="GiordanaJY , FrenayS . Comparative study of pipotiazine (in its non‐esterified form) and of haloperidol in acute or subacute psychotic states [Etude comparative de la pipothiazine (dans sa forme non esterifiee) et de l'haloperidol au cours d'etats psychotiques aigus et subaigus]. Psychologie Medicale1984;16(10):1803‐15. ">Giordana 1984</a> (pipotiazine), <a href="./references#CD009268-bbs2-0047" title="NahunekK , SvestkaJ , CeskovaE , RysanekR . Blind comparison of oxyprothepin and haloperidol in six‐week treatment periods in schizophrenia. Activitas Nervosa Superior1982; Vol. 24, issue 4:219‐20. ">Nahunek 1982</a> (oxyprothepine) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0029" title="GarryJW , LeonardTJ . Haloperidol: a controlled trial in chronic schizophrenia. Journal of Mental Science1962; Vol. 108:105‐7. ">Garry 1962</a>, <a href="./references#CD009268-bbs2-0041" title="MarjerrisonG , BowmanR , KeoghRP . A comparison of chlorprothixene and haloperidol in acute schizophrenia. Canadian Psychiatric Association Journal1971; Vol. 16, issue 6:533‐6. ">Marjerrison 1971</a>, <a href="./references#CD009268-bbs2-0047" title="NahunekK , SvestkaJ , CeskovaE , RysanekR . Blind comparison of oxyprothepin and haloperidol in six‐week treatment periods in schizophrenia. Activitas Nervosa Superior1982; Vol. 24, issue 4:219‐20. ">Nahunek 1982</a>, <a href="./references#CD009268-bbs2-0055" title="TejaJS , GreyWH , ClumJM , WarrenC . Tranquilizers or anti‐depressanrs for chronic schizophrenics: a long term study. Australian and New Zealand Journal of Psychiatry1975;9:241‐7. ">Teja 1975</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0059" title="Adams CliveE , BergmanH , Irving ClaireB , LawrieS . Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews. John Wiley &amp; Sons, Ltd, 2013, issue 11. [DOI: 10.1002/14651858.CD003082.pub3; CD003082] ">Adams 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine versus first‐generation antipsychotic drugs for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0025" title="deLimaMS , deJesusMJ , BreierA , CostaAM , deSenaEP , HotopfM . Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first‐generation antipsychotics. Journal of Clinical Psychiatry. United States, 2005; Vol. 66, issue 7:831‐8. ">de Lima 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0078" title="DugganL , FentonM , RathboneJ , DardennesR , El‐DosokyA , IndranS . Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD001359.pub2] ">Duggan 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sulpiride for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0021" title="CassanoGB , CastrogiovanniP , ContiL . The computer diagnosis in a multicenter study of psychoactive agents. Psychopharmacology Bulletin1976; Vol. 12, issue 2:22‐4. CassanoGB , CastrogiovanniP , ContiL , BonolloL . Sulpiride versus haloperidol in schizophrenia: a double‐blind comparative trial. Current Therapeutic Research1975; Vol. 17, issue 2:189‐201. CastrogiovanniP , CassanoGB , ContiL , MagginiC , BonolloL , SarteschiP . An automated diagnostic process (PDA) in clinical psychopharmacology. An exemplification of its use in a sulpiride versus haloperidol comparative trial. International Pharmacopsychiatry1976; Vol. 11, issue 2:74‐83. ">Cassano 1975</a>, <a href="./references#CD009268-bbs2-0034" title='GuazzelliM , BarracchiaE , BertolinoA , BertolinolA , CasacchiaM , CiapparelliA , et al. Clinical effects of l‐sulpiride vs haloperidol in acutely relapsed chronic schizophrenics: therapeutic efficacy on "disorganization"?. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 Sep 30 ‐ Oct 4; Venice, Italy1995. '>Guazzelli 1995</a>, <a href="./references#CD009268-bbs2-0044" title="MoriA , KazamatsuriH , KanenoS , KamijimaK , KariyaT , MurasakiM , et al. A double‐blind comparison of a new benzamide compound YM 09151 with haloperidol in the treatment of schizophrenia. Rinsho Hyoka (Clinical Evaluation)1989; Vol. 17, issue 3‐4:349‐77. ">Mori 1989</a>, <a href="./references#CD009268-bbs2-0046" title="GerlachJ , BehnkeK , HeltbergJ , Munk‐AndersonE , NielsenH . Sulpiride and haloperidol in schizophrenia: a double‐blind cross‐over study of therapeutic effect, side effects and plasma concentrations. British Journal of Psychiatry1985; Vol. 147:283‐8. Munk‐AndersenE , BehnkeK , HeltbergJ , NielsenH . Sulpiride versus haloperidol in the treatment of schizophrenia. A short preliminary report [Sulpirid versus haloperidol i behandling af skizofreni. En kort, praeliminaer rapport]. Nordisk Psykiatrisk Tidsskrift1984; Vol. 38, issue 4:223‐8. Munk‐AndersenEM , BehnkeK , HeltbergJ , NielsenH , GerlachJ . Sulpiride versus haloperidol, a clinical trial in schizophrenia. A preliminary report. Acta Psychiatrica Scandinavica Supplementum1984; Vol. 311:31‐41. ">Munk‐Andersen 1984</a>, <a href="./references#CD009268-bbs2-0048" title="OkudaO , AkaueY , OkishioY . The efficacy of sulpiride in the treatment of schizophrenia by the double‐blind method. Yakuri To Chiryo1979; Vol. 7, issue 2:439‐58. ">Okuda 1979</a>, <a href="./references#CD009268-bbs2-0050" title="Rama RaoV , BaileyJ , BishopM , CoppenA . A clinical and pharmacodynamic evaluation of sulpiride. Psychopharmacology1981; Vol. 73, issue 1:77‐80. ">Rama 1981</a>, <a href="./references#CD009268-bbs2-0051" title="RopertR , PayanC , AllardS . Sultopride versus haloperidol for the treatment of acute psychosis. Results of a multicenter double‐blind controlled trial [Sultopride versus haloperidol dans le traitement des etats psychotiques aigus]. Annales de Psychiatrie1989; Vol. 4, issue 1:92‐8. ">Ropert 1989</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0110" title="Omori IchiroM , WangJ , SoaresB , FentonM . Sulpiride versus other antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD008126] ">Omori 2009</a>, <a href="./references#CD009268-bbs2-0117" title="Soares BernardoGO , FentonM , ChueP . Sulpiride for schizophrenia. Cochrane Database of Systematic Reviews1999, Issue 1. [DOI: 10.1002/14651858.CD001162] ">Soares 1999</a> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Comparisons suggested by excluded studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/full#CD009268-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009268-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Design of a future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised ‐ clearly described generation of sequence and concealment of allocation.<br/> Blinding: double ‐ described and tested.<br/> Duration: 6 months. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>People with schizophrenia or schizophrenia‐like disorder.<br/> N = 500.<br/> Age: any.<br/> Sex: both.<br/> History: any. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. High‐potency antipsychotic drug (haloperidol).</p> <p>2. Low‐potency antipsychotic drugs.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Response (primary outcome)</p> <p>Global state (number of participants improved)</p> <p>Leaving the study early (including specific causes)</p> <p>Death (natural and unnatural causes)</p> <p>Quality of life</p> <p>Satisfaction with care</p> <p>Days in hospital</p> <p>Number of healthy days</p> <p>Side‐effects</p> <p>Employment and other measures of functioning</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Design of a future study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/full#CD009268-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009268-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Clinical response to treatment</b> <br/> Follow‐up: 2‐12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.11</b> <br/> (0.86 to 1.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>574<br/> (14 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>361 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>401 per 1000</b> <br/> (310 to 520) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>334 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>371 per 1000</b> <br/> (287 to 481) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early ‐ Due to any reason</b> <br/> Follow‐up: 1‐3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.82</b> <br/> (0.38 to 1.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>408<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>164 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>135 per 1000</b> <br/> (62 to 291) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>136 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>112 per 1000</b> <br/> (52 to 241) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects ‐ at least one adverse effect</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.97</b> <br/> (0.69 to 5.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>158<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>346 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>681 per 1000</b> <br/> (239 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>235 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>463 per 1000</b> <br/> (162 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects ‐ movement disorders ‐ At least one movement disorder</b> <br/> Follow‐up: 1‐3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.64</b> <br/> (1.22 to 2.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>170<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>414 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>679 per 1000</b> <br/> (505 to 914) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>375 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>615 per 1000</b> <br/> (458 to 829) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects ‐ other ‐ Sedation</b> <br/> Follow‐up: 6‐12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.3</b> <br/> (0.11 to 0.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>44<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> <br/> (55 to 410) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>420 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b> <br/> (46 to 344) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. <br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: rated 'serious' ‐ many studies did not report the methods for sequence generation and/or allocation concealment, missing or unclear results for incomplete outcome data and selective reporting.<br/> <sup>2</sup> Imprecision: rated 'serious' ‐ the total number of events is less than 300 and the estimate of effect includes appreciable benefit/harm.<br/> <sup>3</sup> Inconsistency: rated 'serious' ‐ the P value for heterogeneity was statistically significant and the I‐square higher than 80%, the direction of the effect was not the same for all the studies.<br/> <sup>4</sup> Imprecision: rated 'serious' ‐ only a few studies contributed to this event and the confidence interval was large. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/full#CD009268-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009268-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Series of similar reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Title</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol versus first‐generation antipsychotics for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0076" title="DoldM , LiC , TardyM , LeuchtS . Haloperidol versus first generation antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD009831] ">Dold 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Perphenazine versus low‐potency antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0119" title="TardyM , LeuchtS , PotapovA , EngelR , HuhnM , KomossaK . Perphenazine versus low‐potency first generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2011, Issue 10. [DOI: 10.1002/14651858.CD009369] ">Tardy 2011b</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluphenazine versus low‐potency antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0120" title="TardyM , LeuchtS , PotapovA , EngelR , HuhnM , KomossaK . Fluphenazine versus low‐potency first generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2011, Issue 8. [DOI: 10.1002/14651858.CD009230] ">Tardy 2011c</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trifluoperazine versus low‐potency antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0121" title="TardyM , LeuchtS , PotapovA , EngelR , DoldM , KisslingW . Trifluoperazine versus low‐potency first generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2011, Issue 10. [DOI: 10.1002/14651858.CD009396] ">Tardy 2011d</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flupenthixol versus low‐potency antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009268-bbs2-0122" title="TardyM , LeuchtS , PotapovA , EngelR , DoldM , KisslingW . Flupenthixol versus low‐potency first generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2011, Issue 8. [DOI: 10.1002/14651858.CD009227] ">Tardy 2011e</a> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Series of similar reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/full#CD009268-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009268-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Response to treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.86, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mental state: 1a. General ‐ overall symptoms ‐ average endpoint score/change (BPRS, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐2.15, 1.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state: 1b. General ‐ overall symptoms ‐ average endpoint score/change (PANSS, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.0 [‐20.69, 12.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐6.77, 4.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐5.20, 5.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global state: Average endpoint score/change (CGI, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.31, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.26, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 due to any reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.38, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 due to adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.16, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 due to inefficacy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.31, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects: 1. General ‐ at least one adverse effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.97 [0.69, 5.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse effects: 2a. Specific ‐ movement disorders <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 at least one movement disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [1.22, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.56, 2.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.34, 26.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 dystonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.71 [1.95, 11.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 loss of associated movement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.33 [0.39, 137.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 oculogyric crisis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.14 [0.13, 74.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7 rigor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.28, 90.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.8 tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [0.16, 29.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.9 use of antiparkinson medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.88 [1.19, 7.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects: 2b. Specific ‐ movement disorders ‐ average endpoint score/change (ESRS, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [1.35, 2.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse effects: 3. Others <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 allergy ‐ allergic reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.14 [0.13, 74.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 allergy ‐ rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 69.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 allergy ‐ tongue alterations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.28, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 anticholinergic ‐ blurring of vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.35, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 anticholinergic ‐ constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.21, 11.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6 anticholinergic ‐ drooling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [0.20, 22.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.7 anticholinergic ‐ dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.63, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.8 anticholinergic ‐ micturition disturbances</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.01, 4.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.9 anticholinergic ‐ repercussions on sexual life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.01, 4.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.10 anticholinergic ‐ sweating</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.15 [0.36, 27.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.11 anticholinergic ‐ urinary retention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.12 cardiovascular ‐ ankle edema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.13 cardiovascular ‐ dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.21, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.14 cardiovascular ‐ hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.10, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.15 cardiovascular ‐ orthostatic symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.16, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.16 cardiovascular ‐ palpitations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.07, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.17 cardiovascular ‐ syncope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 2.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.18 central nervous system ‐ asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [0.98, 4.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.19 central nervous system ‐ confusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.65 [0.12, 60.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.20 central nervous system ‐ excitement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.21 central nervous system ‐ headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.67 [0.50, 14.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.22 central nervous system ‐ nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.28, 8.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.23 central nervous system ‐ photosensitivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.05, 3.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.24 central nervous system ‐ sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.11, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.25 central nervous system ‐ sleep disturbances</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.30 [0.83, 47.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.26 central nervous system ‐ somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.49, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.27 hormonal ‐ amenorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.28 metabolic ‐ weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.06, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.29 metabolic ‐ weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.06, 6.06]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/references#CD009268-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009268-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Response to treatment ‐ each low‐potency antipsychotic separately <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>558</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.85, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 versus chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.97, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 versus levomepromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.50, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 versus perazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.62, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 versus thioridazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.31, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Response to treatment ‐ treatment resistance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>558</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.85, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 not treatment resistant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.89, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 treatment resistant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.38, 2.17]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/references#CD009268-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009268-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sensitivity analysis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Response to treatment ‐ fixed‐effect model <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>558</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.91, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Response to treatment ‐ exclusion of studies in which randomisation was assumed from blinding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.82, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Response to treatment ‐ exclusion of non double‐blind studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.80, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Response to treatment ‐ exclusion of outlier study leading to heterogeneity (Dufresne 1993) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.93, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sensitivity analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009268.pub2/references#CD009268-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009268.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009268-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009268-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009268-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD009268-note-0001">Hrvatski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009268\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009268\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009268\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009268\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009268\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009268\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009268\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009268\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009268\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009268\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009268\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009268\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009268\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009268\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009268\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009268\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009268\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009268\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009268.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009268.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009268.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009268.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009268.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725259249"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009268.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725259253"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009268.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e76dcdd38936e',t:'MTc0MDcyNTI1OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 